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Chapter 1. 
Introduction 
1 
1.1 Haematopoietic Stem Cells 
Stem cells are immature, clonogenic . cells with a high proliferative potential, 
which are able to self-renew and give rise to differentiated progeny. 
In vertebrates they are classified in two groups: embryonic stem (ES) cells 
and adult stem cells. ES cells are found in the inner mass of the blastocyst and are 
able to generate all the differentiated cells' of the organism (pluripotency). Adult 
stem cells derive from ES during foetal development and are tissue/organ specific 
stem cells, which are able to differentiate into a limited number of lineages 
(multipotency) and are responsible for homeostatic cell replacement and tissue 
regeneration, virtually for the entire life span of the organism (Harrison 1973). 
The frequency of adult stem cells in the total organ/tissue cell population is very 
low. Stem cells are slow-cycling ~nder steady-state conditions and are able to 
balance self-re~ewal against differentiation when cycling. 
Haematopoietic stem cells (HSCs) are adult stem cells that give rise to all 
blood cell lineages, including lymphoid (T and B) and myeloid cell lineages. 
Their existence was first postulated in the context of a clinical study, whose aim 
was the identification of a cell population able to protect patients that underwent 
lethal irradiation or chemotherapy. Although at that time the cause of death for 
irradiation was not known, it had been observed that death could be prevented if 
the haematopoietic tissues were protected (Jacobson, Marks et al. 1949). In the 
same period another group showed that intravenous injection of syngeneic bone 
marrow (BM) cells could prevent the death of lethally irradiated mice (Lorentz, 
Uphoff et al. 1951). Ten years later, Till and McCulloch identified a population of 
progenitor cells in the BM that.were able to form myelo-erythroidcolonies in the 
spleen of irradiated recipients (Till 1961; Wu, Till et al. 1967); they also showed 
that these colonies were clonal (Wu, Siminovitch et al. 1968; Wu, Till et al. 1968) 
2 
.) 
and that the colony-forming-cells, in many cases, were able to generate new 
colonies upon transplantation into secondary recipients (Siminovitch, McCulloch 
et al. 1963). Thus, the existence of a radioprotective cell population residing in the 
BM was postulated; these cells, which were able to self-renew and differentiate 
into different blood cell lineages, were termed haematopoietic stem cells 
(Siminovitch, McCulloch et al. 1963; Wu, Siminovitch et al. 1968). After 40 years 
of research HSC biology is still not completely understood, even though HSCs are 
still the best characterized stem cells. 
1.1.1 Ontogeny 
HSC development has been extensively studied in mammals, mainly in the 
mouse. The first site of haematopoiesis is the yolk sac, in which at embryonic day 
(E) 7.0 a population of progenitor cells emerges that originates primitive 
erythroblasts and macrophages. By rapid expansion the primitive erythroblasts 
and macrophages fill the nascent yolk sac capillary bed with flowing cells that 
begin to be propelled by the developing heart tube on E 8.25. At this time, 
multi potent progenitors giving rise to definitive lineages possibly also arise in the 
yolk sac (for a review of yolk sac haematopoiesis see, (McGrath and Palis 2005). 
All these blood elements enter the bloodstream and through the umbilical cord 
vein mig~ate to the developing liver, where progenitor cell maturation takes place 
(Weissman, Papaioannou et al. 1978; Godin and Cumano 2005). In the mean time, 
at E 8.0, HSCs emerge in the mesoderm-derived paraaortic splachnopleure/aorta-
gonad-mesonephros (P-Spl AGM) region and migrate to the liver, where they 
mature (Muller, Medvinsky et' al. 1994; Godin, Dieterlen-Lievre et al. 1995; 
Medvinsky and Dzierzak 1996). Starting' from E 12.0 the foetal liver is the 
3 
primary site of haematopoiesis through birth (Morrison, Hemmati et al. 1995), 
although the spleen and BM become active sites of haematopoiesis prior to birth 
(E 18.0). However, the primary site of development of the HSCs that will support 
haematopoiesis in the adult is still debated. In fact, while there is some evidence 
that both the yolk sac and the P-Sp/AGM region playa role (Cumano, Ferraz et al. 
2001; Matsuoka, Tsuji et al. 2001; de Bruijn, Ma et al. 2002), there are different 
interpretations about temporal and spatial emergence of these cells. Moreover, a 
number of studies have recently suggested that foetal placenta also functions as 
haematopoietic organ, which plays an important role in establishing the HSC pool 
during development (Alvarez-Silva, Belo-Diabangouaya et al. 2003; Gekas, 
Dieterlen-Lievre et al. 2005; Ottersbach and Dzierzak 2005). These new findings 
add a level of complexity to the established paradigms and prompt the needing of 
revising the model for foetal haematopoiesis. 
1.1.2 HSC fate decision 
In the adult, HSCs reside mainly in the endosteal niche of BM, where they are 
associated to stromal cells, which support maintenance of stem cells and 
haematopoiesis by secretion of factors and cell-cell interactions. In order to 
generate mature blood cells, HSCs are engaged in a differentiation process 
towards 'inultilineage progenitors; these cells can generate either common myeloid 
progenitors or take the lymphoid path to generate common lymphoid progenitors. 
These progenitors undergo further commitment steps that restrict their 
developmental potentials, in term of both proliferative and lineage potential, and 
end up with the generation of terminally differentiated progeny (Figure 1.1). 
4 
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Figure 1.1. Hematopoiesis. LT-HSC: Long-term hematopoietic stem cell. ST-HSC: Short-term 
hematopoietic stem cell. MPP: multipotent progenitor. CMP: common myeloid progenitor. 
CLP: common lymphoid progenitor. MEP: megakaryocyte-erythrocyte progenitor. GMP: 
granulocyte-macrophage progenitor. 
The ability of HSCs to differentiate without exhausting relies on the ability 
of stem cells to perform both symmetrical and asymmetrical divisions. 
Symmetrical divisions give rise to two daughter cells with the same potential of 
the dividing cell, whereas asymmetrical divisions give rise to a cell with the same 
potential of the dividing cell and a progenitor that has a higher degree of 
Symmetrical division: 
ml!lintenance/expansion 
Asymmetrical division: 
maintenance/differentiation 
Symmetrical division: 
differentiation/exhaustion 
Figure 1.2. Symmetric and 
asymmetric divisions. S: stem cell. 
P: progenitor cell. 
commitment, lower self-renewing and 
proliferative potential and that will generate 
the differentiated progeny (Figure 1.2). Thus, 
symmetrical mitoses are responsible for the 
maintenance and expansion of the HSC 
compartment, while asymmetrical mitoses are 
responsible for both self-renewal and 
differentiation. Since both the absolute 
5 
number and the relative frequency of the different cell types in the haematopoietic 
system exhibit little variation and remain robust with regards to extrinsic 
perturbations, tightly regulated mechanisms must govern the balance between 
HSC differentiation and self-renewal, i.e. symmetrical versus asymmetrical 
division. The debate about these regulating mechanisms has evolved around two 
contrasting lines of thoughts: the stochastic hypothesis infers that 
differentiation/self-renewal decision is a cell-intrinsic process that occurs 
randomly, while the inductive hypothesis infers the existence of external stimuli 
that drive cell fate (for a review see (Morrison, Shah et al. 1997). More recently, 
on the basis of systems that model HSC development within a cell population, the 
chaos hypothesis has been proposed (Furusawa and Kaneko 2001). This theory is 
based on a chaotic behaviour at the level of a single HSC, where chaos does not 
represent disorder but a state of intracellular dynamic equilibrium sensitive to 
small variations and allowing HSCs to integrate diverse internal/external signals. 
According to this theory, lineage commitment and loss of multipotency are 
accompanied by a decrease in the complexity of the system. This hypothesis is in 
agreement with gene expression studies, which found low expression levels of 
many different lineage-commitment genes in HSCs; the expression of each 
lineage-related gene set is then enhanced or repressed during commitment, 
according to the differentiation lineage undertaken (see paragraph 1.1.4.1 Intrinsic 
signals). 
Integrating these different hypotheses, it is now believed that the first 
driving force to HSC differentiation is an unknown random event at the 
intracellular level and that, in order to be effective, this choice must be 
consolidated by permissive external stimuli. In this view, HSC fate decision is the 
outcome of both stochastic events and external instructive signals and resembles 
6 
morphogenesis during embryonic development (for a comprehensive review on 
HSC cell fate determination see (Faubert, Lessard et al. 2004; Hoang 2004). 
1.1.3 HSC maintenance 
Since HSCs sustain haematopoiesis for the entire life span of the organism, they 
must use specific mechanisms to avoid the risk of damage from long replicative 
histories and to regulate the phenomenon of aging. It was initially proposed that a 
strategy exerted by HSCs to this aim is through clonal succession. In this model, 
the vast majority of the population is homeostatically maintained in a quiescent 
state, and one or at most some stem cells are actively supplying differentiated 
cells at any given time (Kay 1965; Lemischka, Raulet et at. 1986; Abkowitz, 
Linenberger et at. 1990). Accordingly, this model implies that cycling HSCs 
generate differentiated progeny until exhaustion and thus implies a reduction of 
HSC number with age. This hypothesis has been challenged by later studies that 
demonstrated that every 1-3 months all HSCs have replicated, supporting the 
evidence that they divide on a regular basis (Bradford, Williams et at. 1997; 
Cheshier, Morrison et at. 1999). Moreover, drawbacks and limitations of a work 
that supported the clonal succession model have been uncovered by successive 
studies. Indeed, Lemischka and coworkers (Lemischka, Raulet et at. 1986) used 
oncoretrovirus-mediated ex-vivo gene transfer to mark HSCs and track them in 
vivo after transplant. However, it has been later shown that retroviral vectors can 
integrate only in proliferating cells (Miller, Adam et al. 1990; Roe, Reynolds et al. 
1993)(see paragraph 1.2 Gene transfer into haematopoietic stem cells). Thus, the 
authors marked and followed in vivo only HSCs that were already proliferating ex 
vivo and lost in their analysis cells that did not proliferate during the ex vivo 
7 
period. In addition, a gene therapy clinical trial has very recently shown that 
oncoretroviral integration is not neutral, as believed for a long time, and can 
activate growth-enhancing genes and induce in vivo expansion of selected clones 
(Ott, Schmidt et al. 2006). Thus, by using the oncoretroviral marking Lemischka 
et al. analysed HSC clones that were not only selected in vitro but also, possibly, 
selected in vivo. 
Thus, the theory has been revised. In agreement with the clonal succession 
model, it is still believed that at any time the majority of HSCs is in a quiescent 
state and only a limited number enter cell cycle. However, this new view does not 
link cell cycle entry with differentiation and exhaustion and, thus, does not imply 
a reduction of HSC number. Indeed, when HSCs proliferate they can give rise to 
one or two HSCs with the same potential of the dividing cell (see paragraph 1.1.2 
HSC fate decision); these cells go back to a quiescent state and maintain the HSC 
compartment. 
A strategy exerted by HSCs to prevent exhaustion was proposed to be the 
maintenance of telomeres (Morrison, Prowse et al. 1996). However, contrasting 
results have been shown. Indeed, activity of telomerase (TERT), which 
compensates the telomeres shortening due to DNA replication and prevents 
induction of senescence, has been detected in different progenitor/stem cells, but 
has been found to be low or absent in HSCs (Samper, Fernandez et al. 2002; 
Allsopp, Morin et al. 2003; Allsopp, Morin et al. 2003). Moreover, it has been 
found that, whereas murine HSCs deficient in TERT show accelerated telomere 
erosion and an impaired long-term self-renewability (Allsopp, Morin et al. 2003), 
over-expression of TERT does not induce an increase in self-renewal (Allsopp, 
Morin et al. 2003). Thus, even if in human HSCs the role of TERT still needs to 
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be clearly assessed, these findings support the idea that prevention of telomere 
length is a mechanism necessary, but not sufficient for HSCs maintenance. 
1.1.4 Molecular Mechanisms regulating HSCs 
The homeostasis of the haematopoietic system mainly relies on the pathways 
undertaken by haematopoietic stem and progenitor cells (Figure 1.3). Whereas 
progenitors are mainly responsible for development 
I 
I 
I 
I 
I the short-term maintenance, HSCs are sell-renewal 
malignant 
transformation 
I 
T 
responsible for long-term maintenance. 
Thus, to sustain the system without 
apoptosis 
/ \ ~ quk!sa!oce 
undergoing exhaustion, HSCs must be t 
tightly regulated. HSC regulation is a mlgnll~ differentiation 
key issue not only for basic biology, but Figure 1.3. HSC fate 
also for applied biology. Indeed, its understanding, and possibly its exploitation, is 
at the base of the development of efficacious gene and cell therapy protocols. 
Because of this, we will discuss in the following paragraphs the known HSC 
regulators. They are commonly divided in intracellular regulators (intrinsic 
signals) and external stimuli (extrinsic signals). 
1.1.4.1 Intdnsic signals 
Intrinsic signals converge at the level of gene expression, and have been better 
characterized in the developmental pathways of HSCs than in the homeostatic 
maintenance of HSCs in the adult state. 
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Although the transcriptional machinery governing the HSC developmental 
pathways is very complex, some families of transcription factors involved in this 
process have been identified. Indeed, SCL/tall, Rbnt2 (also known as LMO-2) 
and AML-l genes have been shown to be essential for the generation of the 
haematopoietic system in the mouse (Warren, Colledge et al. 1994; Shivdasani, 
Mayer et al. 1995; Okuda, van Deursen et al. 1996; Lacaud, Gore et al. 2002). 
Another set of genes reported to be major players in regulating in haematopoiesis 
is the homeobox (Hox) genes family (Sauvageau, Lansdorp et al. 1994; Lawrence, 
Sauvageau et al. 1995). The proteins encoded by these genes are evolutionary 
preserved and characterized by a DNA-binding motif called homeodomain. 
Among them, HoxB3 and HoxB4 are preferentially expressed in the most 
primitive population of haematopoietic cells and over-expression of HoxB4 
favours self-renewal over differentiation in both murine and· human HSCs 
(Sauvageau, Lansdorp et al. 1994; Sauvageau, Thorsteinsdottir et al. 1995; 
Thorsteinsdottir, Sauvageau et al. 1999; Antonchuk, Sauvageau et al. 2001; 
Buske, Feuring-Buske et al. 2002). Moreover, HoxB4, directly delivered of fused 
to HIV -TAT protein, has been shown to sustain haematopoietic stem/progenitor 
cell (HSPC) expansion in vitro (Amsellem, Ptlumio et al. 2003; Krosl, Austin et 
al. 2003). Other Hox proteins have been identified as regulators of early 
haematopoiesis, such as Hox9, Hox8 and Hox6 (Lawrence, He1gason et al. 1997; 
Izon, Rozenfeld et al. 1998; Shimamoto, Tang et al. 1999; Kappen 2000; So, 
Karsunky et al. 2004). However, a relatively mild effect on haematopoiesis was 
observed as consequence of the deficiency of each single Hox gene, whereas a 
more profound defect has been shown in mice lacking Hox cofactors, such as 
Pbxl and Meisl (DiMartino, Selleri et al. 2001; Hisa, Spence et al: 2004), or 
upstream regulators, such as MIl (Ernst, Fisher et al. 2004), suggesting redundant 
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and compensating functions of Hox gene(s). The role of these genes in 
haematopoiesis is still under investigation, but is now known that they target cell 
cycle genes, and that Hox proteins interact with both nuclear factor and signal 
transducers (for a comprehensive review on Hox regulation of HSCs see 
(Abramovich and Humphries 2005). 
A factor believed to playa critical role in maintaining HSCs, both during 
embryogenesis and in the adult, is the zinc-finger transcription factor Gata-2 
(Tsai, Keller et al. 1994; Tsai and Orkin 1997). Indeed, the disruption of the gene 
encoding for it leads to a reduction of all haematopoietic precursors and the 
enforced expression blocks normal haematopoiesis (Persons, Allay et al. 1999). 
Similarly, the TEL locus, encoding an Ets family transcription factor, seems to 
have a role in BM haematopoiesis (Wang, Swat et al. 1998). 
More recently, the policomb group gene Bmi-l has been shown to be 
absolutely required for HSC maintenance. Its expression is enriched in stem and 
progenitor cells in the adult (Lessard, Baban et al. 1998; Lessard and Sauvageau 
2003) and it has been shown that its absence leads in mice to a progressive 
impairment of BM HSC and committed progenitors function (van der Lugt, 
Domen et al. 1994; Lessard, Schumacher et al. 1999). Moreover, it has been 
demonstrated that knock-down of Bmi-l strongly reduces HSC self-renewing 
ability (Park, Qian et al. 2003). In this study Park et ale also studied HSC 
.> 
expression pattern and found a significant up-regulation of the cyclin-dependent 
kinase inhibitors (CKIs) p16INK4a and p19~RF when Bmi-l was knocked-down. 
Thus, they proposed a model in which Bmi-l, by down-regulating the expression 
of these two CKIs, maintains self-renewing proliferation and prevents senescence 
and apoptosis (Park, Qian et al. 2003). 
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Indeed, some CKIs have been proposed as players in the control of 
HSPCs. Cheng et al. found that p21 cipl/wafl is highly expressed in the quiescent 
fraction of BM cells and that its absence leads to cell-cycle entry and premature 
exhaustion of murine HSCs (Cheng, Rodrigues et al. 2000). The same group has 
also demonstrated that mice lacking p27kip1 , a CKI belonging to the same family 
of p21, have normal HSC number, cell-cycling and self-renewal, but they show an 
increase in progenitors (Cheng, Rodrigues et al. 2000). Among the family of CKIs 
encoded by the INK4 locus, p 16 expression is highly enriched in HSPCs and 
down regulated during differentiation (Furukawa, Kikuchi et al. 2000). In mice its 
absence seems not to lead to defects in haematopoiesis (Serrano, Lee et al. 1996), 
possibly due to activation of compensating mechanisms, while in vitro p 16INK4a 
seems to negatively regulate HSPC proliferation (Park, Qian et al. 2003). 
Moreover, recently Ito el al. (Ito, Hirao et al. 2004) have showed a reduced HSC 
self-renewal in mice knocked-down for ataxia telangiectasia mutated (A TM) 
gene, which is responsible for genomic stability maintenance in stress conditions 
(Shiloh 2003). They associated this defect with an intracellular increase of 
reactive oxygen species that upregulated p16INK4a and p19ARF by activating p38 
MAPK (Ito, Hirao et al. 2004; Ito, Hirao et al. 2006) and thus suggested a role of 
the INK4 CKIs in HSC regulation. p18INK4 has also been proposed as HSC 
regulator, since its absence in mice induces an increase in self-renewal (Yuan, 
Shen et al. 2004). 
All these findings suggest that the balance between self-renewal and 
differentiation in HSCs may be obtained through the balance of different CKIs 
classes and support the idea that HSC maintenance is tightly linked to the 
maintenance of quiescence. The role of CKIs has been confirmed by a·recent gene 
expression study, in which Weissman's group analysed different subsets of 
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murine HSPCs and found that expression of several CKIs is up-regulated in the 
quiescent fraction (Passegue, Wagers et al. 2005). In the same work, the authors 
showed a precise pattern of expression of the cyclin genes for each 
haematopoietic population analysed and proposed that the activation of different 
cyclins may evolve in specific cellular outcomes. 
Understanding the molecular mechanisms governing HSC behaviour is 
important not only for basic biology studies, but also for health issues. Indeed, the 
extensive clonal proliferation and the long-term self-renewability make HSCs 
more susceptible to genetic alteration; this, together with the capacity to 
counteract the phenomenon of senescence, raises the issue of the development of 
cancer. In fact, it has been shown that in cancers of the haematopoietic system the 
initially transformed cell is a primitive stem cell that took an aberrant 
developmental pathway, which can be initially driven by a deregulation of critical 
intrinsic factors (Bonnet and Dick 1997; Reya, Morrison et al. 2001; Jordan 
2002). 
In the recent years, with the advent of new high-throughput gene 
expression analyses, several groups have attempted to define the complete 
molecular phenotype of HSCs (Phillips, Ernst et al. 2000; Zhou, Chen et al. 2001; 
Ivanova, Dimos et al. 2002; Ramalho-Santos, Yoon et al. 2002; Akashi, He et al. 
2003; ,Georgantas, Tanadve et al. 2004; Venezia, Merchant et al. 2004). 
Surprisingly, in most of these studies many lineage-restricted ge~e sets have been 
found to be expressed in HSCs. These findings have supported the development 
of the ground state model (Enver and Greaves 1998). This model, which is now 
widely accepted by the scientific community, proposes that HSCs display a 
molecular "ground state" composed of low levels of different commitment-related 
transcripts and that the commitment/differentiation process takes place by 
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selecting and amplifying the appropriate set of available transcripts and possibly 
repressing the remaining. This "lineage priming" is believed to be maintained by a 
promiscuous state of wide-open chromatin, which allows the simultaneous 
binding of multiple competing/alternative lineage specific transcription factors 
(for a review see (Akashi 2005). 
1.1.4.2 Extrinsic signals 
In the adult, HSCs reside mainly in the BM, where they are anchored to stromal 
cell and extracellular matrix through adhesion molecules. As aforementioned, the 
BM microenvironment (niche) provides factors that profoundly influence HSC 
fate. Some of the pathways involved in HSC regulation in the adult are also active 
during embryogenesis. 
Wnt and Notch pathways. The Wntl~-catenin pathway has been recently 
implicated in the regulation of HSC self-renewal. Indeed, over-expression of 
constitutively activated J3-catenin in murine HSCs prevents differentiation while 
promoting self-renewal (Reya, Duncan et al. 2003). Moreover, Wnt3a purified 
protein was shown to induce HSC proliferation without apparent differentiation in 
vitro (Willert, Brown et al. 2003). Interestingly, the activation of this pathway 
increased the expression of HoxB4 (see paragraph 1.1.4.1 Intrinsic signals) and 
Notchl (Reya, Duncan et al. 2003). Indeed, activation of Notch 1 transmembrane 
receptor has been shown to promote HSC self-renewal (Varnum-Finney, Purton et 
al. 1998; Karanu, Murdoch et al. 2000; Varnum-Finney, Xu et al. 2000; Karanu, 
Murdoch et al. 2001; Ohishi, Varnum-Finney et al. 2002), although critical targets 
for the Notch signalling pathway in HSCs still need to be elucidated. A very 
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recent study proposed glycogen syntase kinase-3 (GSK-3) as modulator of gene 
targets of Wnt and Notch-l (Trowbridge, Xenocostas et al. 2006). In this work, an 
enhancement of human and murine HSC self-renewing proliferation was shown 
upon administration of GSK-3 inhibitors in vivo and this enhancement was 
correlated to an increased expression of Notch-l target genes (Trowbridge, 
Xenocostas et al. 2006). 
TGF-fJ superfamily of ligands. Notchl ligand, Jagged-l has been shown to be 
highly expressed on activated osteoblasts and to mediate the maintenance of 
Notchl activated HSCs (Calvi, Adams et al. 2003). Recently, osteoblasts have 
been proposed by several groups as potent regulators of HSCs in the BM niche. 
Beyond the Jagged-llNotch 1 interaction, two other mechanisms have been 
suggested. The first is the homotypic N-caderin interaction between osteoblasts 
and HSCs and the second is the bone morphogenetic protein (BMP) signalling, 
which has been shown to control the number of primitive HSCs (Zhang, Niu et al. 
2003). However, a different group demonstrated that different BMPs induce 
opposite effects on human HSPCs in vitro, some inducing block of proliferation 
and maintenance of primitive phenotype and others inducing proliferation and 
differentiation (Bhatia, Bonnet et al. 1999). BMPs belong to the TGF-(3 
superfamily of ligands; another component of this family, TGF-(31, has been 
shown to be a negative regulator of HSC proliferation and appears to be a 
regulator of quiescence in vitro (for a review see (Fortunel, Hatzfeld et al. 2000). 
In contrast, recent studies demonstrated that mice, in which TGF -(3 receptors were 
knocked-down, showed normal HSC self-renewal and proliferation (Larsson, 
Blank et al. 2003; Larsson, Blank et al. 2005). Moreover, in vitro e~periments 
have shown opposite effects, depending on the concentration, of TGF-(32 on 
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HSCs, while TGF -(32 knock-down reduced HSC self-renewal in vivo (Langer, 
Henckaerts et al. 2004). The apparent contrasting results obtained in vitro and in 
vivo can be explained by compensatory mechanisms operated by other factors 
present in the BM niche but absent in the in vitro culture. All together these 
findings suggest an important role of TGF-(3 family in regulating HSC 
compartment and strongly support the concept that the outcome of HSC fate 
decision is context dependent and regulated by a complex cross talk of many 
different pathways. Indeed, a possible mechanism exerted by TGF -~ 1, behind the 
Smad signalling activation, is the down-regulation of the expression of some 
cytokine-receptor, such as c-kit (stem cell factor - SCF - receptor), Flt3 (fms-like 
tyrosine kinase 3) and IL6-receptor (Sansilvestri, Cardoso et al. 1995). 
Cytokines. Several. cytokines, such as SCF, Flt3-Ligand, IL6 and thrombopoietin 
(TPO), have been shown to promote growth of murine and human HSPCs in vitro 
(Petzer, Zandstra et al. 1996; Sitnicka, Lin et al. 1996; Veda, Tsuji et al. 2000; 
Nakauchi, Sudo et al. 2001). However, some receptors, such as FL T3, were not 
found to be expressed in HSCs (Adolfsson, Borge et al. 2001), whereas others, 
such as c-kit and TPO receptor (c-mpl), were found; knock-out of these receptors 
induce in mice severe HSC deficiencies (Miller, Rebel et al. 1996; Kimura, 
Roberts et al. 1998), suggesting a role of these cytokines in promoting HSC in 
vivo maintenance. 
Flt3-Ligand, SCF, IL6 and TPO, upon binding to their receptor, activate 
the JAK2/STAT5 pathway (Bacon, Tortolani et al. 1995; Sattler, Durstin et al. 
1995; Linnekin, Mou et al. 1997; Piekorz, Nemetz et al. 1997; Hayakawa, 
Towatari et al. 2000). In agreement with a positive role of these cytokines in HSC 
maintenance, recent studies have shown that knock-down of STAT5 in mice 
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reduce HSC self-renewal and multipotency, while its constitutive activation 
induce expansion of multipotent progenitors and promote HSC self-renewal 
(Bunting, Bradley et al. 2002; Snow, Abraham et al. 2002; Kato, Iwama et al. 
2005). Another interesting study has shown that SHIP (SH2-containing inositol 5-
phosphatase), a negative regulator of numerous signal transduction pathways, is 
probably involved in regulation of the cytokine-receptors pathways involved in 
HSC maintenance, because its knock-down in mice induce defects in HSC 
homeostasis and this defect is linked to an enhanced cytokine responsiveness (Liu, 
Shalaby et al. 1998; Helgason, Antonchuk et al. 2003). 
Tie21Angiopoietinl pathway. HSC cell cycle regulation has been linked to the 
Tie2/Angiopoietini signalling pathway. The activation of this pathway by the 
ligand, which is produced by both endothelial cells and HSCs, through the 
tyrosine kinase receptor Tie2 maintained HSC self-renewal and is though to playa 
critical role in the maintenance of quiescence (Takakura, Huang et al. 1998; Arai, 
Hirao et al. 2004). Moreover, Angiopoietinl increases the'interaction of HSC 
integrins and fibronectin present in the extracellular matrix and this interaction 
was shown to enhance in tum growth and survival of HSCs (Yokota, Oritani et al. 
1998). 
Inorganic compounds. Recent reports have proposed a role of oxygen in the 
regulation of HSCs in BM niche. Most primitive cells would reside in hypoxic 
areas, where low oxygen levels would enhance survival and expansion of self-
renewing HSCs (Danet, Pan et al. 2003; Ceradini, Kulkarni et al. 2004). 
Moreover, very recently Scadden's group has proposed the high concentration of 
calcium ions at the BM. endosteal surface as signal for HSC localization. The 
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calcium-sensing receptor expressed by HSCs would help in retaining these cells in 
close physical proximity to the endosteal surface and, thus, the regulatory niche 
(Adams, Chabner et al. 2006). 
Negative regulators. HSC fate is determined by the balance of positive and 
negative stimuli in the BM niche but, beyond TOF-J3I, negative regulators are less 
known. Some studies proposed tumor necrosis factor-a and interferon-y as players 
in the negative regulation of haematopoietic progenitors (Jacobsen, Ruscetti et al. 
1992; Maciejewski, Selleri et al. 1995; Zhang, Harada et al.'1995; Yang, Dybedal 
et al. 2005). 
Overall, a big effort has been made by several groups in the last fifteen years to 
understand the molecular mechanisms involved in HSC regulation. Nonetheless, 
the high level of complexity, the difficulty of studying HSCs in physiological 
conditions and possibly the difference between mouse and human haematopoiesis 
have not yet allowed to fully address it. 
1.1.4.2.1 Homing 
HSCs are mostly BM-resident cells. However, under stress conditions and, to a 
o lesser extent; in physiologic conditions HSCs can migrate within the BM or to 
extra-medullary organs. In a BM transplant setting, transplanted HSCs must 
migrate through the blood, cross the vasculature and seed in the BM niche. This 
migration requires an active process termed homing. Like other HSC features, 
homing is tightly regulated by factors expressed in the BM microenvironment, 
such as adhesion ,molecules and haematopoietic cytokines. Although the 
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molecular mechanisms are not fully understood, major advance have been made 
in the recent years in the elucidation of the homing process and the molecular and 
cellular pathways involved. 
The Stromal cell Derived Factor 1 (SDF-l)/CXC chemokine receptor 4 
(CXCR4) interaction has been proposed as a fundamental axis regulating 
retention, migration and mobilization of HSCs during homeostasis and stress (for 
a review see (Cottier-Fox, Lapidot et al. 2003). Lapidot's group has shown that 
HSC homing to the BM require functional interaction between CXCR4 expressed 
on the surface of HSCs and SDF-l expressed by BM endothelium and stromal 
cells (Peled, Petit et al. 1999; Kollet, Spiegel et al. 2001). Moreover, it has been 
shown that over-expression of CXCR4 leads to increased cell motility and 
increased HSC engraftment (Brenner, Whiting-Theobald et al. 2004; Kahn, Byk et 
al. 2004). Very recently, a role for protein kinase C l; (PKC l;) as intracellular 
signal transducer downstream to CXCR4 activation has been shown. Indeed, 
PKC l; translocates to the membrane upon SDFI stimulation and increases 
CXCR4 expression and matrix metalloproteinase 9 (MMP-9) secretion (Petit, 
Goichberg et al. 2005; Goichberg, Kalinkovich et al. 2006). Proteolytic enzymes, 
such as MMP-9 and MMP-2, then facilitate HSC homing by degrading 
extracellular matrix and increasing HSC motility. Nevertheless, it has been shown 
.) that some cell surface peptidases, such as CD26, have a negative role in the HSC 
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homing process. Indeed, inhibition of CD26 has been shown to enhance HSC 
homing in response to SDF-l, possibly because CD26 is responsible for cleavage 
and inactivation of SDF-l itself (Christopherson, Hangoc et al. 2002; 
Christopherson, Hangoc et al. 2004). 
Adhesion molecules, such as integrins and selectins, mediate rolling and 
adhesion of homing cells before extravasation. Very late antigen 4 (VLA-4) and 
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VLA-5 integrins have been found to participate in HSC homing to the BM (van 
der Loo, Xiao et al. 1998; Kollet, Spiegel et al. 2001). Moreover, SDF-l has been 
shown to increase adhesiveness of the integrins VLA-4 and LF A-I to their 
respective endothelial ligands (Peled, Petit et al. 1999). 
Together, these results propose SDF-l as key player in regulating HSC 
homing and suggest that several pathways are involved in its action. 
1.1.5 HSC transdifferentiation 
As discussed above, the adult stem cell has been believed for long time to be able 
to differentiate only in the lineages belonging to the resident organ/tissue. 
However, several recent studies have claimed that adult stem cells may 
transdifferentiate in response to particular external stimuli. Transdifferentiation is 
the conversion of a cell of one tissue lineage into a cell of an entirely distinct 
lineage, with concomitant loss of the tissue-specific markers and function of the 
original cell type, and acquisition of markers and function of the 
transdifferentiated cell type. Indeed, some groups have reported that BM cells 
contribute to the formation of non-blood cells within different tissues (Asahara, 
Murohara et al. 1997; Ferrari, Cusella-De Angelis et al. 1998; Gussoni, Soneoka 
et al. 1999; Petersen, Bowen et al. 1999; Lagasse, Connors et al. 2000; Theise, 
Badve et al. 2000; Jackson, Majka et al. 2001; Krause, Theise et al. 2001; Lyden, 
Hattori et al. 2001; Orlic, Kajstura et al. 2001; Grant, May et al. 2002; Theise, 
Henegariu et al. 2002). Surprisingly, a significant number of following studies 
failed to detect these contributions in similar experimental system (Castro, 
Jackson et al. 2002; Wagers, Sherwood et al. 2002; Choi, Uchino et al. 2003; De 
Palma, Venneri et al. 2003; Ono, Y oshihara et al. 2003; Vallieres and Sawchenko 
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2003). The reason for this apparent irreproducibility of the first set of experiments 
is not entirely clear, but could be partially linked to different models and detection 
strategies. There are also two alternative explanations. The first is related to the 
purity of the test population; in fact, it is possible that the supposed 
transdifferentiation was in reality due to the contribution of distinct contaminant 
cells, since most of the studies inferred such activity following transplant of large 
numbers of heterogeneous populations. The second is a mechanism known as cell-
cell fusion; by this mechanism a haematopoietic cell could contribute to the 
formation of a non-haematopoietic tissue fusing to a resident cell, rather then 
transdifferentiating. Thus, after a first wave of excitement, the scientific 
community is now cautious about adult stem cell transdifferentiation, which is 
now believed to be, if real, extremely rare~ 
1.1.6 Markers and purification 
HSCs are rare cells among the haematopoietic cell population residing in the BM 
and their isolation from the BM is further complicated because these cells lack a 
distinctive phenotype. The use of flow cytometry techniques allowed the isolation 
of HSPCs, based on the ~xpression of surface markers (Visser, Bauman et al. 
1984; Muller-Sieburg, Whitlock et al. 1986). Nevertheless, to date, a single HSC-
specific marker has not been identified. 
The most studied animal model for haematopoiesis is the mouse, where 
several HSC markers have been discovered. Among these markers, the most used 
are c-kit (the tyrosine kinase receptor of stem cell factor - SCF), Thy-l (a 
transmembrane protein present on HSCs and lymphocytes) and Sca-l (Stem Cell 
associated Antigen); moreover, since HSPCs do not express lineage markers, it is 
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possible to use a combination of lineage specific antigens to negatively select 
differentiated/committed cells (Baum, Weissman et al. 1992; Morrison, Wandycz 
et al. 1997). Using this combination of cell markers it is possible to isolate a 
population of cells, called KTLS (c_kitpositive/Thy_llow/Lineagenegativellow/Sca_ 
IpositiVj highly enriched in HSCs (Uchida and Weissman 1992; Uchida, 
Tsukamoto et al. 1998). Moreover, very recently, it has been shown that SLAM 
receptors are differentially expressed in haematopoietic stem versus progenitor 
cells, and that they can be used to isolate a highly pure population of HSCs (Kiel, 
Yilmaz et al. 2005; Yilmaz, Kiel et al. 2006). 
Less predictive surface markers have been established for the isolation of 
human HSCs. Among these, the more widely used is CD34, a heavily 
glycosylated type I transmembrane protein belonging to the sialomucin-like 
adhesion molecule family. This antigen was initially discovered in an attempt to 
develop antibodies specifically· directed against human marrow cells, but not 
mature blood cells (Civin, Strauss et al. 1984). CD34 is expressed by 
stem/progenitor cells and is down-regulated during differentiation (Civin, Strauss 
et al. 1984; Katz, Tindle et al. 1985; Andrews, Singer et al. 1986; Strauss, Rowley 
et al. 1986; Andrews, Singer et al. 1989; Krause, Fackler et al. 1996); it is also 
expressed by small vessel endothelial cells and by some fibroblasts (Fina, 
Molgaard et al. 1990; Brown, Greaves et al. 1991). It has also been found that the 
more primitive haematopoietic progenitors are CD34positivelbrigh\ while the more 
committed ones are CD34positive/dim (Andrews, Singer et al. 1989; Krause, Ito et al. 
1994); this different level of expression allows for further enriching the 
population of primitive HSPCs. The physiological function of this molecule is still 
not yet clear, although its involvement in adhesion and localization of HSPCs in 
the BM niche has been postulated (Fina, Molgaard et al. 1990; Healy, May et al. 
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1995). In the BM niche, the CD34positive cells represent 1.5% of the mononucleated 
cells, while in the peripheral blood they are more rare (0.1-0.5%) (Civin, Strauss 
et al. 1984; Civin, Banquerigo et al. 1987; Loken, Shah et al. 1987). Although 
CD34 is commonly used to purify HSPCs, there is some evidence that its 
expression may vary with the activation stage of the cells (Osawa, Hanada et al. 
1996; Bhatia, Bonnet et al. 1998; Sato, Laver et al. 1999; Zanjani, Almeida-
Porada et al. 1999; Dao, Arevalo et al. 2003; Hess, Karanu et al. 2003; Zanjani, 
Almeida-Porada et al. 2003). A confounding issue is that whereas some studies 
suggested that the more primitive HSCs are CD34negative and that they are the 
precursors of the CD34positive population (Osawa, Hanada et al. 1996; Bhatia, 
Bonnet et al. 1998; Sato, Laver et al. 1999), other studies proposed that 
CD34positive cells transplanted in mice can generate in vivo CD34negative cells (Dao, 
Arevalo et al. 2003). 
In association with CD34, other antigens can be used to further enrich 
HSCs. The most frequently used marker is CD38 (Terstappen, Huang et al. 1991; 
Cardoso, Li et al. 1993; Randall, Lund et al. 1996; Novelli, Ramirez et al. 1998). 
This transmembrane protein has a higher expression in committed progenitors 
(both lymphoid and myeloid) than primitive HSCs, so that its use in combination 
with CD34 (CD34positiveCD38negative selection) allows for the enrichment of more 
pure stem cells (Xiao and Dooley 2000). Moreover, human HSCs, similar to 
murine HSCs, do not express surface markers that are associated with the terminal 
maturation of blood cells, thus enabling the selection of HSPCs based on the 
exclusion of cells expressing lineage-specific markers (lineage negative selection). 
Other selection procedures have been developed based on markers 
expressed by CD34+ cells. One such marker is CD133 (also known as ACI33), 
which is expressed only by the CD34positivelbright fraction (Miraglia, Godfrey et al. 
23 
1997; Yin, Miraglia et al. 1997). Others are the vascular endothelium grow factor 
receptors 1 and 2 (VEGFR-l and VEGFR-2 or KDR), c-kit (CDI17; stem cell 
factor receptor), CD90 (Thy-I) and CDI09 (Craig, Kay et al. 1993; Murray, 
Bruno et al. 1999; Ziegler, Valtieri et al. 1999; Hattori, Heissig et al. 2002). 
Beyond the use of surface markers, it has been shown the possibility to use 
metabolic markers for HSPCs, such as rhodamine and Hoechst 33342 dye 
loading. The dye efflux depends on the expression of membrane pumps. High 
expression of such membrane pumps is associated with primitive HSPCs 
(Goodell, Brose et al. 1996; Goodell, Rosenzweig et al. 1997). The Hoechst 
33342-low cells, termed side population (SP), were found to overlap with HSPCs 
in the mouse (Goodell, Brose et al. 1996). SP cells have been identified also in the 
human BM (Goodell, Rosenzweig et al. 1997) and in foetal liver (Uchida, Fujisaki 
et al. 2001). However, Hoechst 33342 intercalates into DNA and is slightly toxic, 
thus its use for the selection of HSCs is not suitable for transplantation. Moreover, 
the dye efflux properties could be related to the cell cycle status of the cells (Cai, 
Weiss et al. 2004). Another metabolic marker associated with immature cells is 
the aldehyde dehydrogenase (ALDH), whose expression correlates with high stem 
cell activity in vivo (Storms, Trujillo et al. 1999; Fallon, Gentry et al. 2003; Hess, 
Meyerrose et al. 2004). 
It should be noted that all the strategies described above allow for 
enrichment of HSCs together with more committed progenitors. This 
heterogeneous population is useful for transplant purposes (because committed 
progenitors radioprotect the host), but it hampers the study of stem cell biology. 
To this aim, in the future it would be desirable to develop sorting procedures that 
enable the isolation of pure primitive HSCs. 
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1.1. 7 Functional Assays 
Because of the lack of specific markers and the functional heterogeneity of any 
population enriched in HSPCs, indirect and retrospective functional assays are 
required to characterize HSCs. 
Two sets of functional assays have been developed in the last 30 years: the 
in vitro assays and in vivo assays. The first set typically evaluates two parameters: 
cell proliferation and differentiative potential. Indeed, primitive progenitor must 
accomplish a high number of divisions before they produce differentiated cells, 
whereas lineage-committed progenitors differentiate in a shorter time. However, 
the in vitro assays fail to assess some features -that are critical for the 
characterization of HSCs: long-term self-renewal and multilineage differentiation. 
The in vivo assays are used to evaluate these latter parameters. 
1.1.7.1 In vitro assays 
In vitro assays can be divided in short-term and long-term assays. Short-term 
assays identify committed progenitors, while long-term assays are used to 
characterize primitive progenitors. 
1.1.7.1.1 Short-term in vitro assays 
The prototype of this kind of assay is the Colony-Forming Cell (CFC) assay. This 
is a clonogenic assay, which is based on the ability of haematopoietic progenitors 
to give rise to different cell lineages. Haematopoietic cells are seeded at low 
density in a semi-solid medium containing grow-factors that induce 
differentiation. As they are immobilized, the progenies of each single cell 
accumulate in tight colonies, which are scored, 2 weeks after seeding, for 
morphology. Several types of myeloid progenitors can differentiate 
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simultaneously in the same culture medium (Broxmeyer 1984), whereas CFC 
assay culture medium for lymphoid progenitors have not been well established. In 
this assay the number and type of haematopoietic progenitors seeded is evaluated, 
distinguishing granulocyte colonies (CFC-G), macrophage colonies (CFC-M) and 
erythroid colonies (CFC-E or BFU-E) (Figure 1.4). Moreover, progenitors at 
different maturation stages can be recognized based on time required to generate 
differentiated cells and the size of colony. Large colonies composed of different 
types of progenitors and differentiated cells are identified as colony-forming cell 
granulocyte-erythroid-macrophage-megacaryocyte (CFC-GEMM). It has been 
postulated that these CFC-GEMM colonies indicate the presence of a high 
proliferative multipotent progenitor in the culture (Ash, Detrick et al. 1981). 
H SPCs enriched 
population 
o ., ~ 10-14 I. " days . 
CFC-G 
CFC-M 
CFC-E 
CFC-GEMM 
Figure 1.4. CFC assay. HSPCs are seeded at low-density in semi-solid medium. After 10-14 
days colony number and morphology are scored by microscopy. For a detailed description of 
the assay see relative paragraph in the Methods section. 
However, clonality of these colonies had to be proven to rule out that cells within 
a mixed colony were produced by two overlapping restricted progenitors and not 
by one multipotent progenitor cell. Only replating of cells from the primary 
colony in secondary assays can unmask the full potential of the multipotent 
progenitors. Still, more primitive immature progenitors cannot be detected by this 
assay, because the time of culture is too short for these progenitors to produce 
differentiated cells. 
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1.1.7.1.2 Long-term in vitro assays 
Every system designed to detect immature progenitors extends beyond 5 weeks. 
This long-term culture eliminates mature progenitors that exhaust by the time of 
analysis. A common feature of the long-term systems is the use of feeder cells that 
provide growth factors, which surrogates the complexity of the BM niche. 
The most frequently used long-term in vitro assay is the Long-Term Cell-
Initiating Culture (LTC-IC). In this assay haematopoietic cells are seeded on a 
fibroblast monolayer and their ability to give rise to daughter cells able to form 
colonies is evaluated after 5-8 weeks by performing standard CFC assays 
(Sutherland, Eaves et al. 1989). Since cells are usually maintained in myeloid 
conditions, lymphoid precursors . are usually not detected; switching of the 
medium to lymphoid by changing certain factors can reveal lympho-myeloid 
progenitors (LTC-ICML or ML-IC) and induce B-cell differentiation (Lemieux, 
Rebel et al. 1995; Punzel, Wissink et al. 1999), although T-cell differentiation has 
never been observed with this assay. In an attempt to identify a cell whose 
longevity resembles that of a stem cell, LTC-IC has been extended to up to 10-12 
weeks (ELTC-IC), but it is still unclear if this extension of the culture period can 
help identifying more primitive progenitors (Hao, Thiemann et al. 1996). 
An alternative long-term in vitro assay is represented by the cobblestone 
area-forming cell (CAFC) assay. The difference between CAFC and L TC-IC is 
the use of a different feeder layer that allows the growth of dense hematopoietic 
colonies tightly associated with adherent cells (Ploemacher, van der Sluijs et al. 
1989; Breems, Blokland et al. 1994). Thus, re-seeding of cells in semi-solid 
medium is not required in this assay. LTC-IC and CAFC assays have been though 
for long time to identify the same progenitor population, indeed it has been shown 
that human week-6 CAFC are equivalent to week-5 LTC-IC (Pettengell, Luft et 
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al. 1994). However, this view has been recently challenged (Denning-Kendall, 
Singha et al. 2003). 
The discussed long-term assay are, to date, the best performing in vitro 
assays available to characterize haematopoietic progenitors, however it should be 
highlighted that they fail to detect lymphoid differentiation. Thus, other assays 
have been developed in order to determine the lymphoid potential of 
haematopoietic progenitors. B-cell potential is usually assessed in liquid culture 
on stromal feeders after 5-6 weeks in low serum conditions (Cumano, Dorshkind 
et al. 1990; Baum, Weissman et al. 1992; Barker and Verfaillie 2000; Ficara, 
Superchi et al. 2004). T-cell potential is more difficult to assess in vitro, mainly 
because of the need of the thymus three-dimensional structure for T-cell 
maturation. As surrogate of thymic architecture, murine foetal thymus organ 
cultures (FTOC) have been used to identify human T-cell progenitors, even 
though this chimera (human/mouse) does not allow for sustained proliferation and 
full differentiation of human progenitors (Barcena, Galy et al. 1994; Plum, De 
Smedt et al. 1994; Robin, Bennaceur-Griscelli et al. 1999; Weekx, Snoeck et al. 
2000). A promising strategy to assess T-cell differentiation is the use of 
genetically engenired OP9 murine stromal cells. These cells, which have been 
shown to support in vitro the differentiation of hematopoietic progenitors into 
multiple lineages, including B cells, have been shown to support T-cell 
differentiation of early murine progenitor cells when engenired to costitutively 
express the Notch ligand Delta-1 (Schmitt and Zuniga-Pflucker 2002). 
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1.1.7.2 In vivo Assays 
In vitro assays can identify haematopoietic progenitors, but not primitive stem 
cells, because they cannot assess self-renewal and full multilineage (lympho-
myeloid) differentiation. In order to assess these features it is necessary to use 
indirect and retrospective assays in which human cells are transplanted into an 
animal model (xenotransplant model). This setting allows for tracking the injected 
cells for a long period (monitoring self-renewal) and to analyse their ability to 
produce different mature cell lineages (monitoring multilineage differentiation). It 
should be noted that the outcome of these assays is affected also by the ability of 
HSCs to home to the BM of the recipient. 
The readouts of the xenotransplant models are usually flow cytometry 
analysis with specific antibodies of BM, peripheral blood and/or other 
haematopoietic organs (Le. spleen or thymus) in order to evaluate the extent of the 
human graft and evaluate differentiation of the human cells towards the different 
lineages. Some in vitro assays, such as CFC assay, are also usually performed 
from cells derived from BM of transplanted mice, in order to verify the ability of 
engrafting cells to give rise to clonogenic progenitors following the in vivo time 
window.; Recently, a novel set of tracking technologies based on magnetic 
nanoparticles and quantum dots have been proposed (Gao, Cui et al. 2004; Perez, 
Josephson et al. 2004) to detect by in vivo imaging techniques (MRI or laser-
based macro illumination systems) limiting numbers of cells in a non-invasive 
experimental setting. However, because these molecules are lost during cell 
proliferation, their application in HSC xenotransplant settings is limited to the 
tracking of HSC homing and do not allow the long-term evaluation of HSC 
engraftment. Moreover, issues regarding toxicity and catabolism of these particles 
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and the need of refining the resolution of analysis have limited the applications of 
these in vivo imaging techniques to date. 
In 1961 Till and McCulloch developed the first in vivo repopulation assay, 
transplanting murine BM, and identified a population of cells that were able to 
give rise to mixed colonies in the spleen of mice recipient 12 days after the 
transplant (Till 1961). These Colony-forming Units-Spleen (CFU-Ss) were 
initially regarded as HSCs. However, later studies demonstrated that the short 
time in which colonies were generated was not enough for stem cells to 
differentiate and that these CFU -Ss were progenitors rather than true primitive 
stem cells (Morrison and Weissman 1994; van der Loo, van den Bos et al. 1994). 
In the following years, transplant models that characterize murine HSCs have 
been established, although transplant models are still missing that satisfactorily 
characterise human HSCs. 
The most used xenotransplant model for human HSC characterization is 
the NODlLt-Sz-Scid/Scid (NOD/SCID - nonobese diabetic / severe combined 
immunodeficient) mouse (Shultz, Schweitzer et al. 1995) (Figure 1.5). 
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Figure 1.5. SRC assay. NOD/SCm mice are sublethally irradiated 24 hours before intravenous 
injection of human HSPCs. 6-10 weeks after transplant mice bone marrow is harvested and 
engraftment and transduction levels are determined by flow citometry, CFC assay or Real-time 
quantitative PCR. For a detailed description of the assay see relative paragraph in the Methods 
section. 
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In pioneering studies Dick's group showed that intravenous injection of human 
BM or cord blood (see paragraph 1.1.8 Sources) cells into sub-lethally irradiated 
SCID mice resulted in engraftment of primitive cells that were able to produce 
L TC-ICs, CFCs as well as differentiated myeloid, lymphoid and erythroid cells 
(Lapidot, Pflumio et al. 1992; Vormoor, Lapidot et al. 1994; Dick 1996). Because 
of these properties, the primitive cells were considered to be closely related to 
HSCs and were defined as SRCs (SCID Repopulating Cells). Later studies 
showed that SCID mice were not ideal recipient of human transplants, because 
they possessed antigen non-specific immunity, and proposed NOD/SCID mice as 
a better model to support human engraftment (Larochelle, Vormoor et al. 1995; 
Lowry, Shultz et al. 1996; Pflumio, Izac et al. 1996; Cashman, Lapidot et al. 
1997). Indeed, in NOD/SCID mice the DNA repair gene defect of SCID mice, 
which severely impaIrs B- and T-cell development, is combined with impaired 
natural killer cell activity, absence of complement activity and the defect in 
macrophage function of the NOD mice (Shultz, Schweitzer et al. 1995). As in BM 
transplantation clinical settings, conditioning of the recipient before injection of 
the cells is necessary in order to ablate host BM cells and reduce competition 
between injected and host cells. The widely used conditioning is irradiation. 
Unfortunately, NOD/SCID mice are radiosensitive, thus permitting only low 
o irradiation doses and, consequently, variable levels of engraftment. It has been 
demonstrated that irradiation induces production of chemoattractant factors by 
osteoblasts and endothelial cells in the BM, thus favouring homing of transplanted 
cells (Ponomaryov, Peled et al. 2000). 
Kinetics studies showed that only 0.1 % of the injected CFCs and LTC-ICs 
are detectable in the BM of transplanted immunodeficient mice 2 days after cell 
injection and that there is a large expansion of these cells over the next 4 weeks, 
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window as long as human life-span. In this view, non-human primates would 
appear as more adapted than mice to characteriie human HSCs. Unfortunately, the 
existing immunological barriers do not allow transplant of human cells in 
primates, thus requiring transplantation in utero when foetuses are 
immunologically tolerant. This strategy has been successfully applied by 
Zanjani's group, which used the sheep as large animal model. They showed 
persistence of human cells several years after transplant, with myeloid and 
lymphoid (T and B) differentiation (Porada, Porada et al. 2004). However, the 
complexity of these techniques may limit the use of these models. 
An alternative approach to test HSC self-renewal in a long-term setting is 
serial transplantation in immunodeficient mice, in which BM of engrafted animals 
is transplanted into secondary recipients a~d, possibly, from secondary to tertiary 
mice. In this setting, o.nly long-term self-renewing HSCs will maintain the ability 
to engraft and repopulate, whereas less primitive HSC will exhaust. The 
feasibility of this approach has been shown by different groups (Peled, Petit et al. 
1999; Guenechea, Gan et al. 2001; Ailles, Schmidt et al. 2002; Dao, Arevalo et al. 
2003). Moreover, taking advantage of clonal tracking and gene marking by 
lentiviral vectors, we have identified a single multipotent and long-term self-
renewing HSC able to repopulate primary and secondary recipient and 
differentiate into both lymphoid and myeloid lineages (Ailles, Schmidt et al. 
2002). 
1.1.8 Sources 
For both research and clinical applicat.ions three tissue sources are widely used to 
purify HSCs: BM, mobilised peripheral blood (MPB) and umbilical cord' blood 
(CB). 
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Although the presence of SRCs in all of these sources has been 
demonstrated (Lapidot, Ptlumio et al. 1992; Vormoor, Lapidot et al. 1994; Hogan, 
Shpall et al. 1997), SRCs seem to be more abundant and/or endowed with higher 
proliferative potential, engraftment and self-renewal ability when isolated from 
CB (Wang, Doedens et al. 1997; RosIer, Brandt et al. 2000). CB is more easily 
available than the other tissues and for this reason it is the most exploited source 
of HSCs for research purposes. However, in a clinical setting, CB may not contain 
sufficient numbers of HSCs for transplantation in adult individuals (Abboud, Xu 
et al. 1992; Rubinstein, Carrier et al. 1998). To solve this issue many efforts have 
been made to define a protocol for CB-derived HSC expansion (see paragraph 
1.2.1.2 HSC culture and gene transfer). 
For a long time, BM has been used as a source of HSCs for clinical 
applications. Later on,. MPB has been exploited as an alternative source. MPB is 
enriched in HSCs thanks to the injection of growth factors, such as granulocyte-
colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating 
factor (GM-CSF) and/or SCF into the donor. These factors induce proliferation 
and/or mobilization of BM HSCs. Some clinical transplantation trials that used 
MPB as source of HSPCs have suggested that MPB-derived HSPCs induce a 
more rapid myeloid recovery than the BM-derived counterparts (Bensinger, 
Weaver et al. 1995; Korbling, Przepiorka et al. 1995). 
As discussed above (see paragraph 1.1.4 Molecular mechanisms regulating 
HSCs), external stimuli have an important role 'in regulating HSC features. For 
this reason, it is commonly believed that HSCs derived from different sources 
possess different characteristics, even though a comprehensive analysis. is still 
missing. Indeed, some studies demonstrated different frequency of proge"nitors, 
cell cycle status, gene expression profiles and engraftment ability of HSCs derived 
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from CB, BM or MPB. In particular, it has been found that MPB-derived HSPCs 
are less cycling and more susceptible to apoptosis than BM-derived HSPCs, and 
this has been linked to a different gene expression profile in the two cell 
population (Uchida, He et al. 1997; Steidl, Kronenwett et al. 2002). Moreover, a 
lower engraftment ability and proliferative potential of BM- and MPB-derived 
HSPCs have been shown when compared to CB-derived HSPCs (Ueda, Yoshida 
et al. 2001; Ng, van Kessel et al. 2004; Theunissen and Verfaillie 2005). 
Because of the differences in the biological properties of HSCs derived 
from different sources~ the most appropriate source has to be chosen according to 
each application. 
1.2 Gene transfer into haematopoietic stem cells 
HSCs are attractive targets for the gene therapy of a variety of inherited and 
acquired genetic diseases, including immunodeficiencies, metabolic disorders and 
haemoglobinopathies. These disorders have been treated for a long time by 
al.logeneic bone marrow transplantation. However, the development of graft 
versus host diseases in the transplanted patients is not infrequent in this setting. To 
overcome this problem, transplant of gene corrected autologous HSCs has been 
proposed as alternative therapy. HSCs can be transduced ex vivo and be re-infused 
in the donor where they self-renew and generate large numbers of gene corrected, 
differentiated progeny, theoretically for the lifespan of the host. To be efficacious, 
the genetic material must be inserted into the target cell chromatin in order to be 
maintained during HSC proliferation and differentiation processes. Moreover, 
efficient gene transfer should occur in primitive HSCs, without affecting their 
features. 
. 35 
Several gene transfer methods have been developed. Non-viral approaches 
take advantage of physical delivery methods (Le. direct DNA injection, 
electroporation, nucleofection, gene guns) and chemical approaches (Le. 
liposomes). The low frequency of integration into the target cell chromatin has 
limited the application of gene transfer in HSC by non-viral approaches. A new 
non-viral approach based on a transposon system (Le. sleeping beauty transposon) 
has been recently developed; although it should ensure integration of the genetic 
material into the target cell chromatin, efficiency and safety of this system still 
need to be evaluated in HSCs (for a review see (Hackett, Ekker et al. 2005). The 
more widely used viral approaches are based on Retrovirus, Adenovirus, Adeno-
Associated virus, Herpex Simplex virus and Flavivirus (Tomanin and Scarpa 
2004) and take advantage of the viral life ,cycle to transfer genetic material into 
target cells. Since viral methods are usually more efficient than non-viral 
methods, they have been largely studied as tool for HSC gene transfer. Moreover, 
some viral vectors allow for stable integration into the cell chromatin. 
Nevertheless, concerns about the safety of the viral sequences contained within 
the gene transfer vector, the risk of insertional mutagenesis and the potential 
immunogenicity of the vector particles have been raised, 
1.2.1 HSC gene transfer by viral vectors 
During the last twenty years the viral vectors most exploited for HSC transduction 
. ' 
(abortive infection) have been those derived from Retroviruses, mainly because of 
their ability to integrate into the target cell chromatin. 
In addition to retroviral vectors, other viral vectors have been tested. 
Vectors derived from Adenovirus have high titers, wide tropism and the ability to 
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transfer relatively large genes. However, their high immunogenicity, their 
inability to integrate in the host chromatin and the absence of viral receptors on 
HSCs have limited their application. Recently, new strategies to generate hybrid 
adenoviral vectors that overcome some of these limitations have been developed, 
but definitive evidence of their efficiency is still missing (for a review see 
(Marini, Shayakhmetov et al. 2002). Contrasting results have been shown about 
HSC transduction by Adeno-Associated virus-derived vectors (Alexander, Russell 
et al. 1997; Hargrove, Vanin et al. 1997; Nathwani, Hanawa et al. 2000). 
However, their tendency to remain in episomal forms limits their application in 
the haematopoietic field. 
1.2.1.1 Retroviruses-derived vectors 
Retroviruses are RNA viruses, whose replication strategy is based on an 
intermediate DNA form (provirus), which stably integrates into the infected cell 
fSU 
FR 
Figure 1.6. Retroviral virion. The following 
viral proteins are depicted: SU: surface; TM: 
transmembrane; RT: retrotranscriptase; IN: 
integrase; NC: nucleocapsid; CA: capsid;" PR: 
protease; MA: matrix. 
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chromatin. Retroviruses possess a 
RNA genome, a proteic core 
(capsid) and a lipidic envelope, in 
which viral glycoproteins are 
inserted (Figure 1.6). This family 
of viruses has been divided into 
three subfamilies: Oncoviruses, 
Lentiviruses and Spumaviruses 
(Coffin, Hughes et al. 2000). To 
date, vectors for HSC gene transfer 
have been developed from viruses 
belonging to each of these subfamilies. However, while oncoretroviral and 
lentiviral vectors have been extensively studied, Spumavirus-derived vectors have 
been applied only recently to the HSC field. 
Vector design is based on the spatial separation between cis-acting and 
trans-acting sequences present in the retrovirus genome. Indeed, retroviral vectors 
are constructed starting from a wild-type virus, from which portions of the 
genome (trans-acting sequences) that encode for protein requested for the viral 
life cycle have been removed. Since these types of transfer vector contain only 
cis-acting sequences, production of retroviral vectors relies on the supply of the 
products of the deleted sequences by separated plasmid(s) (Figure 1.7) (Kay, 
Glorioso et al. 200 1). 
Retrovirai Genome 
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Figure 1.7. Retroviruses-derived 
vectors. Retroviral vectors are 
constructed by splitting cis- and 
trans-acting sequences of the 
retrovirus genome in different 
constructs. Cis-acting (regulatory) 
sequences, including the 
encapsidation signal (\jJ), are present 
only in the transfer vector containing 
the gene of interest, whereas trans-
acting (encoding for viral proteins) 
sequences are provided by helper 
plasmids for the production of the 
vectors. 
This strategy can be based on either co-transfection procedures or transfection of 
the transfer vector into packaging cell lines stably producing the viral proteins. In 
both cases, all the structural proteins needed for vector production are present 
only in the producer cells. Indeed, in the target cells the sequences encoding for 
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viral protein will be absent, because they lack the signals for encapsidation, and 
thus replication of the vector will be inhibited, unless recombination events occur. 
Retroviral tropism is dictated by the envelope glycoproteins. Thanks to the 
viral assembling process and to the strategy used to generate these vectors, it is 
possible to exchange the wild-type envelope proteins with other envelope proteins 
(a process termed pseudotyping) and, thus, modify the tropism of the vector. 
Different envelopes have been shown to efficiently pseudotype retroviral vectors 
and target haematopoietic cells (Movassagh, Desmyter et al. 1998; Kelly, 
Vandergriff et al. 2000; Gatlin, Melkus et al. 2001; Ailles, Schmidt et al. 2002; 
Sandrin, Boson et al. 2002). 
1.2.1.1.1 Oncoretroviruses-derived vectors 
The vast majority of Oncoretroviruses (also known as y-Retroviruses)-derived 
vectors (RVs) are based on Moloney murine leukaemia virus (MLV). In vivo 
transplantation studies established RV ability to transduce murine HSCs (Dick, 
Magli et al. 1985; Keller, Paige et al. 1985). However, initial clinical trials of 
autologous bone marrow transplantation with retrovirally gene marked cells on 
cancer patients revealed a very low frequency of transduced cells (Brenner, Rill et 
al. 1993; Deisseroth, Zu et al. 1994; Rill, Santana et al. 1994; Dunbar, Cottler-Fox 
et al. 1995), even though transduced cells were present up to 18 months after 
transplantation, suggesting transduction of primitive HSCs (Dunbar, CottIer-Fox 
et al. 1995). These results uncovered both the potential and the limitations ofRVs 
in HSC gene transfer; these limitations are mainly related to the inability of RVs 
to transduce quiescent cells, because they need nuclear membrane disruption, and 
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thus mitosis, to have access to chromatin (Miller, Adam et al. 1990; Roe, 
Reynolds et al. 1993). 
Since HSCs are mostly non-proliferating cells, they require a cytokine 
stimulation that trigger them to the cell cycle in order to be transduced by RV s. 
Thus, all the protocols developed for retroviral vector-mediated HSC gene 
transfer involve a prolonged ex vivo manipulation and/or induction of cell cycle 
entry and proliferation (Larochelle, Vormoor et al. 1996; Conneally, Eaves et al. 
1998; Dao, Taylor et al. 1998; Barquinero, Segovia et al. 2000; Guenechea, Gan 
et al. 2001), conditions that were shown to compromise HSC potential, in 
particularly by decreasing HSC frequency and long term repopulating ability 
(Glimm, Oh et al. 2000; Guenechea, Gan et al. 2001). Nevertheless, three 
successful clinical trials for SCID disease have demonstrated that R V s can be 
useful tools for HSC .. based gene therapy (Cavazzana-Calvo, Hacein-Bey et al. 
2000; Aiuti, Slavin et al. 2002; Gaspar, Parsley et al. 2004). Two issues, however, 
should be highlighted: 1) there is still not evidence that haematopoietic 
reconstitution was due to stem rather than progenitor cell engraftment; 2) a major 
factor in the succ.essful haematopoietic reconstitution by gene-corrected cells was 
the selective growth advantage conferred in vivo to transduced cells, that enable 
the amplification of a small input of transduced HSPCs. 
Finally, .. other concerns have been raised about HSC transduction by RVs. 
The first is linked to the discovering of promoter silencing mechanisms that shut 
down trans gene expression in these vectors (Challita and Kohn 1994; Gram, 
Nielsen et al. 1998; Klug, Cheshier et al. 2000; Zentilin, Qin et al. 2000; Pannell 
and Ellis 2001). Another issue is related to vector safety, since insertional 
mutagenesis leading to leukaemia associated to retroviral vector insertion has 
been demonstrated in a recent clinical trial (Hacein-Bey-Abina, von Kalle et al. 
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2003; Hacein-Bey-Abina, Von Kalle et al. 2003) (see paragraph 1.2.1.4 Safety of 
retroviral vectors). 
1.2.1.1.2 Lentiviruses and derived vectors 
Lentiviruses are complex retroviruses. The most studied lentivirus is the human 
immunodeficiency virus 1 (HIV -1). Lentiviruses differ from oncoretroviruses for 
their genome, which encodes for the structural proteins common to all retroviruses 
and for a set of regulatory and accessory proteins, which are mainly responsible 
for the pathogenicity of the virus (Anderson and Hope 2004) (Figure 1.8). 
Figure 1.S. HIV genome. The principal HIV cis-acting (italic font) and trans-acting (regular 
font) sequences are indicated. L TR: long terminal repeat; it contains the viral 
promoter/enhancer region. PBS: primer binding site of the retrotranscriptase. SD: splice donor. 
\II: encapsidation signal. (c )PPT: (central) polypurine tract. RRE: Rev-responsive element. 
PolyA: polyadenilation signal. GAG, PRO, POL and ENV genes are present in all retroviruses. 
GAG encodes for the structural proteins Capsid, Matrix and Nucleocapsid. PRO encodes for 
the Protease enzyme. POL encodes for the enzymes Retrotranscriptase and Integrase. ENV 
encodes for the envelope glycoproteins Surface and Transmembrane. VIF, VPR (R), VPU (U), 
TAT, REV and NEF genes encode for regulatory and accessory proteins and are characteristic 
of the mv genome. 
mv regulatory proteins are TAT and REV. TAT is a potent trans-
activator of transcription that, binding to the TAR sequence in the U3 L TR region, 
activates the transcription of HIV genome. Alternative splicing of the full-length 
transcript generates the array of mRNAs required for expression of all viral genes. 
The full-length transcript itself also serves as a translational template, as well as 
the source of new viral genomes. Thus, the unspliced genome must be transported 
from the nucleus to the cytoplasm, an event that ordinarily does not occur in the 
cell. This problem is overcome by REV, which binds the RRE sequence of the 
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transcribed genome and allows nuclear export of the unspliced RNA. Since TAT 
induces a number of potentially detrimental cellular responses (for a review see 
(Peruzzi 2006), it has been deleted in the design of late generation lentiviral 
vectors. This is possible if the U3 region of the 5' LTR in the transfer vector 
construct is replaced by constitutively active promoter sequences, thus rendering 
TAT dispensable (see below Figure 1.10). Instead, REV is the only 
regulatory/accessory protein that has been maintained in the design of late 
generation lentiviral vectors. Indeed, its activity is required to express the transfer 
vector RNA. The presence of REV in the vector system· has also allowed the 
development of lentiviral vectors containing complex genetic elements, such as 
introns. 
HIV accessory proteins are Vif, Vpr, Nef and Vpu. Vif is incorporated in 
the virion and is required for replication in "nonpermissive" cells, which include 
the natural targets of HIV -1 (lymphocytes, monocytes, dendritic cells, and brain 
, 
microglia). In "permissive" cells (most HIV -1-infectable cell lines), Vif is 
completely dispensable. In "nonpermissive" cells delta-Vif HIV are unable to 
complete reverse transcription (von Schwedler, Song et al. 1993). This phenotype 
can be explained by recent studies that demonstrated that Vif counteracts the 
activity of a potent restrictive factor of HIV -1 replication incorporated in the 
virions produc~d by "nonpermissive" cells (see paragraph 1.2.1.3.2 APOBEC 
proteins). It has also been suggested that Vif stabilizes the viral core and, 
associating with the HIV genomic RNA, directs efficient reverse transcription by 
affecting the nucleic acid components of the RT complex (Ohagen and Gabuzda 
2000) (Dettenhofer, Cen et al. 2000). . 
Vpr is present in the viral particle and it has been shown to induce Ch cell 
cycle arrest (He, Choe et al. 1995). As expression of the viral genome is optimal· 
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in the G2 phase of the cycle, Vpr increases virus production by delaying infected 
cells at this point of the cell cycle. Vpr has also proposed to playa role in the 
nuclear import of the pre integration co~plex (see below). 
Nef has several roles in the HIV -1 life cycle. One of these is the down-
regulation of the trans-membrane molecules CD4 and MHC-I; down-regulation of 
CD4, which is the receptor for HIV envelope glycoproteins, helps budding of the 
virus from infected cells by preventing binging of the envelope proteins to this 
molecule at the cell membrane level, whereas MHC-I down-regulation protects 
infected cells from recognition and killing by cytotoxic T lymphocytes 
(Mangasarian, Foti et al. 1997). In addition, Nef enhances virion infectivity, likely 
because it is involved in the uncoating and reverse transcription processes (Aiken 
and Trono 1995; Aiken 1997). The exact mechanism of these effects remains to 
be elucidated. 
Vpu mainly acts facilitating virus release. It down-regulates CD4 
expression in the ER to prevent interaction with HIV -1 envelope proteins during 
virus budding and stimulates the release of virions possibly by acting as ion 
. channel. Together with Nef, Vpu also down-regulates expression of MHC-I 
molecules in infected cells (for a review on Vpu see (Bour and Strebel 2003). 
All the HIV accessory proteins have been deleted in the design of late 
generation lentiyiral vectors. This means that these proteins are dispensable in the 
vector system. Indeed, Vif is only required during HIV -1 assembly in cells which 
have a "nonpermissive" phenotype. 293T cells, in which vector particles are 
produced, are "permissive" cells, and thus Vif is not required for infectious 
particle assembly. Vpu down-regulates CD4 expression to prevent interaction 
with HIV -1 envelope proteins. However, the vectors have a heteroiogous 
envelope an~ are produced in cells that do not express CD4. Vpu is also believed 
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to stimulate the release of virions from the cell, but this effect was not observed in 
293T cells. As with Vpu, the CD4-downregulating activity of Nef would 
obviously not be required in this system. However, Nef also functions to promote 
the infectivity HIV -1 virions. The lack of a requirement for Nef may be explained 
by the use of the VSV -G envelope. Aiken (Aiken 1997) showed that pseudotyping 
of HIV -1 with VSV -G, which changes the mechanism of target cell entry to an 
endocytic pathway rather than direct fusion with the plasma membrane, markedly 
suppressed the requirement for Nef. Finally, the lack of a requirement for Vpr in 
most cell types can be explained by the redundancy of nuclear import signals 
present in the PIC, as described below. It should be highlighted, however, that the 
dispensability of the accessory proteins in the lentiviral vector system has been 
demonstrated in permissive cell types. It cannot be excluded that in some less 
permissive primary cells, which could also express restrictive factors (see 
paragraph 1.2.1.3 Retroviral restriction in mammalian cells), some accessory 
proteins can be needed for efficient transduction. 
Beside the regulatory/accessory proteins encoded by lentiviruses and not 
by oncoretroviruses, a major difference between these two families or retroviruses 
resides in the early steps of their life cycle. Indeed, lentiviruses, but not 
oncoretroviruses, are able to cross the intact nuclear membrane and thus can 
integrate into the chromatin of non-proliferating cells (Weinberg, Matthews et al. 
1991; Lewis, Hensel et al. 1992; Lewis and Emerman 1994). Because of the 
relevance of the issue for gene transfer applications, the early stages of lentiviral 
life cycle will be discussed. 
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1.2.1.1.2.1 Early stages oflentivirus life cycle 
The early part of lentivirus life cycle is usually divided in different phases, 
although some of them are strictly linked and occur at the same time. The early 
Figure 1.9. Early stages of lentivirus life 
cycle. The incoming virion particle 
contains two single stranded RNA 
molecules within a protein core, 
surrounded by a lipid bilayer. Upon 
receptor binding and fusion of the viral and 
cellular membrane the core is release into 
the cytoplasm (Entry). The core is then 
disassembled (uncoating) and the RNA 
genome is retrotranscribed in linear double 
stranded DNA (RT: retrotranscription), 
giving rise to the viral preintegration 
complex (PIC). The PIC is transported 
through the cytoplasm and through the 
nuclear membrane. The viral DNA 
integrates into the host chromatin to form 
the provirus. 
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stages of lentivirus life cycle are: entry, uncoating, reverse transcription, nuclear 
import and integration into the host cell chromatin (Figure 1.9). 
Entry is mediated by binding of the viral envelope glycoproteins to 
specific cell membrane receptors. To enter the target cells only one membrane 
molecule is needed for most retroviruses, whereas for HIV -1 a receptor for initial 
binding (CD4) (Maddon, Dalgleish et al. 1986) and a co-receptor (the chemokine 
receptor CCR5 or CXCR4) (for a review see (Berger, Murphy et al. 1999) for the 
fusion between virus and cell membrane are needed. Following fusion, the viral 
core is released into the target cell cytoplasm. Indeed, HIV entering is pH-
independent as' indicated by HIV resistance to drugs blocking endosome 
acidification (McClure, Marsh et al. 1988). 
Immediately after release into the cytoplasm the viral core undergoes a 
progressive disassembly, known as uncoating, and the viral RNA genome is 
retrotranscribed into double stranded DNA by the viral reverse transcriptase. The 
trigger for the beginning of DNA synthesis is not known. However, it appears that 
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initiation of reverse transcription is strictly linked to the uncoating process 
(Zhang, Domadula et al. 2000) and it is possible. that the exposure of the 
retrotranscription complex to the significant concentration of deoxiribonucleotides 
in the cytoplasmic environment is what allows reverse transcriptase to begin to 
act. While the steps of the reverse transcription have been well described (for a 
review see (Telesnitski and Goff 1997), much less is known about the events and 
the proteins (both cellular and viral) involved in the uncoating process. 
Disassembly of the lentiviral core is characterized by dissociation of the Gag 
encoded Capsid protein (B ukrinsky, Sharova et al. 1993; F assati and Goff 2001). 
Still, the composition of the pre integration complex (PIC; also known as reverse-
transcription complex), which is the result of the viral core uncoating, is still not 
fully understood. This is mainly because of technical limits in the isolation of the 
particles and the fact that the vast majority of the particles present in the 
cytoplasm are not on a productive pathway for infection. However, the complexes 
isolated by most protocols retained the Pol encoded proteins (reverse 
transcriptase, protease and integrase), whereas the majority of the Gag encoded 
matrix and nucleocapsid proteins, initially believed to be associated with the PIC 
(Bukrinsky, Sharova et aI. 1993; Miller, Famet et al. 1997), are lost during 
uncoating (Fassati and Goff2001). Some cellular proteins have also been found in 
the HIV PIC. Cyclophilin A, a peptidyl-prolyl isomerase, is brought into the target 
cell inside the viral particle and is apparently important to allow uncoating and 
reverse transcription (Franke, Yuan et al. 1994; Braaten, Franke et al. 1996). 
Moreover, the high mobility group protein HMG I(Y) seems to be recruited by the 
PIC and has been proposed to be important for integration (Famet and Bushman 
1997). 
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Interestingly, it seems that oncoretroviral core persists longer than that of 
HIV, since MLV nucleocapsid, matrix and even capsid proteins are found to be 
associated to the PIC in the vicinity of the nuclear membrane (Bowerman, Brown 
et aI. 1989; Risco, Menendez-Arias et aI. 1995). This difference in uncoating may 
be relevant to the pathways lentiviruses and oncoretroviruses use to access the 
nucleus, as uncoating is likely to be necessary for the ability of HIV to migrate 
through the nuclear pore (see below). 
To reach the nuclear membrane, the particles must travel through the 
cytoplasm. HIV transport has been shown to exploit the cellular cytoskeleton. In 
particular, initial movements at the cell periphery occur in association with actin 
(Bukrinskaya, Brichacek et aI. 1998), while subsequent translocation toward the 
nucleus takes place along the microtubule· network, likely by interaction of HIV 
with the dyne in-dependent motor complex (McDonald, Vodicka et aI. 2002). 
After reaching the nuclear envelope HIV PIC is translocated through the nuclear 
pore, most likely by relying on the cellular nuclear import machinery. For a long 
time the most favoured model for HIV nuclear import has been that the PIC itself 
is karyophilic. Indeed, some viral proteins such as matrix, integrase and Vpr have 
been shown to contain nuclear localization signals (NLSs) in addition to the cis-
acting element central polypurine tract (cPPT) (Bukrinsky, Haggerty et aI. 1993; 
Heinzinger, Bu~insky et aI. 1994; Gallay, Swingler et aI. 1995; Gallay, Hope et aI. 
1997; Vodicka, Koepp et aI. 1998; Zennou, Petit et aI. 2000; Bouyac-Bertoia, 
Dvorin et aI. 2001). However, these results are controversial, since HIV with 
mutations in each of the identified NLSs still infects non-dividing cells (Fouchier, 
Meyer et aI. 1997; Reil, Bukovsky' et aI. 1998; Dvorin, Bell et aI.· 2002). 
Moreover, very recently Emerman's group has shown that deletions in all four of 
the described NLSs do not abrogate the ability of the virus to infect non-dividing 
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cells (Yamashita and Emerman 2005). The same group previously showed that the 
capsid protein is involved in the HIV infectious phenotype in non-dividing cells 
(Yamashita and Emerman 2004), although capsid is not nucleophilic and is not 
associated with HIV PIC. Thus, they have proposed a new model in which the 
determinant step for the ability of HIV to cross the nuclear membrane is the 
uncoating process. Although there is not agreement about the viral components 
needed for nuclear translocation, this translocation is likely to be mediated by the 
importinlkaryopherin cellular machinery. 
Like all retroviruses, HIV then integrates into the host chromatin. The 
process of integration of the linear viral DNA is carried out by the viral integrase 
protein (for a review see (Brown 1997). Several cellular DNA binding proteins 
have been described to interact with integrase. A major regulator of integration is 
the barrier to auto-integration factor (BAF), which indirectly promotes integration 
in the target DNA by preventing integrase-mediated auto integration of the viral 
genome (Lee and Craigie 1998). Other three proteins have been proposed as 
positive regulators of HIV integration. HMO I (Y) dramatically stimulates 
integration reactions in vitro, probably by inducing changes in DNA structure 
(Farnet and Bushman 1997). Similarly, the integrase interactor 1 (Inil), a subunit 
of the SWIISNF chromatin remodelling complex, has been proposed to stimulate 
the in vitro DNA-joining ability of integrase (Kalpana, Marmon et al. 1994). 
Finally, the lens epithelium-derived growth factor (LEDGF/p75); a protein 
implicated in the regulation of gene expression and in cellular stress responses, 
has been found to interact with integrase and seems to be absolutely required to 
dock the PIC to the host chromatin (for a review see (Ciuffi and Bushman 2006). 
F or a long time integration of lentiviruses and more in general of all retroviruses 
was believed to occur randomly into the host chromatin. Nevertheless, recent 
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reports have challenged this notion and indicated specific biases for integration 
into transcriptionally active genes (see paragraph 1.2.1.4 Safety of retroviral 
vectors). 
Overall, despite the intensive study of HIV in the last twenty years, many 
steps in the lentiviral life cycle are still not fully understood. Elucidating the 
mechanisms and identifying the cellular factors involved in these processes will 
lead on one hand to discover new ways to inhibit HIV replication and on the other 
to improve lentiviral vectors for gene transfer. 
1.2.1.1.2.2 Lentiviruses-derived vectors 
To broaden significantly the scope of HSC-based gene therapy, transduction of 
the majority of HSC without compromising their biological properties would be 
required. Lentiviral Vectors (LVs) are good candidates to this aim. 
The most studied lentivirus is HIV -1. Because of its tropism for human 
cells and the acquired knowledge of its structure, many efforts have focused on 
the design of HIV -1 derived vectors. Starting from initial constructs (Naldini, 
Blomer et al. 1996), which contained all HIV -1 sequences~ several studies have 
been performed to limit viral sequences/proteins without loosing transduction 
efficiency. The state of the art of HIV-l derived vectors is a packaging system 
constituted by four plasmids, in which all the accessory proteins have been 
deleted, and a Self-Inactivating (SIN) transfer vector (Figure 1.10) (Dull, Zufferey 
et al. 1998; Zufferey, Dull et al. 1998; Follenzi, AHles et al. 2000; Delenda 2004). 
In this design the sequence homologies between the different plasmids have been 
greatly reduced, making recombination and production of replication competent 
lentiviruses very unlikely to occur. Moreover, the SIN design of the transfer 
vector, in which the enhancer/promoter sequence (U3) of HIV -1 has been deleted, 
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strongly improved safety. In fact, the SIN-Long Terminal Repeat (SIN-LTR) 
cannot initiate transcription of the vector genome and, thus, should not allow 
mobilization of the vector, for instance following superinfection by HIV; the SIN-
L TR should also reduce the potential impact of the vector on flanking gene 
expression. Finally, the SIN design improved vector performance, allowing for 
the use of internal promoters, which can be selected from a large variety of 
cellular transcription regulatory elements or viral sequences, according to the 
application. 
A 
U3 substitution U3 deletion 
SD SA 
B 
SD SA 
c 
Figure 1.10. Four plasmids system for the production oflate generation LVs. A) Transfer 
vector: the mv 5'LTR U3 has been substituted with the Raus Sarcoma Virus or 
Citomegalovirus promoter-enhancer sequence; the 3'L TR U3 sequence containing the mv 
promoter-enhancer region has been deleted. Upon retrotranscription 3'LTR is copied at the 5' 
obtaining a Self-Inactivating (SIN) vector. Wpre: Woodchuck post-regulatory elements. B) 
Packaging constructs encoding mv structural proteins. CMV: citomegalovirus enhancer-
promoter sequence. C) Envelope construct encoding for the envelope glycoproteins. RSV: 
Raus sarcoma virus enhancer-promoter. For other abbreviations see Figure 1.8 legend. 
The main advantage of using LV s is their ability to transduce non-
proliferating cells (Naldini, Blomer et al. 1996). In the HSC field, this would 
imply no needing for prolonged stimulation and, thus, a reduce risk of affecting 
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HSC features. Others and we have shown efficient transduction of CB SRCs after 
a short incubation with LVs (Uchida, Sutton et al. 1998; Miyoshi, Smith et al. 
1999; Guenechea, Gan et al. 2000; Ailles, Schmidt et al. 2002). Although LV s 
transduce non-proliferating cells, they seem to be unable to transduce quiescent T 
lymphocytes, which must exit from Go, and presumably progress to the G. b phase 
of the cell cycle, in order to be infected by HIV -1, or transduced by LV s (Korin 
and Zack 1999; Unutmaz, KewalRamani et al. 1999; Wu and Marsh 2001; 
Cavalieri, Cazzaniga et al. 2003; Verhoeyen, Dardalhon et al. 2003). A similar 
transduction block has been demonstrated in macrophages (Kootstra, Zwart et al. 
2000). It is still under investigation whether the transduction block in quiescent 
cells is due to the lack of required cellular co-factors, and/or to the expression of 
restrictive factors (see paragraph 1.2.1.3 Retroviral restrictive factors). Moreover, 
it is not clear if this Go· block of LV s is active also in HSCs. 
1.2.1.1.3 Spumaviruses-derived vectors 
Similarly to Lentiviruses, the Spumavirus genome encodes for structural proteins 
common to all retroviruses and for a set of regulatory and accessory proteins. 
Despite the name of the prototype Spumavirus, Human Foamy Virus (HFV), 
which is now known to be a chimpanzee virus (Nemo, Brown et al. 1978; 
Herchenroder, Renne et al. 1994; Schweizer and Neumann-Haefelin 1995), FVs 
are not endemic in human populations (Schweizer, Turek et al. 1995). This, 
coupled to their non-pathogenicity in their natural hosts (non-human primates), 
has supported the idea that HFV -derived vectors (FVV) could be safer than 
vectors derived from other retroviruses. In addition to safety considerations, the 
broad host and tissue tropism ofFV (Russell and Miller 1996; Hill, Bieniasz et al. 
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1999), and the ability of FVV to package up to 9.2 kb of foreign genetic material 
(Trobridge, Josephson et al. 2002; Vassilopoulos, Josephson et al. 2003), made 
FVV promising gene transfer tools. 
FV s have a characteristic cell cycle, in which reverse transcription occurs 
In cells that produce virions rather than in infected target cells, so that the 
functional genome is double-stranded DNA (Yu, Baldwin et al. 1996; Moebes, 
Enssle et al. 1997; Yu, Sullivan et al. 1999). Beside this, they differ from RVs and 
LV s also for their cell cycle requirements for transduction. Indeed, it has been 
recently shown that FV vectors for transgene expression ultimately require 
mitosis, but a transduction intermediate is stable and persists in non-dividing cells 
for some days (Trobridge and Russell 2004). This means that cells that are non-
proliferating during exposure to the vector can be transduced by FV vectors only 
if they divide in the following short period. 
Thus, even though some studies have reported efficient transduction of 
SRCs by FV -derived vectors (Josephson, Vassilopoulos et al. 2002; Leurs, Jansen 
et al. 2003; Josephson, Trobridge et al. 2004), it is still under investigation 
whether these vectors can transduce more primitive HSCs, which possibly are 
quiescent during transduction and will not divide soon after. 
1.2.1.2 HSC ex vivo culture and gene transfer 
The development of protocols that maintain HSCs in culture without affecting 
their biological properties is strictly linked to the knowledge of extrinsic signals 
regulating HSC in vivo. Since the majority of these stimuli still need to be 
elucidated, the specific combination of most suitable factors for ex vivo culture 
and gene transfer remains to be determined. 
52 
Several studies have addressed this issue. IL-6, IL-3, SCF, F1t3L and TPO 
have been the most studied factors; they have been shown to preserve function, 
allow a moderate expansion and aid in transduction of HSPCs (Bodine, Karlsson 
et al. 1989; Bodine, Orlic et al. 1992; Petzer, Zandstra et al. 1996; Bhatia, Bonnet 
et al. 1997; Dao, Hannum et al. 1997; Glimm and Eaves 1999; Piacibello, Sanavio 
et al. 1999; Shpall, Quinones et al. 2002; McGuckin, Forraz et al. 2004). As 
discussed above, more recently, some of the newly discovered players in HSC 
regulation have been exploited in vitro (see paragraph 1.1.4 Molecular 
mechanisms regulating HSCs). BM stromal cells or extra-cellular matrix 
fragments have been used to ameliorate HSPC culture and gene transfer (Moritz, 
Patel et al. 1994; Nolta, Smogorzewska et al. 1995; Hanenberg, Xiao et al. 1996; 
Dao, Hashino et al. 1998; Yokota, Oritani, et al. 1998). Also, it has been shown 
that in vitro exposure to SDF-1 increased haematopoietic progenitors proliferation 
in vitro and HSC engraftment in vivo (Lataillade, Clay et al. 2000; Glimm, Tang 
et al. 2002). Two different groups have also recently proposed the histone 
deacetylase inhibitor valproic acid as stimulator of HSPC proliferation and self-
renewal (Bug, Gul et al. 2005; De Felice, Tatarelli et al. 2005). Bug et ale have 
shown down-regulation of p21 and up-regulation of HoxB4 induced by valproic 
acid that could explain this effect. 
Beyond the choice of the best factors to maintain HSPCs, an issue that has 
been investigated in the gene transfer field is the period of cell culture.' Since RV s 
have been the most exploited vectors for HSC gene transfer, most of the designed 
protocols included a several days of cell stimulation, in order to induce cell 
proliferation. Some of these protocols have been shown to have a therapeutic 
potential in clinical trials (Cavazzana-Calvo, Hacein-Bey et al. 2000; Aiuti, Slavin 
et al. 2002; Gaspar, Parsley et al. 2004). However, the benefits observed are 
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partially due to a selective advantage of the transduced cells. Only long-term 
analysis of the patients' graft will determine if transduced cells were progenitor, 
short-term or long-term stem cells. On the other hand, in NOD/SCID 
xenotransplant models, Dick's group showed that 4 days in culture strongly 
reduced HSC engraftment ability in a competitive setting (Mazurier, Gan et al. 
2004), supporting the idea that minimal HSC manipulation is warranted. LVs are 
good candidates to efficiently transduce HSCs without extensive manipulation. 
Nevertheless, in apparent contrast with the lack of LV requirement for target cell 
proliferation, we have found a significant enhancement in gene transfer in the 
presence of a combination of early-acting cytokines (IL6, SCF, TPO and Flt3L) 
(Ailles, Schmidt et al. 2002). Although cytokine enhancement of SRC 
transduction by LV s has now been reproduced in other works (Zielske and Gerson 
2003), it remains to be established whether the gain in gene transfer could be 
offset, even for a short cytokine exposure, by a decreased engraftment or long-
term repopulation capacity of the transduced cells. Indeed, a recent study has 
shown that even a short period of exposure to SCF, F1t3L, IL6 and IL3 is 
detrimental for MPB-derived haematopoietic progenitors homing (Ahmed, Ings et 
al. 2004). 
Finally, it should be highlighted that the differences in the biological 
properties imply different cytokine requirements for the in vitro maintenance and 
gene transfer of HSCs derived from different sources (see paragraph 1.1.8 
Sources). Indeed, the different proliferative potential, susceptibility to apoptosis, 
and cell cycle status can strongly influence the ability of the cells to grow in vitro 
and the susceptibility to transduction. Thus, specific protocols for HSCs derived 
from CB, BM and MPB are under investigation. 
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1.2.1.3 Retroviral restriction in mammalian cells 
Retroviruses, like all viruses, exploit cellular factors in order to establish 
productive infection. More recently, it has been demonstrated that host factors can 
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Figure 1.11. Retrovirus . life cycle and 
restrictions. RT: retrotranscription. IN: 
integration. 
also inhibit retroviral infection. Such 
factors may affect several infection steps, 
both in the early phases (Le. viral entry, 
uncoating, reverse transcription, nuclear 
import and integration) and in the late 
stages (Le. transcription, translation, 
assembling and budding) (Figure 1.11). 
Because of the recent advances in the 
field and the relevance of the issue also 
for gene transfer applications, in this 
paragraph only the restrictive factors 
acting in the early phases of retrovirallife cycle will be discussed. 
1.2.1.3.1 Restrictivefactors targeting the capsid 
The first antiretroviral gene to be identified is the Fv 1 locus in the mouse (pincus, 
Hartley et al. 1971; Lilly and Pincus 1973; Rowe, Humphrey et al. 1973; Pincus, 
Hartley et al. 1975). Two major alleles were identified: Fvl n, found in NIH Swiss 
mice, blocked the replication of the B-tropic ML V oncoretrovirus, but allowed 
replication of N-tropic strain of the same virus; and Fvl b, found in Balb/c mice, 
allowed replication of B-tropic viruses and blocked N-tropic strains. The block 
was found to be dominant and to act at early stages of infection, after reverse 
transcription and before integration into the host chromatin (Jolicoeur 1979; 
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Yang, Kiggans et al. 1980). Later on, the determinant of the Fvl tropism was 
identified as a specific amino acid residue in the capsid (CA) domain of the gag 
protein (Boone, Myer et al. 1983; DesGroseillers and Jolicoeur 1983; Boone, 
Glover et al. 1988; Kozak and Chakraborti 1996). These studies demonstrated that 
interaction between Fv 1 and viral CA is needed for the restriction activity. It was 
further shown that the block was saturable, indeed increasing doses of virus could 
overcome the restriction; in addition, the block was abrogated also by inactivated 
virions (Duran-Troise, Bassin et al. 1977; Bassin, Duran-Troise et al. 1978). 
However, the mechanism of restriction of Fvl still needs to be identified. It may 
sequester the PIC in the cytoplasm, thus inhibiting the binding to the PIC of 
cellular factors, which are needed by the virus. Alternatively, Fvl may target the 
PIC to degradation (for a review on Fvl see (Goff 1996). 
More recently,· interest in retroviral restrictive factors increased when 
human cells were found to have specific resistance to N-tropic ML V (Towers, 
Bock et al. 2000; Besnier, Ylinen et al. 2003). The restriction of this MLV strain, 
pseudotyped with Vescicular Stomatitis Virus (VSV) envelope in order to be 
infective for non-murine cells, was ascribed to the Ref! gene in different 
mammalian cells, including pig, cow and non-human primate cells (Towers, Bock 
et al. 2000). The Ref! block is similar to that of Fvl. Indeed, it is dominant, it is 
directed against.the same CA amino acid residue as Fvl and is abrogated by pre-
exposure to restricted virus (Cowan, Hatziioannou et al. 2002; Munk, Brandt et al. 
2002; Towers, Collins et al. 2002). However, Ref! seems to act earlier than Fvl in 
the viral life cycle, by blocking reverse transcription. Interestingly, Ref! 
restriction in human cells has later been shown to act also against a distantly 
related lentivirus, the equine infectious anaemia virus (EIA V) (Hatziioannou, 
Cowan et al. 2003). The non-similarity in CA sequences between ML V and 
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EIA V, thus suggested the presence in these two viruses of similar conformational 
structures that are recognized by Refl. 
At the same time of Refl identification, several studies showed that 
lentiviruses, including HIV -1, were restricted in non-human primates by a factor, 
which was called LvI (Besnier, Takeuchi et al. 2002; Cowan, Hatziioannou et al. 
2002; Munk, Brandt et al. 2002; Hatziioannou, Cowan et al. 2003). The 
identification of LvI was a very relevant finding for the virology field, because it 
provided a molecular mechanism for the well-known species-specificity of 
Lentiviruses. Like FvI and Refl, LvI was found to target the CA protein and to 
be saturable (Kootstra, Munk et al. 2003; Owens, Yang et al. 2003). 
Very recently, a major breakthrough in the field was achieved with the 
cloning of the gene responsible for LvI activity in rhesus macaque (Stremlau, 
Owens et al. 2004). The gene was found to encode TRIM5a, a member of the 
Tripartite Motif (TRIM) family. In the same year, 4 different groups demonstrated 
that African green monkey TRIM5a gene encoded for the activities, which were 
previously identified as Refl and LvI (Hatziioannou, Perez-Caballero et al. 2004; 
. . 
Keckesova, Ylinen et al. 2004; Perron, Stremlau et' al. 2004; Yap, Nisole et al. 
2004). Although the mechanism of action was similar between TRIM5a and Fv 1, 
an obvious sequence homology between TRIM5a and FvI was not found. Later, 
it was shown that the restriction activity of Fv 1 ectopically expressed in human 
cells was dependent on TRIM5a expression (~eckesova, Ylinen et al. 2004), 
suggesting the involvement of a murine TRIM5a-c1osely-related protein 
cooperating with Fv 1. 
Several groups have confirmed and extended the importance of TRIM5a 
as a retroviral restrictive factor. An interesting finding has been that the various 
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primate TRIM5a proteins could restrict a variety of retroviruses, but, generally, 
not the viruses normally found in that species. These findings supported the idea 
that TRIM5a was selected during evolution as cellular defence against cross-
species transmission. 
Despite the efforts made, the mechanism of action of TRIM5a still needs 
to be defined. TRIM proteins are characterized by 'a RING domain, which is 
typically involved in protein-protein interaction and found in many E3 ubiquitin-
ligase, one or two B boxes and a coiled-coil region. TRIM5a and other family 
components contain the SPRY domain, in which the restriction specificity has 
been mapped (Stremlau, Perron et al. 2005; Yap, Nisole et al. 2005). Three main 
hypotheses have been formulated about the TRIM5a mechanism of restriction, 
based on the structure of the protein: 1) TRIM5a traps the virus in the cytoplasm 
and avoids nuclear translocation; this speCUlation is based on the ability of 
TRIM5a to aggregate in large structures that bind different proteins. 2) TRIM5a 
binding to CA interferes with CA modification needed by the vector to uncoat. 3) 
TRIM5a targets the entering virus to degradation. This last hypothesis was based 
on the finding that other TRIM5 isoforms manifested ubiquitin ligase activity. 
Although induction of viral degradation has been the most accredited hypothesis 
since TRIM5a has been discovered, very recently it has been shown that the 
TRIM5a owl monkey-specific variant restricts HIV -1 independently of the 
proteasome system (Perez-Caballero, Hatziioannou et al. 2005), thus suggesting 
either that other proteases are involved in the restriction or that the virus is trapped 
(and/or uncoating is inhibited) rather than be degraded following TRIM5a 
binding. 
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Other TRIM proteins have been assayed for restriction activity. TRIM 19 
has been proposed as viral restrictive factor in human cells. TRIMI9, also known 
as PML, was originally identified as fusion partner in the oncogenic activation of 
the retinoic acid receptor (de The, Lavau et al. 1991). However, whereas 
restriction by TRIM19 has been demonstrated for some viruses (Doucas, Ishov et 
al. 1996; Chelbi-Alix, Quignon et al. 1998), contrasting results have been shown 
about the role ofTRIM19 in HIV-l infection (Bell, Montaner et al. 2001; Turelli, 
Doucas et al. 2001; Yap, Nisole et al. 2004). TRIMI has been found to act against 
MLV, but not HIV (Yap, Nisole et al. 2004) (for a review on TRIM family and 
retroviral restriction see (Nisole, Stoye et al. 2005). 
Very recently a novel HIV restrictive factor has been discovered. It has 
been termed Lv2 and, although it remains to be characterized, it has been shown 
to exert a more complex mechanism of restriction. Indeed, Lv2 is specific for both 
the entry pathway (dictated by the viral envelope) and the capsid proteins of the 
virus (Schmitz, Marchant et al. 2004). 
1.2.1.3.2 APOBEC proteins 
In the last years another factor has been implicated in retroviral restriction in 
human cells and has been shown to exert an intriguing mechanism for viral 
resistance. This restriction factor has been originally identified as dominant 
restrictive player in a T cell line non-permissive. for HIV -1 infection, and called 
CEM15 (from the name of the non-permissive cell line) (Sheehy, Gaddis et al. 
2002). Sheehy et al. have also found two interesting features of CEM 15: it has to 
be packaged into the nascent virion to restrict it in the successive infection and its 
activity is overcome by the HIV -1 accessory protein Vif. By sequencing they have 
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found close homology of CEMI5 to the apolipoprotein B mRNA editing enzyme 
catalytic polypeptide I (APOBECI) (Teng, Burant et al. 1993; Sheehy, Gaddis et 
al. 2002). This finding suggested a RNA editing ability of CEMI5, but its main 
mechanism of action has been identified only when several groups sequenced 
retroviral DNA from cells that have been infected with Vif-deficient HIV -I that 
were produced in the presence of CEMI5 (Harris, Bishop et al. 2003; Lecossier, 
Bouchonnet et al. 2003; Mangeat, Turelli et al. 2003; Zhang, Yang et al. 2003). 
These authors have shown that CEM 15, now designated APOBEC3G, induced 
hypermutation in the retroviral plus strand DNA, in which up to 25% of all 
deoxyguanosine (G) sequenced were mutated to deoxyadenosine (A). This 
hypermutation then induced the degradation of the viral genome or, in the case of 
successful reverse transcription and insertion into the cell chromatin, the 
production of non-functional viral proteins. 
As aforementioned, APOBEC3G restriction is overcome by HIV -I Vif 
protein. A number of studies have addressed this issue and, through the analysis 
of virions produced in presence of APOBEC3G with or without Vif, have 
demonstrated that APOBEC3G is not packaged into the budding virus when Vif is 
present (Conticello, Harris et al. 2003; Kao, Khan et al. ·2003; Marin, Rose et al. 
2003; Sheehy, Gaddis et al. 2003; Stopak, de Noronha et al. 2003). This exclusion 
,.) has been shown. to be mediated by the ability of Vif to target APOBEC3G for 
ubiquitination and thus proteasomal degradation (Marin, Rose et al. 2003; Sheehy, 
Gaddis et al. 2003; Stopak, de Noronha et al. 2003). 
Later, it has been shown that APOBEC3G can act against other viruses, 
such HBV (Turelli, Mangeat et al. 2004) and that other members of the APOBEC 
family, such as APOBEC3F and APOBEC3B, have anti-retroviral activity 
(Bishop, Holmes et al. 2004; Liddament, Brown et al. 2004; Wiegand, Doehle et 
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al. 2004; Zheng, Irwin et al. 2004). All these findings support a dominant role of 
these deaminating enzymes in the cellular defence against viral infection. 
Finally, several publications have identified G-to-A hypermutations In 
subjects with HIV-1 infection (Borman, Quillent et al. 1995; Deacon, Tsykin et al. 
1995; Huang, Zhang et al. 1998; Janini, Rogers et al. 2001). These results would 
suggest some activity of APOBEC3G even in presence of Vif. Indeed, a very 
recent work has supported this hypothesis, suggesting that APOBEC3G can be 
induced in macrophages by interferon-a and overcomes the effect of Vif (Peng, 
Lei et al. 2006)(Peng G 2006 j exp med 203). Other studies have added further 
complexity to the APOBEC3G mechanism of action model, proposing that its 
activity can be dissociated from cytidine deaminase activity and that it can act in 
the target cell without the need to be incorporated in the virion (Chiu, Soros et al. 
2005; Newman, Holmes et al. 2005; Strebel 2005). Chiu et af. have also shown 
the existence of two different forms of APOBEC3G in quiescent and activated 
CD4 T cells, one enzymatically active and the other inactive, respectively (Chiu, 
Soros et al. 2005). The expression of the active form in quiescent T cells could 
account for the HIV block observed in these cells. 
In conclusion, although it is now clear that mammalian cells exploit 
several defence mechanisms against early steps of retroviral infection, our 
,) knowledge about retroviral restrictive factors and their mechanisms of action is 
still partial. A deeper understanding of these mechanisms will help to find 
strategies on one hand to counteract viral infection and on the other hand to 
improve gene transfer efficiency. 
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1.2.1.4 Safety of retroviral vectors 
Integration of a transgene into the cell chromatin may ensure stable expression of 
the gene product in the target cell and its progeny. As discussed above, because of 
this feature, integrative vectors, such as retrovirus-based vectors, have been the 
preferred choice for gene delivery into HSCs. On the other hand, vector 
integration represents an insertional mutagen that may significantly affect the 
expression of cellular genes found at, or near to, the insertion site, and may 
consequently alter the cell growth control and eventually trigger cell 
transformation. Indeed, integrated L TR sequences may act as promoter/enhancer 
recruiting ubiquitous and cell type-specific transcription factors to upregulate 
expression of flanking genes. Although the mechanisms of proto-oncogene 
activation by retroviral insertional mutagenesis has been well described (for a 
review see (Mikkers and Berns 2003), their occurrence at a relatively high 
frequency using replication-defective gene transfer vectors had not been 
anticipated until recently. 
Recent clinical trials of severe combined immunodeficiency gene therapy 
have highlighted the therapeutic potential R V -mediated gene transfer into HSCs 
(Cavazzana-Calvo, Hacein-Bey et al. 2000; Aiuti, Slavin et al. 2002; Gaspar, 
Parsley et al. 2004). Unfortunately, in one X-linked Severe Combined 
Immunodeficiency (X-SCID) trial, three out of eleven successfully treated 
subjects developed leukaemia caused by the clonal outgrowth of transduced cells 
(Hacein-Bey-Abina, von Kalle et al. 2003). Transformed cell growth was 
triggered by vector integration close to the LM02 proto-oncogene, resulting in its 
over-expression, and a putative synergistic interaction between LM02 and the IL-
2R common y-chain therapeutic transgene (Hacein-Bey-Abina, Von Kalle et al. 
2003; Fischer, Abina et al. 2004). Synergistic interaction is controversial, still the 
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occurrence of this adverse event has prompted a reassessment of the insertional 
mutagenesis risk by retroviral vectors. Recent reports have also challenged the 
notion that retroviral integration occurs randomly in the target cell chromatin, and 
indicated specific biases for integration into transcriptionally active genes for both 
ML V and HIV (Schroder, Shinn et al. 2002; Wu, Li et al. 2003). 
All these recent findings have triggered the scientific community to deeply 
study and compare integration site selection among different integrating vectors to 
evaluate the risk-benefit ratio in gene therapy applications and to develop safer 
vectors. Towards these aims, several groups have engaged in high-throughput 
retrieval of vector integration sites. Instead, we have used a novel and 
complementary approach based on genetic trapping, which allows quantitative 
and comparative assessment of some vector~specific integration biases by probing 
hundred thousands integrations at once in different types of target cells, including 
primary cells tested in different conditions (De Palma, Montini et al. 2005) (see 
appendix B). 
Some studies have shown that ML V and ML V-derived vectors have a 
strong bias for integration next to the promoter region (Laufs, Gentner et al. 2003; 
Wu, Li et al. 2003), a behaviour which may increase the risk of transcriptional 
deregulation of the targeted endogenous gene. On the other hand, the superior 
,<> proficiency of LV s at integrating into primitive HSCs, a feature that may provide 
a critical advantage over R V s for the success of gene therapy, may also confer an 
increased risk of insertional mutagenesis. Even though the advanced SIN-LTR 
design of LV s may reduce the risk of insertional mutagenesis, a complete 
evaluation of the oncogenicity of RV arid LV is still missing. 
To this aim, a number of groups are currently developing mouse models 
assessing the oncogenic potential of vector-mediated gene transfer in HSCs. Upon 
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transplanting wild-type mouse HSCs treated with increasing doses of RV 
expressing the multidrug resistance 1 (MDRI) gene, Modlich et al. reported the 
occurrence of tumours harbouring multiple integrations, several of which mapped 
close to known proto-oncogenes (Modlich, Kustikova et al. 2005). Moreover, 
using a tumour-prone mouse model, very recently it has been shown a dose-
dependent acceleration of tumour onset triggered by RV, whereas tumourigenesis 
was unaffected by LV (Montini, Cesana et al. 2006). These results suggest a low 
oncogenic potential of LVs. Since the RV tested in this work had full LTR, 
whereas the LV had a SIN-L TR, it is likely that, beside the different integration 
site selection patterns of the two vectors, the lack of transcriptionally active L TRs 
was a major determinant of the low genotoxicity of lentiviral vectors observed in 
this model. 
Overall, obtaining a reliable assessment of the genotoxic risk of retroviral 
vectors integration is needed to validate vector safety and to advance the 
prospective applications of HSC-based gene therapy. 
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1.3 Scope of the work 
HSCs are attractive targets for the gene therapy of a variety of inherited diseases. 
Because of their self-renewing ability, multipotency and high proliferative 
potential, HSCs may reconstitute all haematopoietic lineages in a transplanted 
host. For gene therapy to be efficacious, effective gene transfer must be reached 
into HSCs without inducing detrimental effects on their biological properties. 
Because of their ability to transduce non-proliferating cells, LVs have been 
proposed as efficient tools for HSC gene transfer. Although HSCs can be 
transduced by LV in very short ex vivo culture, they display low permissivity to 
the vector, requiring high vector doses and exposure to cytokines to reach high-
frequency gene transfer. Indeed, we have found that a significant enhancement in 
gene transfer was obtained by transducing the cells in the presence of a 
combination of early-acting cytokines (IL6, SCF, TPO and Flt3L) (Ailles, 
Schmidt et al. 2002). 
First aim of this project was to establish in stringent xenotransplant models 
whether cytokine-stimulation affected HSC properties and whether cytokine 
enhancement of LV transduction was linked to the induction of cell cycle 
progression in HSCs. To determine whether cytokine exposure decreased 
engraftment or repopulation capacity of the transduced cells, we have performed 
competitive repopulation assays, by comparing engraftment ability of stimulated 
versus unstimulated SRCs. To determine whether cytokine enhancement of 
transduction was due to an early induction of cell cycle progression in HSCs, we 
performed an S-phase suicide assay .. This assay was also used to det~rmine 
whether triggering HSCs, which are mostly quiescent, to the 0 1 phase of the cell 
cycle was required in order to transduce them. In this regard, it has been shown 
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that LV s are restricted in quiescent T lymphocytes, which must exit from Go of 
the cell cycle in order to be infected by HIV -1, or transduced by LV s (Unutmaz, 
KewalRamani et al. 1999; Cavalieri, Cazzaniga et al. 2003; Verhoeyen, 
Dardalhon et al. 2003). Progression into late G., however, commits the cells to 
DNA replication and mitosis, and may thus impair the long-term repopulating 
ability of HSCs, a feature that is difficult to assess in the NOD/SCID model. 
Second aim of this work was to determine the rate-limiting factor(s) that 
make HSCs poorly permissive to LV transduction, and to eventually develop 
strategies to overcome these restrictions. Indeed, the impaired transduction may 
be due to the lack of required cellular co-factors, and/or the expression of 
restrictive factors (Chiu, Soros et al. 2005). Some of these factors may affect viral 
uncoating, reverse transcription, and/or target the internalised viral particles to 
degradation by the ubiq"uitin-proteasome pathway. Thus, we evaluated the role of 
the ubiquitin-proteasome pathway in L V-mediated transduction of hematopoietic 
stem and progenitor cells. 
Third aim was to investigate integration site selection of LV in HSPCs. 
Indeed retroviral vector integration may have detrimental effects on HSPCs, for 
instance by altering gene expression and inducing aberrant developmental 
pathways. Analysis of integration site selection can help to predict the 
.:> consequence of the insertional mutagenesis induced by these vectors. We used a 
promoter trapping approach built into LV and RV (ML V) vectors to evaluate 
integration site selection in the target cell genome. 
Overall, the results of this project will help to develop better protocols for 
HSC gene therapy and improve understanding of the interactions between target 
cells and LV s. 
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Chapter 2. 
Methods 
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2.1 Reagents and suppliers 
2.1.1 Chemicals 
All chemicals were obtained from FLUKA or Sigma-Aldrich. 
Other chemicals used during the study were obtained from the following sources: 
Lymphoprep Axis-Shield PoC AS 
MG132 Calbiochem, EMD Biosciences 
PS341 Millennium Pharmaceuticals 
CH296 (retronectin) Takara BIO 
2.1.2 Radiochemicals 
3H_ Thymidine (25 Ci/mol): Amersham Biosciences, GE Healthcare. 
2.1.3 Enzymes and buffers 
All DNA modification enzymes and buffers were obtained from Roche. 
All restriction enzymes and buffers were obtained from either Roche or New 
England Biolabs. 
AmpliTaq Platinum polimerase enzyme was supplied by Invitrogen. 
2.1.4 Bacterial strains 
The Top 10 bacterial strain was supplied by Invitrogen (code number 44-0301). 
2.1.5 Cell culture 
Cells were incubated at 37°C in a 5% CO2 incubator. 
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All tissue culture plastic ware (tissue culture plates and tubes) was obtained form 
BD Falcon. 
Trypsin-EDTA solution: Phosphate Buffered Saline 0,05% trypsin, 4mM EDT A 
pH 7,3. 
Media, sera and supplements: 
IMDM Sigma-Aldrich 
RPM I 1640 Euroclone 
StemSpan Stem Cell Technologies 
MethoCult GF4434 Stem Cell Technologies 
Foetal Bovine Serum (FBS) BioSera 
Trypsin Invitrogen 
L-Glutamine Invitrogen 
Penicillin/Streptomycin Invitrogen 
HEPES Invitrogen 
Polybrene Sigma-Aldrich 
All cytokines were supplied by Peprotech. 
Phosphate buffered saline (PBS) was obtained from Sigma-Aldrich. 
2.1.6 Antibodies 
All antibodies for flow cytometry were supplied by DAKO AlS. 
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2.2 Plasmids . 
LV s were produced by co-transfection of 4 plasmids: transfer construct, 
packaging construct, Rev-encoding construct and envelope construct. The 
retroviral trap vector was produced by co-transfection of 3 plasmids: transfer 
construct, packaging construct and envelope construct. All the plasmids contain 
the gene encoding for Ampicillin resistance. 
Transfer constructs: 
pRRL.sin.PPT.hPGK.eGFP.pre (Follenzi, AHles et al. 2000) and 
pRRL.sin.PPT.hPGK.YFP.pre, obtained by replacing the fragment SaII-SpeI of 
pRRL.sin.PPT.hPGK.YFP.pre with the fragment SaII-SpeI containing YFP from 
pRRLsin.hPGK.YFP (kindly provided by T9m Dull, Cell Genesis) were used in 
competitive repopulatiof.l experiments. 
pCCLsin.PPT.hPGK.eGFP.pre (Dull, Zufferey et al. 1998; Zufferey, Dull 
et al. 1998; Follenzi, Ailles et al. 2000) was used in all the other experiments, 
excluding promoter trapping experiments. 
Lentiviral and Retroviral Trap (LT and RT, respectively) were used for 
promoter trapping experiments. A PuroR -GFP fusion gene was cloned into the 
promoter trap pROSA-GFNR (Medico, Gambarotta et al. 2001) in place of 
GFNR.PGKneo, and the resulting expression cassette (Splice Acceptor site.PuroR-
GFP.polyA) was excised by AjlIIINheI digestion, and cloned in reverse orientation 
into the HIV-based self-inactivating . (SIN) lentiviral vector 
pRRL.SIN.cPPT.PGK.eGFP in place of PGK.eGFP or into the MLV -based SIN 
retroviral vector pRkat43.3.PGK.YFP (Roberts MRj immunol 1998) in place of 
PGK. YFP, to generate L T and RT vectors, respecti~ely. 
Packaging constructs: 
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pCMV ~R8.74 (Dull, Zufferey et al. 1998) was used in the production of 
vectors used in competitive repopulation assay and in the production of the L T 
vector. 
pMDLg/pRRE (Dull, Zufferey et al. 1998) was used to package vectors 
used in all the other experiments. 
pCMV.GAG.POL (Naldini, Blomer et al.' 1996) was used in the 
production of the RT vector. 
Rev-encoding construct: 
pRSV -REV (Dull, Zufferey et al. 1998). 
Envelope constructs: 
pMD2.VSV-G (Follenzi, Ailles et al. 2000) was used for VSV-G-
. pseudotyped vectors. 
phCMV-I0Al ·(Sandrin, Boson et al. 2002) was used for A-MLV 
amphotropic-pseudotyped vectors. 
phCMV-RDI14ITR was used for RDI14/TR-pseudotyped vectors. 
2~3 Transformation of competent bacteria and plasmid preparation 
Plasmid DNA (0,5-5ng) to be transformed was mixed with 50JlI of chemically 
competent Top 1 0 cells (Invitrogen) prepared specifically for the heat shock 
mediated transformation method. The mix was incubated on ice for 30 minutes, 
then 1 minute in a water bath at 42°C, and then returned to ice for a further 5 
minutes. The mix was then plated onto Luria Bertani (LB) agar plates, containing 
100Jlg/ml ampicillin and placed overnight in a 37°C bacterial incubator. The 
following day, colonies were picked and placed into 1 ml of LB media containing 
carbenicillin (ampicillin homologue), and grown over day with agitation at 37°C. 
71 
Ten J..lI of the over day culture were placed in 200ml of LB media containing 
carbenicillin, and grown overnight shaking at 37°C. The following day, cell 
suspension was measured by spectrophotometer analysis (A=600nm) to check for 
optimal cell density (about 1-1,5 O.D.) and subjected to large-scale plasmid DNA 
preparation. 
Plasmid DNA preparation was performed using High Purity Plasmid 
Purification Systems (Marligen Biosciences). This system is based on alkaline 
lysis, followed by DNA purification on an anion exchange resin. After elution, 
plasmid DNA was then desalted and concentrated by alcohol precipitation, 
washed in 70% ethanol and resuspended in TE buffer (lOmM Tris-HCI pH 8,0, 
0.1 mM EDTA). 
2.4 Vector production 
2.4.1 Transfection 
Reagents: 
2XHBS: 
2.5MCaCh: 
O.IX TE buffer: 
. 281mM NaCI, 100mM HEPES, 1,5mM Na2HP04, pH 7,12, 
0,22J..lM filtered, stored at -20°C or -80°C. 
tissue culture grade (Sigma-Aldrich), 0,22J..lM filtered, 
stored at -20°C. 
10mM Tris (PH 8,0), ImM EDTA (PH 8,0) diluted 1:10 
with dH20, 0,22J..lM filtered, stored at 4°C. 
endotoxin-free, ti~sue culture grade (Sigma-Aldrich). 
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Vector stocks were prepared by calcium phosphate transfection and 
concentrated by ultracentrifugation. Vectors were produced by transfection of 
human embryonic kidney 293T cell line (containing the mutant gene of SV 40 
Large T Antigen, see paragraph 2.S Cell lines), because these cells are optimal 
DNA recipients in transfection procedures and the backbones of the vector 
construct contain SV 40 origin of replication. 
9xl06 293T cells per dish were seeded and incubated in IS cm dishes, 24 
hours before transfection in IMDM, 10%FBS, Penicillin (2SU/ml), Streptomycin 
(2SU/ml). Two hours before transfection medium was replaced. 
To produce LVs, plasmid DNA mix was prepared by mixing 9J.lg pMD2-
VSV-G or 22,SJ.lg phCMV-IOAl or 12,SJ.lg phCMV-RDI14fTR, 16,2SJ.lg 
pCMV ~R8.74 or 12,SJ.lg pMDLg/pRRE, 6,2SJ.lg pRSV-REV and 2SJ.lg transfer 
construct together per dish. To produce RT vector, plasmid DNA mix was 
prepared by mixing 9J.lg pMD2-VSV-G, ISJ.lg pCMV.GAG.POL and 20J.lg of 
transfer construct together per dish. The plasmid solution was made up to a final 
volume of 112SJ.lI with 0.1XTE/dH20 (2:1) in a IS ml polypropylene tube. Finally 
I~SJ.lI of 2.SM CaCh were added. The precipitate was formed by drop wise 
addition of 12S0J.lI 2X HBS solution to the 12S0J.lI DNA-TE-CaCh mixture while 
vortexing at full speed. The precipitate was added to 293T cells immediately 
following addition of the 2X HBS and cells were incubated at 37°C. 14-16 hours 
after transfection, medium was replaced. 24 hours after medium changing, 
supernatant was collected, filtered through 0.22J.lm pore nitrocellulose filter and 
ultracentrifugated at 19.500 rpm in SW32Ti rotor (Optima L-60 preparative 
Ultracentrifuge; Beckman) 2 hours at room temperature for VSV -pseudotyped 
vectors or 7000rpm in SW32Ti rotor (Optima L-60 preparative Ultracentrifuge; 
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Beckman) 12 hours at 4°C for A-ML V- and RDl14/TR-pseudotyped vectors. 
Pellets containing the vector were resuspended in a volume of sterile PBS (Sigma-
Aldrich) representing 1/500 of the starting medium volume, pooled and rotate on 
a wheel at room temperature for 1 hour. The concentrated vector preparation was 
then divided into small aliquots (25-50J.lI) and stored at -80°C. Once thawed, 
vector aliquots were not frozen again (each freeze and thaw approximately halves 
vector titer). 
2.4.2 Vector particle amount determination 
Vector particle amount was determined by immunoenzymatic assay, using the 
Alliance HIV-l p24 antigen ELISA kit (PerkinElmer), following manufacturer's 
instructions. 
Serial dilutions of the vector stock (see below vector titer determination) 
were plated in triplicate in microplate wells, which are coated with a highly 
specific mouse monoclonal antibody to the HIV -1 capsid protein p24, and vector 
particle envelope was lysed by 5% Triton X-I00. The captured antigen was then 
complexed with biotinilated polyclonal antibody to HIV -1 p24, followed by a 
streptavidin-HRP (horseradish peroxidase) conjugate. The resulting complex was 
detected by incubation with ortho-phenylenediamine-HCI (OPD), which produces 
a yellow colour that is directly proportional to the amount of HIV -1 p24 captured. 
-
The absorbance of each microplate well was determined using a microplate reader 
(Versa Max, Molecular Devices) (/... 490nm) and quantity of p24 protein was 
calculated using an HIV -1 p24 antigen standard curve. 
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2.4.3 End-point titration 
End-point titration is performed by transducing a permissive target cell line with 
serial dilutions of the vector preparation. 
The protocol used was as follows: 
oPIate 5x104 HeLa ~r 293T cells per well in 3,5cm wells (in order to have the 
follo~ing day 105 cells/well approximately) 
o The following day, thaw a vector aliquot and prepare serial ten-fold dilutions 
of2X viral stock (from 10-3 to 10-8) in IMDM 10% FBS 
o Aspirate medium from cell wells and add 500J-ll of medium 16J-lg/ml 
polybrene (2X final polybrene concentration). 
o Add 500J-ll of serial dilutions (one dilution per well) 
o Incubate at 37°C in a 5% C02 incubator for 72 hours (for expression titer -
FACS analysis) or for 10-15 days, dividing them (for integration titer - Real-
time Quantitative-Polimerase Chain Reaction (Q-PCR) analysis) 
o Detach cells and, for expression titer, fix them in 1mllsample PBS, 1% 
paraformaldehyde, 2% FBS; for integration titer see paragraph 2.12 
o Perform FACS analysis or Q-PCR analysis 
The titer is defined as number of transducing units per milliliter (TV/ml) of 
vector preparation. Expression titer is based on the assumption that a single vector 
.. 
copy integrated in the host genome will give a positive cell. Assuming that all the 
cells are equally susceptible to transduction, fo1l9wing Poisson distribution for 
random independent events, a single transduction event, and not more, has 
occurred in most positive cells, when the percentage of positive cells in the total 
population is below 25%. It follows that expression titer must be calculated fr~m a 
sample corresponding to a vector dilution where positivity of cells ranges between 
1 % (to ensure an acceptable signal over the instrument noise) to 25%, in order not 
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to underestimate the titer when multiple transduction events per cell have 
occurred. Integration titer must be calculated from a sample corresponding to a 
vector dilution where vector copies per cells rages between 0,01 and 0,25. Proof 
of linearity must be obtained showing that different dilutions in the optimal testing 
range yield linear increase in transduction frequency. 
The equation to calculate expression titer is: 
Titer (TV/ml) = (number of cells at the time of vector addition) X 
X (% transgene+ cellsll 00) X (dilution factor) 
The equation to calculate integration titer is: 
Titer (TV/ml) = (number of cells at the time of vector addition) X 
X (vector copies per cell) X (dilution factor) 
For FACS and Q-PCR analyses see relative paragraphs below. 
Titers of vectors used i~ this project ranged between 109 and 1010 TV/ml (vector 
stock concentrated 500x). 
2.4.4 Infectivity of the vector stocks 
Infectivity is a reliable parameter to evaluate the quality of the vector stock and 
can be defined as the transducing activity per unit of physical particle, where the 
first parameter is expressed as TV/ml, as obtained by end-point titration and the 
second as ng p24/ml, as determined by immunoenzymatic assay. 
Since one ng of p24 could theoretically contain 1.2 X 107 particles, if all 
the particles in the vector stock were infectious, a titer of 108 TV/ml would 
correspond to a p24 concentration· of about 10 ng/ml. Indeed, a concentration in 
the range of 500-1000 ng p24/ml is more reasonably expected. This is due t() two 
major reasons. The first reason is that end-point titer fails to estimate the real 
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content of infectious particles in a vector prep~ration, because vector particles 
move by Brownian motion in the medium and only a fraction of them has the 
chance to get in contact with a cell in the monolayer and transduce it in the time 
window of the assay. The second reason instead is crucially linked to the quality 
of the vector batch tested. In fact, the efficiency of packaging of infectious 
particles is lower than what is predicted by theoretical calculations, and a good 
fraction of the total p24 protein is not assembled into infectious virions. 
Vector infectivity can be calculated by the following equation: 
Infectivity = (TU/ml)/(ng p24/ml) = TU/ng p24 
Infectivities were 104_105 TU/ng p24 for all vector types. 
Notes: 
When the vector titer is calculated on a permissive cell line, refractory targets may 
need to be transduced employing a high number of TU per ml. It should be taken 
into account the fact that the expression TU/cel/, which is equivalent to MOl 
(multiplicity of infection) is an arbitrary definition, because it does not consider 
the volume in which the transduction is performed, and therefore the particle 
concentration. Within this context, it is well acknowledged that vector 
concentration in the transduction medium is more important than the absolute 
number of particles available for each cell, since only a fraction of them comes 
into contact with the target, especially when cells "are cultured in mono layers in a 
large volume of medium. 
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2.5 Cell lines 
HeLa (ATCC Number CCL-2), 293T (originally called 293tsA1609ne, and 
derived from 293 cells, a continuous human embryonic kidney cell line 
transformed by sheared Type S Adenovirus DNA, by transfection with the tsA 
1609 mutant gene ofSV40 Large T Antigen and the Neor gene ofE. Coli - ATCC 
Number CRL-lS73; (Graham, Smiley et al. 1977) and K-562 (ATCC Number 
CCL-243) cells were maintained in Iscove's Modified Dulbecco's Medium 
(IMDM; Sigma-Aldrich) and U-937 (ATCC Number CRL-lS93.2) in RPMI-1640 
(Euroclone), both supplemented with 10% foetal bovine serum (FBS; BioSera), 
100 IU/ml penicillin, 100 J.Lg/ml streptomycin, and 2mM L-glutamine. To detach 
adherent cells PBS 0,05% trypsin, 4mM EDTA (PH 7,3) is used. 
2.6 Haematopoietic stem/progenitor cell (HSPC) enrichment 
2.6.1 Human HSPCs 
Cells from human subjects were obtained with informed consent according to the 
Declaration of Helsinki, and to a protocol approved by the San Raffaele Scientific 
Institute Bioethical Committee. 
Mononuclear cells were obtained from human cord blood scheduled for 
discard. by density separation, and CD34+ cells were isolated by positive 
selection. 
Mononuclear cells separation protocol used was as follows: 
o dilute cord blood 1:2 in PBS 
o stratify 30ml of diluted cord blood on ISml Lymphoprep (Axis-Shield PoC 
AS) 
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o spin at 1500 rpm in Heraeus Megafuge 1.0 (~endro Laboratory products) 30 
minutes at room temperature, without brake 
o remove plasma upper layer containing platelets 
o transfer the interphase between plasma and lymphoprep in a new tube; this 
fraction contains mononuclear cells, whereas Lymphoprep lower layer 
contains granulocytes and erythrocytes 
o wash cells in 25ml PBS, spinning at 1000 rpm in Heraeus Megafuge 1.0 
(Kendro Laboratory products) 10 minutes at room temperature 
o pour off supernatant and resuspend all cells in 20ml MACS buffer (PBS pH 
7,2,0.5 % Bovine Serum Albumin - BSA, Sigma-Aldrich - and 2mM EDTA) 
o count cells an aliquot of cells in a Burker chamber after a 1 :50 dilution (l: 1 0 
in acetic acid to lyse erythrocytes possibiy remained, followed by 1:5 dilution 
," 
in trypan blue (Invitrogen) to exclude dead cells) 
Mononuclear cells were then subjected to CD34 positive selection, by 
using the MACS Indirect CD34 Progenitor Cell Isolation Kit. The magnetically 
labelled cells were enriched on LS separation columns in the magnetic field of the 
MidiMACS magnet (all Miltenyi Biotech), following manufacturer's instructions. 
Cells were centrifuged at 1000 rpm in Heraeus' Megafuge .1.0 R (Kendro 
Laboratory products) 10 minutes at 4°C, resuspended in 300JlI MACS buffer per 
108 cells and incubated with 100JlI Fc receptors blocking reagent (to block 
aspecific binding of the antibody) together wit~ 100JlI apten-conjugated anti-
CD34 antibody per 108 cells 20 min at 4°C. Cells were then washed with 20ml 
MACS buffer as above, resuspended in 400JlI MACS buffer per 108 cells and 
incubated with a secondary magnetic beads-conjugated anti-apten antibody 20 
min at 4°C. Cells were washed again, resuspended in 1ml MACS buffer per 108 
counted cells and subjected to two rounds of separation on LS columns. 
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Flow though was discarded. CD34+ cel~s, recovered by removing the 
column from the magnetic field and by using the plunger, were then counted and 
either frozen in IMDM 40% FBS, 10% Dimethyl Sulfoxide (DMSO) or used 
fresh. 
2.6.2 Murine HSPCs 
Bone marrow cells were harvested from six-week-old C57Bl/6 or FVB mice (both 
from Charles River Laboratories) and subjected to negative selection by using the 
StemSep Mouse Hematopoietic Progenitor Cell Enrichment kit and the Green 
StemSep Magnet with StemSep 0.6" Negative Selection Gravity Columns (all 
Stem Cell Technologies), following manufacturer's instruction. 
Bone marrow cells were harvested by flushing from femurs and tibias 
from mice with IMDM 5% FBS and counted in a Burker chamber after a 1 :50 
dilution (1: 1 0 dilution in acetic acid to lyse erythrocytes, followed by a 1:5 
dilution in trypan blue (Invitrogen) to exclude dead cells). IMDM was poured off 
after spinning at 1000 rpm in Heraeus Megafuge 1.0 (Kendro Laboratory 
products) 10 min at room temperature, and cells were resuspended in 25ml PBS 
2% FBS and centrifuged again (washing step). Cells were resuspended at a 
concentration of 5xl07cells/mi in PBS 2% FBS, 5% rat serum and incubated 15 
min at 4°C to block aspecific binding of antibodies. Cells were then incubated 
with 35Jll/mi StemSep Enrichment Cocktail, which contains a combination of rat 
biotinilated monoclonal antibodies anti-mouse lineage specific markers (CD5, 
CDIlb, CD45R1B220, Gr-l, Neutrophils (7-4) and TERI19) 15 min at 4°C. After 
washing with PBS 2% FBS, cells were resuspended at 5xl07cells/ml in PBS 2% 
FBS, incubated with 100Jll/rril Anti-Biotin tetrameric antibody complexes 15 min 
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at 4°C and then with 60J.lI/ml magnetic colloid .15 min at 4°C. Cells were then 
loaded on a primed and equilibrated column in the magnetic field. Flow though, 
which contains Lin- cells, was harvested and cells were washed, resuspended in 
StemSpan medium (Stem Cell Technologies) and counted. Murine HSPCs were 
used fresh. 
2.7 Transduction 
2.7.1 Human HSPCs 
CD34+ cells were incubated at a concentration of 5xl05-1x106 cells/ml in Stem 
Span serum-free medium (Stem Cell Technologies) with or without the following 
cytokines, tested individually or in combination: 20 ng/ml recombinant human-
Interleukin 6 (rh-IL6), 100 ng/ml rh-Stem Cell Factor (rh-SCF), 100 ng/ml rh-
fms-like tyrosine kinase 3 Ligand (rh-FLT3L), and 20 ng/ml rh-thrombopoietin 
(rh-TPO) (all from Peprotech). Transduction was carried out for 20-24 hours with 
the indicated concentration of VSV-pseudotyped LV, or 108 TU/ml where not 
indicated. 
A-MLV or RD114ITR pseudotyped LVs were used at a concentration of 
3xl07 TV/ml, preloaded for 2 hrs on non-tissue culture treated dishes coated with 
recombinant human Fibronectin Fragment (CH296 - Takara BIO) following 
man ufacturer instructions. 
For the proteasome inhibitor experiments, CD34+ were transduced as described 
above with VSV-pseudotyped LV and MG132 (Calbiochem, EMD Biosciences) 
or PS-341 (Millennium Pharmaceuticals) was added to the transduction me~ium 
at the indicated concentration and washed out with the vector after the 20-24 
hours transduction period. 
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For promoter trapping experiments, CD34:- were stimulated 36 hours with 
the abovementioned combination of cytokines before transduction with 107 TO/ml 
(integration titer) of LT and RT in the first experiment or with 107 TO/ml of RT 
and 5x107 TO/ml LT in the second experiment. Prestimulation was needed in 
order to allow comparable level of transduction by RT and LT. 
In all the experiments, after the transduction period CD34+ cells were 
washed and maintained in IMDM medium 10% FBS containing 20 nglml rh-IL6, 
100 ng/ml rh-SCF, and 20 ng/ml rh-Interleukin 3 (rh-IL3) (all from Peprotech) for 
suspension culture and/or plated for Colony Forming Cell Assay (see below) 
and/or transplanted into NOD/SCID mice (see below). CD34+ cells subjected to 
S-phase suicide assay were treated with the S-phase specific killing agent before 
seeding and/or transplant (see relative paragraph below). HSPCs grown in 
suspension were analysed by F ACS 2 weeks after transduction. 
In promoter trapping experiments puromycin selection was performed 
adding 1 J.1g/ml puromycin (Sigma-Aldrich) to the suspension culture medium 3 
days after transduction. 
2.7.2 Murine HSPCs 
For the proteaso~e inhibitor experiments FVB Lin- cells were incubated at a 
concentration of lxl06 cells/ml in Stem Span serum-free medium (Stem Cell 
Technologies) in presence of 20 ng/ml recombinant mouse - rm - IL3, 100 ng/ml 
rm-SCF, rm-FLT3L, and rm-TPO (all from Peprotech) and transduced for 24 
hours with 108 TO/ml of VSV-pseudotyped LV. MG132 (Calbiochem, EMD 
Biosciences) was added to the transduction medium at the indicated concentration 
and washed out with the vector after the transduction period. 
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For promoter trapping experiments 1 o~ cells/ml C57BI/6 Lin- were 
stimulated for 24 hours in StemSpan serum-free medium in presence of the 
abovementioned cytokines, before transduction with 5xl07 TU/ml ofLT and RT. 
Prestimulation of the cells was necessary to reach efficient transduction by both 
vector types. 
In all the experiments, after the transduction period Lin- cells were washed 
and maintained in IMDM medium 10% FBS containing the combination of 
cytokines abovementioned for suspension culture and analysed by F ACS 1 or 2 
weeks later (for promoter trapping experiments or" proteasome inhibitor 
experiments, respectively). 
2.7.3 Cell lines 
U937 cells were seeded at 106 cells/ml in 1,25 cm wells and transduced with 
2xl05 LV TU/ml. K562 were seeded at 2xl05 cells/ml in 1,25 cm wells and 
transduced with 5xl05 LV TU/ml. HeLa and 293T cells were seeded at 5xl04 
cells/ml in 3,5cm wells and transduced the following day with 5xl 04 LV TU/ml. 
MG 132 (Calbiochem, EMD Biosciences) was added to the transduction medium 
at the indicated concentration and washed out with the vector after the 
transduction period. All cell lines were transduced for 12 hours, then washed and 
kept in culture 2 weeks before F ACS analysis. 
2.8 S-phase suicide assay 
CD34+ cells transduction was performed using 108 LV TU/ml as described above, 
in presence or absence of cytokines. Cells were then washed with serum-free 
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medium, plated at a concentration of 2xl06 cells/ml and exposed to 20 JlCi/ml of 
high specific activity 3H_ Thymidine (25 Ci/mmol - Amersham Biosciencies, GE 
Healthcare) or at a concentration of 5xl05 cells/ml and exposed to 2xl0-6M 
cytosine 1-I3-D-arabinofuranoside (Ara-C - Sigma-Aldrich). Cells were incubated 
for 16 hours with 3H_t or 12 hours with Ara-C and then washed twice with serum-
free medium and maintained, as aforementioned, in IMDM medium 10% FBS 
containing 20 ng/ml rh-IL6, 100 ng/ml rh-SCF, and 20 ng/ml rh-IL3 (all from 
Peprotech) for suspension culture and plated for Colony Forming Cell Assay 
and/or transplanted into NOD/SCID mice (see relative paragraphs below). 
To assess killing efficiency of the S-phase specific killing agents, the 
number of cells plated in Colony Forming Cell Assay for each sample was 
calculated on the basis of the number of cells counted before the exposure to 3H-t 
or Ara-C. Thus, killing efficiency was calculated by scoring colonies derived from 
S-phase specific killing agent-treated cells, using colonies derived from untreated 
cells as control. 
2.9 Human HSPC Colony Forming Cell (CFC) Assay 
CFC assay was used to assess transduction, and possible toxicity of the 
,-> treatments, in haematopoietic committed progenitors. When performed on 
NOD/SCID derived bone marrow cells, it was used also as indirect demonstration 
of the presence of SCID Repopulating Cells. Indeed, the presence of CFCs in the 
bone marrow of transplanted mice 6-10 weeks after transplant indicates the 
presence of a more primitive stem cell that generated them, since originally 
transplanted CFCs exhaust before analysis. 
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After transduction, CD34+ cells were wa~hed, counted (excepted for S-
phase suicide assay; see relative paragraph above) and seeded at a density of 1000 
cells/ml in semisolid medium (MethoCult GF4434 - Stem Cell Technologies). 
Cells were mixed by vortexing and 1,1 ml of cell suspension were plated in a 
3,5cm dish. Semisolid medium composition is as follows: IMDM 1 % 
methilcellulose, 30% FBS, 1% BSA, 10-4M 2-mercaptoethanol, 2mM L-
glutamine, 50ng/ml rh-SCF, 10ng/ml rh-granulocyte macrophage-colony 
stimulating factor (rh-GM-CSF), 10ng/ml rhIL3, 3U/ml erythropoietin (EPO). 
When CFC assay was performed on NOD/SCID bone marrow derived cells, cells 
were plated at a density of2,5x105cells/ml. 
For puromycin selection in promoter trapping experiments, CD34+ cells 
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were plated 24 hours after transduction in semisolid medium containing 1 f..lg/ml 
puromycin (Sigma-Aldrich). 
Each sample was plated in duplicate and dishes were put in a humid 
chamber in order to avoid drying of the semisolid medium. Cells were incubated 
for 2 weeks and then scored by light and fluorescence microscopy for number and 
trans gene expression. 
2.9.1 CFC analysis by Polimerase Chain Reaction (PCR) 
Individual, well-isolated colonies were plucked 10-14 days after plating into 0,5 
ml of PBS, vortexed, left at room temperature for 30 minutes, then vortexed again 
and centrifuged at 2000 rpm in Heraeus Biofuge pico (Kendro Laboratory 
products) for 10 minutes. Pellets were resuspended in 25 f..ll of lysis buffer (20 
mM TrisHCI pH 8,4, 50 mM KCI, 1,5 mM MgCh, 0,45% Tween-20, 0,45% 
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Nonidet P-40, and 1,5 mg/ml proteinase K) and i~cubated at 56°C for 1 hour and 
95°C for 15 min. PCR was carried out on 5 J..lI of the preparation. 
Amplification was performed in a total volume of 50 J..lI, with AmpliTaq 
Platinum enzyme (Invitrogen) in 1.5 mM MgCh with 0.5J..lM forward and reverse 
primers. PCR conditions were: one cycle of 94°C for 2 minutes; 30 cycles of 94°C 
for 30 seconds, annealing (for temperatures see below primer sets) for 30 seconds, 
and 72°C for 30 seconds; one cycle of 72°C for 7 minutes. 
20J..lI of the PCR products were analysed by agarose gel electrophoresis. 
For promoter trapping experiments a primer set specific for GFP was used 
(5' GCAGAAGAACGGCATCAAGGT 3' and 5' 
GAACTCCAGCAGGACCATGTGA 3'). Temperature of annealing was 60°C for 
this primer set and it yielded a 202 bp band. 
For the analysis of colonies in the competitive repopulation assay two 
primer sets were used, one specific for GFP (not complementary to YFP) (5' 
CCCTCGTGACCACCCTGAC 3' and 5' TGCTCAGGGCGGACTGGGT 3') and 
one specific for YFP (not complementary to GFP) (5' 
ACCCTCGTGACCACCTTCGG3' and 5' CTTTGCTCAGGGCGGACTGGTA 
3 '). Temperature of annealing were 60°C for YFP and 66°C for GFP primer set. 
Both primer sets yielded a 454 bp band. 
2.10 SCID Repopulating Cell (SRC) Assay 
In order to assess performance and transduction of human HSCs, we performed 
the SRC assay. The xenotransplant model used is the NODlLtSz scid/scid 
(NOD/SCID) (nonobese diabetic/severe combined immunodeficient) mouse 
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(Shultz, Schweitzer et al. 1995) transplanted wi.th cord blood derived CD34+ 
cells. 
NOD/SCID mice were obtained from the British Columbia Cancer 
Research Center (Vancouver, Canada) or from Charles River (Charles River 
Laboratories Inc.) and maintained in ventilated cages in a Specific Pathogen Free 
(SPF) facility, according to approved protocols. All procedures were performed 
according to protocols approved by the Animal Care and Use Committee of the 
Fondazione San Raffaele del Monte Tabor (IACUC 244) and communicated to 
the Ministry of Health and local authorities according to Italian law. 
Six- to eight-week-old mice were sub-lethally irradiated (350 cGy; Rad Gil 
EN 60601-1, Gilardoni) 24 hours before transplant. The following day, transduced 
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CD34+ cells were washed and resuspended in PBS at a density of 1,5x10 cells/ml 
approximately. Mice were then heated under an infrared heat lamp and 
transplanted by intravenous injection in the tail vein of 250JlI (about 4x105 cells) 
of cell suspension per mouse using an U-100 insulin syringe (lml, gauge 26) 
(Terumo). Mice were maintained with sterile acidified water (8 mM HCI), 
containing 16 Jlg/ml neomycin sulfate (Sigma-Aldrich). 
Competitive repopulation assay was performed using cells transduced in 
different conditions and marked with distinguishable vectors. Each non 
competitively repopulated (reference) mouse received 4x105 CD34+ cells 
transduced in presence or absence of cytokines wi~h either LV -GFP or LV -YFP; 
each competitively repopulated mouse received 2x105 CD34+ cells transduced in 
presence of cytokines with LV -GFP or LV -YFP and 2x105 CD34+ transduced in 
absence of cytokines with LV-YFP or LV-GFP, respectively. 
In S-phase suicide assay transduced CD34+ cells, both Ara-C-treated and 
untreated, were not counted before transplant and the number of cells to be 
87 
injected was calculated on the basis of the number. of cells plated before treatment. 
CD34+ cells were injected together with 5xI05 CD34-negative accessory cells. 
Accessory cells were used to substitute the killed progenitors cells in supporting 
the first stages on engraftment. The same number of accessory cells was 
transplanted also with untreated cells in order to avoid any variability in the read 
out due to a possible contribution of these cells to repopulation. CD34-negative 
cells were harvested from the flow-through of CD34 positive selection, counted 
and frozen in FBS 10% DMSO; they were thawed the day before transplantation, 
counted and seeded in IMDM 10% FBS at a density· of I06cells/ml. Before 
transplants viable CD34-negative cells were counted by using trypan blue (1:5 
dilution) (Invitrogen) and pooled with CD34+ cells. 
Six to ten weeks after transplant, mice were euthanised by C02 inhalation 
and bone marrow cells were harvested by flushing from femurs and tibias in 5ml 
IMDM 5% FBS per mouse. The volume of each sample was then made up to 15 
ml with IMDM 5% FBS and cells were counted after a 1: 10 dilution in 3% acetic 
acid to exclude red cells from the count. 6xI05 cells/sample were used for FACS 
analysis, 5xI05 cells/sample for CFC assay and the remaining cells (l07-2xI07 
cells/sample) for Q-PCR analysis (see relative paragraphs)(Ailles, Schmidt et al. 
2002). 
2.11 Flow cytometry 
Since all the vectors used in this work encode for a fluorescent protein, 
transduction was assessed mainly by flow cytometry. The instrument used was 
FACSCalibur (Becton Dickinson Immunocytometry Systems). 
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2.11.1 Assessment of transduction efficiency in ~n vitro cultures 
To determine expression titer, He La or 293T cells were detached by trypsin-
EDTA solution, washed with PBS, fixed with PBS, 1% paraformaldehyde, 2% 
FBS (lmllsample) and analysed by FACS for transgene expression (GFP or YFP). 
To assess transduction efficiency cells were grown for at least 5 days after 
transduction to reach steady state GFP expression and to rule out 
pseudotransduction (detection of GFP protein associated with the virus particles 
during vector production and transferred to the target cells during infection) and 
then is diluted out of the cells as they divide). Adherent cells were detached by 
trypsin-EDTA solution, washed with PBS 2% FBS and resuspended in PBS 2% 
FBS containing 10f..lg/ml 7~amino-actinomycin D (7AAD) (Sigma-Aldrich). Cells 
grown in suspension were washed with PBS 2% FBS and resuspended in PBS 2% 
FBS containing 10f..lg/ml 7 AAD. Only viable, 7 AAD-negative cells were analysed 
for transgene expression. 
Untransduced cells were used as negative control to set parameters and 
gates. 10,000-20,000 events were scored. 
2.11.2 Cell cycle analysis 
CD34+ cells, exposed or not to Ara-C, were washed with PBS and resuspended in 
0,5mL DNA staining buffer per 106 cells (PBS l % saponin containing 300KU 
RNase and 50 f..lg/ml Propidium Iodide - PI (Sigma-Aldrich). Cells were 
incubated in the dark for 10 minutes on ice and then analysed by F ACS for DNA 
staining. Cell aggregates and dead cells were eliminated from further analysis by 
gating individual cells in the FL3-area versus FL3-width plot. 100,000 events 
were scored. 
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2.11.3 NOD/SCID bone marrow analysis 
Cells from bone marrow were retrieved by flushing from femurs and tibias of 
NOD/SCID mice in 5ml/sample IMDM 5% FBS. The volume of each sample was 
then brought to 15 ml with IMDM 5% FBS and cells were counted after a 1: 1 ° 
dilution in 3% acetic acid to exclude red cells from the count. 
6xl05 cells/sample were transferred into a 5mt' polystirene round-bottom 
tube and centrifuged at 1000 rpm in Heraeus Megafuge 1.0 (Kendro Laboratory 
products) 10 min at room temperature. Cells were resuspended in 5ml/sample 7% 
ammonium chloride solution (Stem Cell Technologies) and incubated 20 min on 
ice to lyse red cells. Cells were then centrifuged at 1200 rpm in Heraeus 
Megafuge 1.0 (Kendro Laboratory products) 7 min at 4°C, resuspended in 0,5ml 
PBS 2% FBS, 5% human serum and 5% mouse serum and incubated on ice for 10 
minutes to block aspecific binding sites of the antibodies. Cells were then divided 
into 100 J.lI aliquots and 1 ° J.lI of each of the following human-specific Cy5-
phycoerythrin- (for the competitive repopulation assays) or phycoerythrin- (for 
other assays) conjugated antibodies were used: 
anti-IgG 1 (l0Jlg/ml): isotype control 
anti-hCD45 (20,OJlg/ml): pan-leukocyte marker (used to determine the extent of 
the human graft) 
.. 
anti-hCD34 (lO,OJlg/ml): haematopoietic progenitor marker 
anti-hCDl3 (12,5Jlg/ml): myeloid marker 
anti-hCDl9 (l7,5Jlg/ml): B-Iymphoid marker 
(all from DAKO AlS). Cells were incubated in the dark 20 min on ice and then 
washed by adding Iml PBS 2% FBS and spinning at 1200 rpm in Her~eus 
Megafuge 1.0 (Kendro Laboratory products) 7 min at 4°C. Cells were then 
resuspended in 0,3 ml PBS 2% FBS containing 2 J.lg/ml PI for viable staining and 
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analysed by three-colour flow cytometry. The percentage of aritibody-
positive/transgene-positive cells was determined after excluding nonviable cells. 
PI was not used in combination with Cy5 phycoerythrin-conjugated antibodies 
and YFP, because of emission wavelength overlapping. 
A gate was set to exclude at least 99.9% of cells labelled with the isotype 
control. Mice were considered engrafted if hCD45+ cells exceeded 1 % of total 
mononuclear bone marrow cells. 
In the competitive repopulated mice, since both GFP and YFP signals emit 
in the FL-l channel whereas only YFP emits in the FL-2 channel, we calculated 
the frequency of GFP-expressing cells by subtracting the fraction of YFP-
expressing cells, scored in FL-2, from the percentage of cells scored positive in 
FL-l. 
Untransplanted mice were used as negative control. We scored 10,000-
100,000 events. 
2.12 Genomic DNA extraction and Real-time Quantitative-PCR (Q-
PCR) analysis 
In order to evaluate vector copy number per cell and, in some cases, percentage of 
human cells in NOD/SCID bone marrow, Q-PCR was performed on genomic 
DNA extracted from transduced cells either grown in culture or derived from 
mouse bone marrow. Cells in culture were grown for at least 10 days before 
analysis to exclude non-integrated vector forms from the analysis. 
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2.12.1 Genomic DNA extraction 
Genomic DNA extraction was performed by using the Blood and Cell Culture 
DNA kit (Midi kit; Qiagen). This system is based on cell lysis, followed by DNA 
purification on an anion exchange resin. 
Cultured cells were harvested (for cells grown in suspension) or detached 
by trypsin-EDTA solution (for adherent cells) and washed with ice-cold PBS by 
spinning at 1000 rpm in Heraeus Megafuge 1.0 R (Kendro Laboratory products) 
10 min at 4°C. 
Nuclei precipitation protocol was as follows: 
o resuspend cells with ice-cold PBS to a concentration ofSx106- lx107 cells/ml 
o add I volume of ice-cold Buffer CI and 3 volumes of ice-cold distilled water, 
mix by inverting tubes and incubate 10 min on ice to lyse cells preserving the 
nuclei 
o spin 2000 rpm in Heraeus Megafuge 1.0 R (Kendro Laboratory products) IS 
min at 4°C and discard supernatant 
o resuspend cells in Iml ice-cold Buffer CI and 3ml ice-cold distilled water 
o spin 2000 rpm in Heraeus Megafuge 1.0 R (Kendro Laboratory products) IS 
min at 4°C and discard supernatant to remove residual cell debris 
o resuspend cells in Sml Buffer G2 (lysis buffer) containing 0,4mg/ml RNase A 
For bone marrow derived cells nuclei precipitation was not performed and 
pellets of cells were directly resuspended in Sml ~uffer G2 containing O,4mg/ml 
RNase A. 
Samples were then incubated I hour at 37°C in a water bath to degrade 
RNA. Lysis was then performed by adding proteinase K to the suspension .to a 
final concentration of 0,4mg/ml and incubating samples over night at SO°C in a 
water bath. 
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The following day samples were vortexed. at maximum speed 10 seconds 
and applied to equilibrated anion exchange resin columns, washed and eluted. 
After elution, genomic DNA was precipitated by adding 0,7 volumes of room 
temperature isopropanol and inverting tubes several times. DNA was then 
transferred by winding the floccule onto a loop into a 1,5ml tube containing 1 ml 
of 70% ethanol. Samples were then centrifuged to remove precipitated salts at 
14,000 rpm in Heraeus Biofuge fresco (Kendro Laboratory products) 15 min at 
4°C. After removal of supernatant, DNA was air-dried for 15 min, resuspended in 
100-200JlI TE (10mM Tris, 1mM EDTA; pH 8,0) and dissolved on a shaker at 
55°C for 2 hours. 
Genomic DNA was finally quantified by spectrophotometer analysis and 
run on a 0,8% agarose gel to check for possible RNA contaminations and 
degradation of the sample. DNA was then stored at -20°C. 
2.12.2 Real-time Q-PCR 
Q-PCR was performed in Optical 96-well Fast Thermal Cycling Plates (Applied 
Biosystem) on ABI PRISM 7900 Sequence Detector System (Applied 
Biosystem), using the following thermal cycling conditions: one cycle at 50°C for 
2 min, one cycle .~t 95°C for 10 min, 40 cycles at 95°C for 15 seconds and 60°C 
for 1 min. For each sample, the Sequence Detector System 2.1 software provided 
an amplification curve constructed by relating the fluorescence signal intensity (A 
Rn) to the cycle number. Cycle threshold (Ct) was defined as the cycle number at 
which the fluorescence signal was more than 10 SD of the mean background noise 
collected from the 3rd to the 15th cycle. Vector copy number was determinea by 
using as standard curve serial dilutions (200ng, lOOng, 50ng, 25ng and 12,5 ng) of 
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genomic DNA extracted from a human cell line c.lone stably containing a known 
number of LV -GFP integrations (copy number of the standard curve was 
previously defined by Southern Blot analysis). To determine vector copy number 
per cell, LV copy numbers were normalized to human DNA content, which was 
assessed either by spectrophotometry or by Q-PCR. When assessed by Q-PCR, 
human DNA content was quantified by using the same standard curve used for 
vector copy number assessment. When engraftment in NOD/SCID mice was 
assessed by Q-PCR, murine DNA content was determined by using as standard 
curve serial dilutions (200ng, lOOng, 50ng, 25ng and 12,5 ng) of genomic DNA 
extracted from mouse bone marrow derived cells. 
Each sample was run in triplicate in a total volume of 25J..ll/reaction, 
containing 12,5J.lI TaqMan Universal Master Mix (4304437; Applied Biosystem), 
100ng of sample DNA and one of the following amplification systems at the 
following concentrations. 
For integration titer on promoter trapping vectors oligonucleotides and 
probe complementary to the GFP sequence (common to both LT and RT) were 
used: 
forward primer: 5' - CAGCTCGCCGACCACTA ~ 3' (900nM) 
reverse primer: 5' - GGGCCGTCGCCGA T - 3' (900nM) 
probe: 5' - 6-F AM - CCAGCAGAACACCCCC - MGB -3' (200nM) 
For vector copy number analysis of t~ansduced HSPCs grown In 
suspension two systems were used, one is the system complementary to the GFP 
sequence described above and the other is complementary to the LV 
encapsidation signal psi ('I') sequence: 
forward primer: 5' - TGAAAGCGAAAGGGAA - 3' (200nM) 
reverse primer: 5' - GACTTCGCGCGTGCC - 3' (200nM) 
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probe: 5' - VIC - AGCTCTCTCGACGCAG<;JACTCGGC - TAMRA - 3' 
(200nM) 
In these samples human DNA content was assessed by Q-PCR by using 
oligonucleotides and probe complementary to the human Telomerase Reverse 
Transcriptase (hTERT) sequence (Sozzi, Conte et al. 2003): 
forward primer: 5' - GGCACACGTGGCTTTTCG - 3'(200nM) 
reverse primer: 5' - GGTGAACCTCGT AAGTTT A TGCAA - 3' (600nM) 
probe: 5' - 6-F AM - TCAGGACGTCGAGTGGACACGGTG - TAMRA -3' 
(200nM) 
For the analysis of the genomic DNA extracted from NOO/SCIO bone 
marrow derived cells three different systems were used. To detect vector sequence 
oligonucleotides and probe complementary to the LV Rev Responsive Element 
(RRE) sequence were used: 
forward: 5' -TGAGGGCTATTGAGGCGC-3' (600nM) 
reverse: 5' -TGCCTGGAGCTGCTTGATG-3' (600nM) 
probe: 5' - 6-FAM - TTGCAACTCACAGTCTG - MGB - 3' (200nM) 
To quantify human DNA content the hTERT system described above was used. 
To quantify murine DNA amount oligonucleotides and probe complementary to 
the murine J3-actin gene were used: 
forward: 5' - AGAGGGAAATCGTGCGTGAC - 3' (300nM) 
reverse: 5' - CAATAGTGATGACCTGGCCGT - 3' (750nM) 
probe: 5' - VIC - CACTGCCGCATCCTCTTCCTCCC - MGB - 3' (200nM). 
The level of engraftment in these mice was determined as the ratio between 
human DNA and total DNA content (human and murine). 
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2.13 Proteasome activity assays 
Cellular extracts from cord blood CD34+ cell, stimulated or not with cytokines for 
the indicated time, and from cell lines were prepared as previously described (Mo, 
Cascio et al. 1999) with minor modifications. 
106 cells per sample were harvested or detached by trypsin-EDT A 
solution, if adherent, and washed three times with ice-cold PBS in 50ml tubes. 
Pellets were resuspended in 200~1 of ice-cold lysis buffer (50mM TrislHCI pH 
7,5, ImM dithiothreitol, 0,25M sucrose, 5mM MgCb, 0,5mM EDTA, 2mM 
ATP), transferred in 1,5ml tubes and sonicated. Samples were then centrifuged at 
13000 rpm in Heraeus Biofuge fresco (Kendro Laboratory products) 30 min at 
4°C. Supernatants were then transferred into clean 1,5ml tubes and frozen at -
80°C. 
Peptidase activities of proteasome were assayed by monitoring the 
production of 7-amino-4-methylcoumarin (amc) from fluorogenic peptides as 
previously described (Cascio, Call et al. 2002). Briefly, Suc-LLVY-amc (for the 
chymotrypsin-like activity), Boc-LRR-amc (for the trypsin-like activity) and Ac-
YV AD-amc (for the caspase-like activity) were used at a final concentration of 
100~M in 20mM Tris-HCI pH 7,5, ImM ATP, 2mM MgCb, 0,1% BSA. 
Reactions were started by adding an aliquot of cellular extract and the 
fluorescence of released amc (excitation, 380 nm; emission, 460 nm) was 
monitored continuously at 37°C with a Carry Eclipse spectrofluorimeter. 
Background activity was determined by addition of the proteasome inhibitors 
MG 132 (for the chymotrypsin and the caspase-like activities) and J3-lactone (for 
the trypsin-like activity) at a final concentration of 10~M and 20~M respectively. 
Assays were calibrated using standard solutions of free fluorophores. 
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Consumption of the substrates at the end of incubation never exceeded 1 %. 
Concentration of DMSO (in which stock solution of peptides and inhibitors were 
prepared) in the assays never exceeded 0.7%, which does not affect proteasome 
activity (Akopian, Kisselev et al. 1997). 
2.14 Statistical analysis 
For the Competitive Repopulation Assay we established a statistical model for % 
FP, the percentage of SRC expressing the transgene. Such a percentage is the 
response variable of interest and its distribution may be affected by several 
variables, including the cytokine treatment (variable "cyt" , + or -), the marker 
(variable "dye", YFP or GFP), the cell preparation (variable "batch") and the 
xenotransplant model,' (variable "tx-mod", reference or competitively 
repopulated). Taking into consideration that each reference mouse generates only 
one measurement (either % YFP or %GFP), while each competitively repopulated 
mouse generates two non-independent measurements (%YFP and %GFP), we 
modelled the presence of within-mouse correlated pairs of observations treating 
the variable "mouse" as a random effect. According to the statistical literature (see 
(Searle, Casella et al. 1992) for a comprehensive treatment), random effects 
represent specific, sources of randomness in addition to natural variability 
underlying all biological experiments. Since %FP are percentages, which are by 
definition constrained between 0 and 100, we transformed them into their logodds 
lofp = log (%FP/(100-%FP)). 
A linear mixed effect model for response variable "lofp" was constructed with 
fixed effect variables "cyt", "dye", "batch" and "tx-mod" and random effect 
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variable "mouse". The model was fitted using routine lme from the contributed 
package nlme (Pinheiro and Bates 2000) to the free software R 
(RdevelopmentCoreTeam 2004). 
To compare results obtained in other experiments, we performed the 
following tests. In most cases, t-tests were not appropriate either because 
percentages are naturally bounded between 0 and 100, and cannot be modeled by 
normal distributions, or because the normal distribution assumption for the 
relevant statistics is not appropriate when there are too few observations. We used 
nonparametric tests based on ranks: Wilcoxon signed rank test for paired samples 
and Wilcoxon-Mann-Whitney rank sum test for independent samples. 
Calculations were done using the function wilcox. test, native to the free 
software R (RdevelopmentCoreTeam 2004). 
A standard sign test was used for the data in Figure 4.6. 
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Chapters 3-5. 
Results 
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3. Effect of early-acting cytokines on HS~ features and transduction 
byLVs 
3.1 Effect of cytokine stimulation on repopulating ability of human HSCs 
We have previously demonstrated that Cord Blood (CB)-derived HSCs can be 
efficiently transduced after a short incubation with a lentiviral vector (LV) (20-24 
hours) in serum free conditions, in the absence of cytokine stimulation. 
Nevertheless, we have also found that the presence of a cocktail of early-acting 
cytokines (SCF, TPO, Flt3L and IL6) during the transduction period further 
enhanced transduction efficiency, reaching on average more than 70% of SCID 
Repopulating Cells (SRCs) transduced (Ailles, Schmidt et al. 2002). When we 
transplanted CD34+ cells transduced in the presence or absence of cytokines in a 
NOD/SCID model, we observed similar levels of engraftment between stimulated 
and unstimulated SRCs, suggesting that exposure to cytokines did not 
compromise SRC engraftment ability. However, the limited follow-up of the 
NOD/SCID mice and the heterogeneity of the engrafting SRCs did not allow 
analysing HSC long-term repopulating ability, so that we could not evaluate a 
possible detrimental effect of cytokines on long-term HSCs and on their 
c1onogenic and proliferation ability. Thus, in this work we aimed to establish in a 
,} more stringent model whether the gain in gene transfer could be offset, even for a 
short cytokine exposure, by a decreased engraftment or long-term repopulation 
capacity of the transduced cells. 
In order to stringently assess the engraftment and repopulation capacity of 
human cord blood SRCs after the short ex vivo culture with and without the 
combination of cytokines, we performed a competitive NOD/SCID mouse 
repopulation assay. We transduced CB CD34+ cells in both culture conditions 
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with either of two late generation self-inactivating LVs (Follenzi, Ailles et al. 
2000) differing only for the transgene (Green Fluorescent Protein - GFP - or 
Yellow Fluorescent Protein - YFP). We injected half of the cells transduced with 
cytokines by LV -YFP and half of the cells transduced without cytokines by LV-
GFP into the same NOD/SCID mouse (YFP+cytIGFP-cyt mice, n=12). In order to 
avoid any transgene-specific effect we also swapped transgene and culture 
condition in a parallel group of mice (YFP-cytIGFP+cyt mice, n=8). In parallel, 
we transplanted mice with the same total number of cells transduced in only one 
culture condition, and with either of the two vectors, and obtained four 
experimental groups of reference, non-competitively repopulated mice (GFP+cyt, 
GFP- cyt, YFP+cyt, YFP- cyt mice, n=4,6,5,5 per group, respectively). A scheme 
of the experimental plan is shown in Figure 3.1. 
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Figure 3.1. Competitive repopulation assay: experimental strategy. 
Competitive repopulation assay was performed using cells transduced in different conditions 
and marked with distinguishable vectors. Each non competitively repopulated (reference) 
mouse received 4xl05 CD34+ cells transduced in presence or absence of cytokines with either 
LV -GFP or LV -YFP; each competitively repopulated mouse received 2xl05 CD34+ cells 
transduced in presence of cytokines with LV -GFP or LV -YFP and 2xl05 CD34+ transduced in 
absence of cytokines with LV -YFP or LV -GFP, respectively. 
Aliquots of the transduced cells were kept in culture and plated in CFC 
assays for assessment of transduction. F ACS analysis of suspension cultures 
showed on average 41 % and 20% frequency of trans gene-expressing cells, one 
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week after transduction with and without cytokines, respectively, with the LV-
GFP vector and 49% and 27%, with and without cytokines, respectively, with the 
LV-YFP vector (average of three experiments performed; Table 3.1). 
Table 3.1. Competitive Repopulation Assay. FACS analysis of HSPC 
suspension culture 
% transgene positive cells 
-cyt + 'Yt 
14 31 
LV-GFP 26 43 
20 49 
Average 20 41 
29 54 
LV-YFP 40 58 
13 34 
Average 27 49 
In committed haematopoietic progenitor cells, scored in the CFC assay, we 
reached slightly higher percentages of transgene positive cells (data not shown). 
Ten weeks after the transplant, we analysed NOD/SCID bone marrow by FACS. 
Representative F ACS plots of competitively and non-competitively repopulated 
mice are shown in Figure 3.2. We performed a three-channel analysis to 
. discriminate GFP and YFP signals, because YFP emission reads through the GFP 
channel (Figure 3.2 a). Transgene expression was assessed both in the total human 
,':> CD45+ cell population, and, in order to verify transduction of multi-potent HSCs, 
in the progenitor, lymphoid and myeloid fractions (Figure 3.2 b,c). All 
repopulated mice (> 1 % hCD45+ cells, 40 mice out of 44 assayed; the numbers of 
mice studied per group given above refer to the successfully repopulated mice) 
showed multi-lineage engraftment by transduced SRCs. Human engraftment level 
and frequency of trans gene expression for all the positive mice are shown in Table 
3.2. 
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Figure 3.2. Competitive repopulation assay: representative FACS Analysis. ,-
Three-channels F ACS analysis of mouse BM ten weeks after transplant of human CD34+ cells 
transduced with either LV-GFP or LV-YFP. A) Frequency of transgene expression in the 
human cell (hCD45+) graft. FACS plots from a competitively repopulated mouse, showing 
both GFP and YFP-positive cells (upper panels), and two reference mice, showing either YFP 
or GFP-positive cells (middle and lower panels), as indicated. Percentages of transgene-
positive cells detected in each channel (FL-2: YFP; FL-!: GFP + YFP, FL-3: human CD45) are 
given in the respective quadrant. B) and. C) Multilineage engraftment by transduced SRCs. 
Percentages shown represent the fraction of transgene-expressing cells among the' indicated 
lineage marker-positive cells (scored in the FL-3 channel). Because both GFP and YFP. signals 
emit in the FL-l channel, we calculated the frequency of GFP-expressing cells by subtracting 
the fraction of YFP-expressing cells, scored in FL-2, from the percentage of cells scored 
positive in FL-!. Mouse numbers as in Table 3.2. 
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Table 3.2. Competitive Repopulation Assay. SRC analysis 
Reference Mice Competitively Repopulated Mice 
GFP +cyt YFP+cyt I GFP-cyt. ____________ 
Mouse %hCD45A %GFpB %YFpB Mouse %hCD45A %GFpB %YFpB 
1 45 71 - 1 18 32 27 
2 41 80 - 2 10 40 17 
3 64 83 - 3 19 6 73 
4 16 69 - 4 15 7 65 
------_ ... ----
Average 41 76 - 5 6 9 82 
______ ~_~~_ -cyt 6 40 1 85 
Mouse %hCD45 %GFP %YFP 7 3 26 31 
1 66 60 - 8 4 47 17 
2 53 58 - 9 25 24 20 
3 17 23 - 10 15 20 16 
4 18 33 - 11 45 68 22 
5 20 35 - 12 9 18 11 
----._-.-----
6 59 37 -
----------
Average 17 25 39 
Average 39 41 -
___ .!FP +cyt YFP-cyt / G FP+cy( _________ 
Mouse %hCD45 %GFP %YFP Mouse %hCD45 %GFP %YFP 
1 40 - 85 1 58 30 48 
2 24 - 71 2 15 33 33 
3 50 - 78 3 5 44 22 
4 2 
- 35 4 7 6 85 
5 50 - 44 5 .40 45 15 
---------._--
Average 33 
-
63 6 10 50 8 
______ X¥.~_ -cyt 7 30 67 20 
Mouse %hCD45 %GFP %YFP 8 43 51 2 
-------
1 45 - 82 Average 26 41 29 
2 15 - 53 
3 60 - 63 
4 19 
-
18 
5 ., 11 
- 18 
Average 30 - 47 
A percentage of human cells in the mouse BM 
B percentage of human cells expressing the indicated trans gene 
As expected for the NOD/SCID model, mice were engrafted by human 
cells to variable levels, ranging from 2 to 66% of their bone marrow cells. The 
engraftment level was slightly lower in competitively repopulated than in non-
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competitively repopulated mice (21% versus 35% of CD45+ cells on average, 
respectively, n=20,20). 
The frequency of transgene-expressing cells was on average consistently 
higher for SRCs transduced with cytokines, in all permutations of vector type and 
experimental condition tested. As previously observed (Mikkola, Woods et al. 
2000; Ailles, Schmidt et al. 2002), the frequency of trans gene-expressing cells 
was higher, in each condition tested, for the SRC progeny than for the in vitro 
suspension cultures. 
To assess whether the cytokine stimulation had an impact on the 
repopulating capacity of the transduced SRCs we developed a statistical model, in 
which all the experimental parameters (see paragraph 2.14 Statistical analysis) 
were taken in consideration and the relevant hypotheses tested. The response 
variable of interest wa's the percentage of transduced SRCs, which in the statistical 
model was termed %FP. Its distribution might be affected by several variables, 
including cytokines stimulation ("cyt"), the transgene ("dye"), the cell preparation 
("batch"), and the xenotransplant model ("tx-mod" - non-competitively or 
competitively repopulated). 
Results of the statistical analysis are shown in Table 3.3. We confirmed 
that cytokines had a significant effect on the frequency of trans gene-positive cells, 
with an estimated positive effect in the logodd scale equal to + 1.044. This means 
that if the mean frequency of transduction is for example 30% for unstimulated 
cells (-cyt) , the estimated mean frequency increases to 55% when stimulated 
(+cyt). 
Because the interaction betWeen the parameters "cyt" and "tx-mod" 
(competitive or not) was not significant, we concluded that cytokine stimulation 
had a positive significant impact on SRC transduction without changing 
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significantly its extent and direction between reference and competitively 
repopulated mice, thus showing that cytokine-stimulated SRCs had an 
engraftment capacity similar to that of unstimulated cells, even in a stringent 
repopulation model. 
Table 3.3. Competitive Repopulation Assay. P-values for testing the 
significance of each variable 
A marker: GFP or YFP 
(Intercept) 
dyeA 
CytB 
tx-mode 
batchD 
cytltx-mod interaction 
B cytokine treatment: plus or minus 
p-value 
0.0009 
0.5670 
0.0115 
0.0007 
0.0975 
0.7737 
C xenotransplant model: competitive or reference. This variable is significant, with the 
competitively repopulated mice having a significantly lower %FP than the reference, since the 
competitively repopulated.micereceived half dose of cells for each condition with respect to the 
reference, and both types of injected cells contributed similarly to the graft. 
D batches of CD34+ cells 
Variable "tx-mod" was also significant, with the competitively repopulated 
mice having a significantly lower %FP than the reference; this was expected, 
since the competitively repopulated mice received half dose of cells for each 
condition with respect to the reference, and both types of injected cells 
contributed similarly to the graft. Variables "dye" and ""batch" were not 
,.> significant, showing no evidence of either a difference between YFP and GFP or 
differences across cell preparations. 
In order to confirm our findings at the vector DNA level, we performed 
PCR analysis, with specific primers for each transgene, on DNA extracted from 
human colonies derived from the bone marrow of engrafted mice (Figure 3.3). 
Colonies were plucked either randomly, to assess the absolute frequency of 
vector-positive CFCs for each vector type, or for positive fluorescence by 
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microscopy, to more quickly assess the relative proportion of YFP and GFP 
vector among transgene-expressing CFCs. 
A YFP..cyt I GFP +cyt #2 
21 22 23 24 25 26 27 28 29 30 MW 
-= 
21 22 23 24 25 26 27 28 29 - MW 
B YFP+cytlGFP-cyt YFP-cytIGFP+cyt 
Mouse %GFP %YFP Mouse %GFP %YFP 
-------_._'. __ .'._---_._-----_._------------
-----------.--------.---.. -------.------------
#1 22 78 #1 40 60 
#2 73 27 #2 71 29 
#3 0 100 #3 50 50 
#4 37 63 #4 0 100 
#5 na na #5 100 0 
#6 0 100 #6 33 67 
#7 75 25 #7 80 20 
#8 na na #8 75 25 
-------.-------------------.. ------.----------#9 69 31 Average 56 44 
#10 29 71 Expr. ratio 62 38 
#11 69 31 P 0.74 0.74 
#12 50 50 
.. ---.------.------------.-------------
Average 42 58 
Expr. ratio 39 61 
p 0.85 0.85 
Figure 3.3. Competitive repopulation assay: vector DNA analysis of bone marrow-
derived CFCs. 
Single CFCs were plucked randomly, lysed and analyzed by PCR, using two sets of primers 
specific for either GFP or YFP sequences. A) Agarose gel showing a representative analysis of 
ten colonies from the indicated mouse, scored for YFP (upper panel) and GFP (lower panel). 
B) Relative proportion of GFP and YFP-positive colonies. Values were calculated from the 
total number of.colonies scored positive for transgene DNA for each mouse, and averaged. For 
reference, the average relative proportion of GFP and YFP-expressing cells measured in the 
mouse bone marrow by F ACS, calculated from the data in Table 3.2 (Expr. ratio: expression 
ratio) is shown. Comparison between the two proportions did not show a statistically 
significant difference. P-values were calculated by signed rank two-sided tests. 
The relative proportions of YFP and GFP expressing cells in competitively 
repopulated mice can be calculated from the data in Table 3.2. When we 
compared it to the relative proportions of YFP and GFP vector-positive colonies 
in the human graft, as assessed by PCR analysis and shown in Figure 3.3 b, we 
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found that there was no evidence of a statistically significant difference between 
the distributions of the two groups. In a small panel of mice scored for the 
absolute frequency of each vector-positive CFC, we also verified a satisfactory 
correspondence between the frequency of trans gene expression and of actual 
vector transduction in the SRC progeny (data not shown). 
Overall, these results showed that cytokine treatment, while increasing LV 
transduction of human HSCs, did not affect their engraftment and repopulating 
ability in a stringent xenotransplant model. 
3.2 Cytokine effect on HSC cell cycle 
Although LV s transduce non-proliferating cells, they have been shown to be 
restricted in quiescent. T lymphocytes and macrophages, which must exit from Go, 
and presumably progress to the Glb phase of the cell cycle, in order to be infected 
by HIV-I, or transduced by LVs (Korin and Zack 1999; Unutmaz, KewalRamani 
et al. 1999; Kootstra, Zwart et al. 2000; Wu and Marsh 2001; Cavalieri, 
Cazzaniga et al. 2003; Verhoeyen, Dardalhon et al. 2003). The Go block of LV 
transduction could be active in HSCs as well, implying that quiescent HSCs are 
not transducible. Thus, a possible explanation for the cytokine enhancement of 
LV transduction could be that only the SRCs in the GI phase of the cell cycle are 
susceptible to transduction, and that cytokines enhance transduction tr.iggering the 
exit of SRCs from Go. Progression into late G., however, commits the cells to 
DNA replication and mitosis, and may thus impair the long-term repopulating 
ability of HSCs (Glimm, Oh et al. 2000; Guenechea, Gan et al. 2001), a feature 
that is difficult to assess in the NOD/SCID model. 
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Since we could not measure the cell cycle status of the few SRCs 
contained in the CD34+ population, we performed an S-phase suicide assay on the 
transduced cells. In a first set of in vitro experiments, we transduced with LV-
GFP CB CD34+ cells with or without cytokines, and then exposed the cells or not 
to 3H-thymidine eH-t) for 16 hrs, as described (Ponchio, Conneally et al. 1995). 
This approach relies on the ability of high-specific activity 3H-t to deliver a lethal 
dose of radiation exclusively to cells passing through S-phase (Becker, 
McCulloch et al. 1965), and on the use of a sufficiently prolonged exposure time 
to allow all the cells in late Gt, G2 or M phase, to enter S-phase (Ponchio, 
Co nne ally et al. 1995). After 3H-t treatment, we performed CFC assay. The results 
showed that 3H-t killed the majority of cytokine-stimulated cells (>65% of plated 
CFC) and a much smaller fraction of non~stimulated cells (19%), indicating that 
cytokines triggered the committed progenitors into S-phase, as expected. If the 
enhancement of transduction observed in cytokine-stimulated cells were due to 
their cell cycle progression, the transduced cells should be preferentially killed in 
cytokine-stimulated cultures, abrogating the observed difference in transduction 
between stimulated and unstimulated cells. When scoring transduction frequency 
in the surviving culture, we found 56% and 33% GFP+ cells in cultures not 
exposed to 3H-t, and 56% and 31 % GFP+ in cultures exposed to 3H_t, and either 
stimulated or· not with cytokines, respectively (average of 2 experiments 
performed with similar results). These results strongly suggested that -the cytokine 
enhancement of haematopoietic stem/progenitor cell (HSPC) transduction did not 
require progression into the S-phase of the cell cycle. 
In order to safely perform a· similar analysis in the more relevant SRC 
fraction of the CD34+ cells, we used the cytosine 1-I3-D-arabinofuranoside (Ara-
C) as killing agent. Ara-C was previously shown to be as effective as 3H-t in 
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killing cycling human HSPCs and it was used to evaluate the cell cycle status of 
these cells (Dresch, EI Kebir et al. 1983; Lemoli, Tafuri et al. 1997; Ivanovic, 
Bartolozzi et al. 1999; Lucotti, Malabarba et al. 2000). Similarly to the 
experiments described above, we treated CD34+ cells with or without cytokines, 
and exposed them or not to Ara-C. To verify the cell cycle status of the cells after 
treatment, we stained them with propidium iodide and analysed by F ACS (Figure 
3.4). We observed that cytokines increased the fraction of cells in S-phase, 17% 
for the +cyt condition versus 9% for the -cyt condition, and that this difference 
was completely abrogated when the cells were exposed to Ara-C. 
:~I~ !~tt_ 
PI •• PI •• PI .:.. PI "" 
~ cyt + cyt - cyt Ara-C + cyt Ara-C 
Apopt./Necr. (M1) 32% 28% 42% 42% 
--.------------------------------------... -------------------------------------------------------- .. -------------------
GclG1 (M2) 52% 43% 48% 49% 
------.--------------.-----------------.---------.------.----------------.-------------------------------------.----
S (M3) 9% 17% 6% 5% 
-----------,-------------------------------------------_._-----------------------------------,---------------------.-.-
GiM (M4) 7% 12% 4% 4% 
Figure 3.4. S-pbase suicide assay: HSPC cell cycle analysis. 
Human CD34+ cells were stimulated (+cyt) or not (-cyt) with cytokines for 18 hrs, exposed or 
not to Ara-C for further 12 hrs, as indicated, and immediately analyzed. Upper panels, FACS 
histograms of Propidium Iodide (PI) staining. Lower panel, distribution of the analyzed cell 
populations in the indicated cell cycle phases, marked as Ml to 4 in the histogram. 
Apopt.iNecr.: apoptotic/necrotic cells. 
It should be noted, however, that propidium iodide staining does not allow a 
precise quantification of the fraction of cells in the S-phase of the cell cycle. This 
is because this analysis is based only on the evaluation of the amount of DNA 
present in the cells (cells in the G2/M phases have a 2 fold higher amount of DNA 
when compared to cells in the Go/G1 phases, whereas cells in the S-phase have a 
quantity of DNA that is intermediate between GO/Gl and G2/M cells);. in this 
setting it is also possible that we scored in the S-phase fraction cells in the G2/M 
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phase that underwent apoptosis. In order to have a more precise quantification of 
cells in the S-phase in the different conditions tested, bromodeoxyuridine 
incorporation experiment would be required. However, we decided not to perform 
futher cell cycle analyses on the bulk CD34+ population and chose to prove the 
killing efficacy of Ara-C treatment in the more relevant fraction of hematopoietic 
progenitors (see below). 
We then transduced CD34+ cells with LV -GFP, exposed them or not to 
Ara-C, performed in vitro assays, and injected the cells into NOD/SCID mice. 
The in vitro results reproduced the findings obtained with 3H-t, showing a higher 
killing rate in cytokine-stimulated cultures (the killing efficiency was even higher 
for Ara-C than for 3H-t), and no decrease in transduction levels in the cells 
exposed to Ara-C, both for the plus and minus cytokine samples, as observed in 
suspension culture and CFC assay (Figure 3.5). 
A 
31% 59% 25% 56% 
- -
jl 
.f! 
GFP 
... 
+ cytAra-C 
B 
- cyt + cyt - cyt Ara-C + cyt Ara-C 
-----------.. --------.------------.---------------.------.---.---.------------
%GFP 39 65 34 55 
CFC total number 80 83 40 16 
% killing 50 80 
Figure 3.5. S-phase suicide assay: HSPCs assayed in vitro by suspension culture and CFC 
assay. 
Human CD34+ cells were transduced with LV-GFP in presence (+cyt) or absence (-cyt) of 
cytokines for 18 hrs, exposed or not to Ara-C for further 12 hrs, as indicated, and analyzed after 
1 (A) or 2 (B) weeks of culture. A) Representative FACS analysis of GFP expression in 
suspension culture. Percentages of GFP-positive cells are given. B) CFC assay. GFP+ colonies 
were scored by fluorescence microscopy; CFC total number is expressed as number of colonies 
per 103 CD34+ cells plated; percentage of killing is calculated as the ratio between the number 
of colonies arising from the Ara-C treated and untreated populations. Average values of two 
experiments. 
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Interestingly, despite the seemingly equal distribution along the cell cycle of 
cultures exposed to Ara-C and the higher Ara-C killing rate in the stimulated cells 
fraction, the transduction efficiency remained much higher for the cytokine-
stimulated cells. For transplantation, the transduced cells were matched for the 
number of viable cells prior to the Ara-C treatment, and injected together with 
CD34neg accessory cells. Accessory cells were used in order to substitute the 
killed progenitors cells in supporting the first stages on engraftment. NOD/SCID 
mice were killed 6-8 weeks after transplant and bone marrow was harvested and 
analysed by FACS; bone marrow cells were also plated in methylcellulose for 
CFC assay (Table 3.4). F ACS analysis showed, for the cells not exposed to Ara-
C, a higher SRC transduction efficiency when cytokines were used, reaching on 
average 91 % of GFP+ cells for the stimulated cells and 54% for the unstimulated 
cells. Interestingly, we observed a similarly significant difference in the cells 
exposed to Ara-C, in which we reached, on average, 61 % of GFP+ cells for the 
stimulated cells and 29% of GFP+ cells for the unstimulated cells. The CFC assay 
confirmed these data. 
,Table 3.4. S-phase Suicide Assay. NOD/SCID bone marrow analysis 
FACS Analysis CFC Assay 
____________________________ ~~~_I?~?~ _______ ~_9.~_~~ ______ p.:y~}_l!~_~ ___ ------~g!:~-~-- ____ _ 
,'~ -cyt (n=4). 28±14 54±20 0.0286 39±14 
+cyt (n=4) 42±32 91±5 68±15 
-cyt Ara-C (n=6) 23±23 29±8 0.0277 18±13 
+cyt Ara-C (n=5) 7±6 61±22 45±22 
All values are expressed as mean±SD of two experiments performed 
A percentage of human cells in the mouse BM 
B percentage of human GFP expressing cells 
C p-value calculated by rank sum two-sided test 
D percentage of human GFP expressing clonies, scored by fluorescence microscopy 
n: number of mice per group 
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Because the cytokine enhancement of SRC transduction was not abrogated by 
Ara-C treatment, we conclude that it was not due to cell progression into S-phase. 
Ara-C treatment decreased both the engraftment and the transduction 
levels in both stimulated and non-stimulated SRCs, indicating that a fraction of 
SRCs were sensitive to Ara-C, most likely because they were induced to 
proliferate early after t~ansplant, and that the quiescent SRC fraction was mainly 
responsible for repopulating the mice transplanted with Ara-C exposed cells. 
Because the SRCs successfully engrafting after Ara-C treatment were transduced 
to substantial levels, these data indicated that LV s transduced cells that were not 
committed to early cell cycle progression and thus strongly suggest that LV s are 
able to transduce quiescent SRCs ex vivo. 
3.3 Cytokines effect on LV entry pathway 
We then aimed to better understand how cytokines affect LV transduction in 
HSPCs. In order to verify whether the difference observed in the transduction 
efficiency between cells stimulated and not stimulated reflected a difference in the 
. entry efficiency of VSV -G-pseudotyped vector, we tested vectors pseudotyped 
with the ML V amphotropic (A-ML V) and the modified form of the feline 
endogenous retrovirus RD 114 (RD 1141TR) envelopes. Indeed, these vectors 
exploit different routes to enter the target cell: A-ML V-and VSV -G-pseudotyped 
LV entry is pH dependent (is mediated by . endosome), whereas RD 114ITR 
pseudotyped L V entry is pH independent (envelope fuses to the plasma 
membrane). If cytokines affected t~e specific pathway of VSV -G-pseudotyped 
vector entry, we postulated that the enhancement of transduction would be 
envelope-dependent and possibly abolished by changing it. We performed some 
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experiments transducing CB CD34+ cells with the three vectors above mentioned, 
all carrying the same PGK-GFP expression cassette, and for each vector we used 
the two protocols, with and without cytokine stimulation. We then plated the cells 
for suspension culture and for CFC assay. As shown in Figure 3.6, both in liquid 
culture and in CFC analysis, we observed a higher transduction level for the 
protocol with cytokine stimulation for all vectors tested. Importantly, the 
difference between stimulated and unstimulated cells transduced with the 
RDl14/TR-pseudotyped vector is comparable to that one of cells transduced with 
the VSV-G-pseudotyped vector. Since these two vectors exploit different entry 
pathways, these results indicate that the cytokines did not modulate a specific 
entry pathway. 
Suspension Culture 
+ a. 
Ll-
e) 
~ o 
VSV-G A-MLV RD114ITR VSV-G 
c:I-cyt .. +cyt 
CFC 
A-MLV RD114ITR 
Figure 3.6. Cytokine effect on IISPC transduction by LV pseudotyped with different 
envelopes. 
Human CD34+ cells were transduced with LV -GFP pseudotyped by the indicated envelope, 
with (+cyt) and without (-cyt) cytokines, and analyzed after 2 weeks of culture. Each bar 
represents the "average frequency and standard error (two to six experiments performed, 
depending on the envelope) of GFP expressing-cells in suspension culture and CFC assay, as 
indicated. For suspension culture analysis p=0.022 for the VSV comparison, 0.097 for the A-
ML V comparison and 0.058 for the RD 114n'R, calculated by signed rank two-sided tests. 
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4. Restriction of LV transduction in HSPCs 
4.1 Effect of proteasome inhibition on HSPC IentiviraI gene transfer 
We then evaluated other factors influencing the post-entry steps of viral infection. 
Because of its emerging effector role in many cellular response pathways and its 
postulated antiviral activity observed in earlier studies of HIV -infected 
lymphocytes (Schwartz, !vfarechal et al. 1998), we assessed the influence of the 
proteasome on LV transduction of HSPCs. 
In a first set of experiments we transduced CD34+ cells with the standard 
dose of LV -GFP, with or without cytokine stimulation, and added different doses 
of the reversible peptide aldehyde proteasome inhibitor MG 132 (Kisselev and 
Goldberg 200 I) during the transduction period. After transduction cells were 
washed in order to remove the inhibitor, and kept in suspension culture. After two 
weeks, FACS analysis revealed a substantial MGI32 dose-dependent increase in 
the frequency of GFP-expressing cells and in their Mean Fluorescence Intensity 
(MFI), suggesting increasing vector copy number per cell, both for the stimulated 
and not stimulated cells (Figure 4.1 a,b). Remarkably, at concentrations ranging 
from I to 1,51lM MG132, we were able to transduce virtually all the stimulated 
cells, and to very high MFI, and up to 90% of the non-stimulated cells. We were 
not able to further increase the transduction level in non-stimulated cells without 
reaching toxic doses of MG 132. To verify that the observed enhancement of 
transduction was specifically dependent on proteasome inhibition, we repeated 
these experiments using the more powerful peptide boronate inhibitor PS-341 
(bortezomib) and obtained very similar results to those observed with MG132, 
although the higher toxicity of PS-341 prevented testing doses higher than 80 nM 
(Figure 4.1 c,d). 
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Figure 4.1. HSPC transduction by LV in presence of increasing doses of proteasome 
inhibitors. 
CD34+ cells were transduced with 108 TV/mt of LV-GFP with (+cyt) or without (--cyt) 
cytokines stimulation in the presence of increasing doses of the proteasome inhibitors MG 132 
(A and B) and PS-341 (C and D), and analyzed after two weeks of suspension culture A) and 
C) Percentage of GFP+ cells, and B) and D) Mean Fluorescence Intensity (MFI). Average of 
two experiments per panel. 
In a second set of experiments we evaluated the effect of a constant 
concentration ofMG132 - 1 JlM, chosen because it showed the highest difference 
in response between stimulated and non-stimulated cells - on CD34+ cells 
transduced with or without cytokines, and different LV amounts. The same 
number of cells were treated or not with MG132, transduced and cultured as 
above, and plated in the CFC assay to test the.toxicity of MG132. As shown in 
Figure 4.2, the proteasome inhibitor substantially enhanced transduction at each 
vector dose, both for the stimulated and not stimulated cells, whether assayed in 
suspension cultures or by CFC (p=O.008 and p=O.OI6 for MG132 tre~ted vs. 
untreated cells, in +cJ1 and -cJ1 conditions, respectively, both for suspension 
culture cells and CFC; signed rank test). 
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Figure 4.2. Effect of pro tea some inhibition on HSPC transduction by LV. 
CD34+ cells transduced with or without cytokines (Cyt) stimulation with increasing doses of 
. LV-GFP (TU/ml), and in the absence or presence of IJ.lM MG132 (MG), as indicated, and 
analyzed two weeks after. Upper panel, percentage of GFP-positive cells in suspension culture; 
lower panel, GFP-positive colonies from CFC assays. Toxicity was calculated from the ratio 
between the number of colonies arising from MG 132-exposed and not exposed cells and shown 
as percentage of CFC killed. Average (-) and individual values (triangles and squares) from 
two experiments. Statistical analysis reported in the text. 
Concerning the drug toxicity, the stimulated cells showed higher toxicity in 
response to the inhibi.tor than the non-stimulated cells. A possible contributing 
factor to the higher toxicity, however, was the extremely high GFP expression 
level, and vector integration load, reached in the stimulated cells, as indicated by 
an increasing percentage of CFC death with increasing LV dose (Figure 4.2 CFC 
and data not shown). 
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In order to confirm at the molecular level that the enhancement of 
trans gene expression, observed when proteasome inhibitors were used, was due to 
an increase in integrated vector copies, we performed real-time Quantitative PCR 
(Q-PCR) analysis on the DNA of transduced progenitors after 3 weeks of 
suspension culture. We used two primers-probe systems to amplify different 
vector sequences and found that both proteasome inhibitors (PS341 and MG132) 
increased from three- to seven-fold the average vector copy number per cell, both 
in non-stimulated and cytokine stimulated cells. The enhancement was dependent 
on the inhibitor dose, remarkably reaching an average of 14 and 61 copies per cell 
in non-stimulated and stimulated cells, respectively, at the highest doses of vector 
and inhibitor (Figure 4.3). 
1:1 PSI system 
_GFPsystem 
Figure 4.3. Effect of proteasome inhibition on IISPC transduction by LV: molecular 
analysis. 
Real-time quantitative PCR analysis of DNA extracted after 3 weeks of suspension culture 
from HSPCs stimulated or not with cytokines (Cyt), transduced with different doses of LV-
GFP (TV/ml) and treated or not with different doses of PS341 (PS) or MG132 (MG), as 
indicated. Vector sequences were amplified with a system annealing to the 'V of the vector (PSI 
system) and a system annealing to the GFP sequence (GFP system). For each condition 
average of three detections is shown. 
Overall, these data indicated that the proteasome effectively restricted LV 
gene transfer in HSPCs. 
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4.2 Cytokine effect on proteasome activity of HSPCs 
We assessed the contribution of individual cytokines to the observed enhancement 
of LV transduction by taking advantage of the response amplification mediated by 
MG 132. We transduced CD34+ cells with or without 1 J.1M MG 132 and in the 
absence or presence of IL6, SCF, TPO and Flt3L, tested separately or in 
combination (Figure 4.4). Each cytokine tested induced only a modest increase in 
gene transfer as compared to the unstimulated cells, both when the transduced 
cells were scored in liquid culture and in CFC assay. 
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Figure 4.4. Contribution of individual cytokines to enhanced HSPC transduction by LV. 
A) Percentage of GFP+ cells in suspension culture and colonies (CFC) derived from CD34+ 
cells transduced with 108 TV/mt of LV -G FP without (-cyt) or with the indicated cytokine, 
added separately (IL6, SCF, TPO, Flt3L) or all together (+cyt), and with (MG) or without (NT, 
not treated) IIlM MG 132. B) Mean Fluorescence Intensity (MFI) of suspension culture cells 
shown in A. One experiment of two performed with similar results is shown. 
Although the effect of the separately tested cytokines was barely detectable in the 
absence of MG132, addition of the proteasome inhibitor during tran~duction 
revealed a higher response than that seen in non-stimulated cells. When 
comparing cells stimulated with only one of the cytokines with cells stimulated by 
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their combination, the effect of cytokines on gene transfer appeared to be 
synergistic. This was indicated by comparing both the average fluorescence of the 
transduced cells, which reflected the average number of transduced vector copies 
per cell, and the frequency of transduction, which reached saturation at 100%. 
The 26S proteasome is an A TP-dependent, multifunctional proteolytic 
complex found both in the nucleus and in the cytoplasm of all eukaryotic cells. It 
is responsible for the degradation of a large variety of cell proteins and is essential 
for many cellular regulatory mechanisms. It consists of 50 subunit organized in 
the 20S proteolytic core particle sandwiched between two 19S regulatory 
complexes (Figure 4.5) (for a review on proteasome structure and function see 
(Kisselev and Goldberg 2001). The 20S 
proteasome is a hollow cylindrical particle 
consisting of four stacked rings; the 2 outer 
rings are called alpha and the two inner beta. 
Each beta ring contains three different 
catalytic activities. All these active sites face 
the inner chamber of the cylinder, and the 
only way for substrates to reach this chamber 
is through the gated channels in the alpha 
Figure 4.5. A schematic of the 268 ring. The 19S regulatory particles are 
proteasome. U1:?: ubiquitin. 
associated to the alpha rings and are responsible for recognition, unfolding and 
linearization of polyubiquitinated substrates and inject them into the 20S particle 
by using complex A TP-dependent mechanisms. This complex structure, which 
isolates the catalytic sites from the cytoplasm, ensures that proteins digestion is 
isolated from the surrounding cytoplasm and prevents uncontrolled destruction of 
the bulk of cellular proteins. As aforementioned, the 20S core particle contains 6 
120 
active sites (3 on each beta ring), which differ in their specificities. Two 
proteolytic sites termed "chymotrypsin-like" cut preferentially after hydrophobic 
residues, two termed "trypsin-like" cut preferentially after basic residues and two 
termed "caspase-like" cut preferentially after acidic residues. 
Although in the recent years several molecules have been discovered to be 
associated with the described basic components of the 26S proteasome, the pattern 
of regulation of the activity of this complex is very poorly understood. Some 
cellular factors, such as PA28 (also called lIS) and PA200, have been found to 
enhance proteasome activity by directly associating with 20S and some cellular, 
such as PI31 and PR39, and viral molecules, such as HIV TAT and HBV protein 
x, have been found to decrease proteasomal activity by competing for the binding 
of the abovementioned activators (for a review on proteasome regulation see 
(Schmidt, Hanna etal. 2005). However, the mechanisms of action and the 
upstream signals modulating the expression of activators/inhibitors are still 
mainly obscure. The only pathways known to be involved in proteasome 
regulation are those activated by interferon y and pro inflammatory 
cytokines, which enhance PA28 in professional antigen presenting cells 
(Macagno, Gilliet et al. 1999; Strehl, Seifert et al. 2005). 
Having found that proteasome restriction is active in HSPCs against LV 
and that cytokine stimulation increases LV gene transfer in these cells, we then 
asked if there could be a link between the cytokines we used and the proteasome 
activity. Thus, we tested proteasome activity in CD34+ cells stimulated or not 
with cytokines. We assayed the proteasomal chymotryptic-, tryptic- and caspase-
like activity by using specific fluorogenic peptide substrates and subtracting 
background activity (caused by non-proteasomal degradation) by addition of the 
proteasome inhibitors MG132 (for the chymotrypsin and the caspase-like 
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activities) and J3-lactone (for the trypsin-like activity). We calculated reaction 
velocities from the slopes of the initial linear portions of the reaction progress 
curves and found that, for all activities tested, cytokine-stimulated CD34+ cells 
displayed a significantly lower specific activity, compared to not stimulated cells 
(global p-value= 2x2-18; calculated by sign test on two experiments with 18 
observations) (Figure 4.6 a). 
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Figure 4.6. PrQteasome activities in IISPCs. 
CD34+ cells were treated as indicated, lysed and tested for proteasome peptidase activities. 
Peptidase activities were assayed by monitoring the production of 7-amino-4-methylcoumarin 
(arnc) from fluorogenic peptides: Suc-LLVY-amc for the chymotrypsin-like activity, Boc-
LRR-amc for the trypsin-like activity and Ac-YVAD-amc for the caspase-like activity. A) 
Peptidase activities of cells exposed to cytokines (+cyt) or not (-cyt) for 24 hours. Statistical 
analysis reported in the text. B-D) Chymotripsin-like activity of cells kept in culture for the 
indicated times with (+cyt) or without (-cyt) cytokines (B); exposed to cytokines (+cyt), to 
MG132 (MG132), or to both treatments (+cyt MG132) for 24 hours (C); exposed to the 
indicated cytokine for 24 hours (D). Values in A-C are mean±SD of 3 measurements from one 
of two experiments with similar results, performed with different cell preparations. Values in 
D are the average of two experiments, and are expressed as percentage of the proteasome 
activity of unstimulated cells. . 
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Of note, because apoptosis has been recently shown to decrease the proteasome 
activity (Sun, Butterworth et al. 2004), and the unstimulated cultures may contain 
a higher fraction of apoptotic cells, the difference between unstimulated and 
stimulated cells may even be higher than measured. 
It should be noted that we measured proteasome activity at saturating 
doses of substrate (Vmax) and thus we could not distinguish if the difference 
observed was due to a difference in enzymatic activity or in amount of enzyme in 
the two samples. Unfortunately, the measurement of the affinity constant (kM), 
which could be easily done by performing the assay at non-saturating doses of 
substrate, is not predictable of the actual activitylkinetic of the proteasome (two 
enzyme may have same kM but different kinetics). The best assay to determine 
the activity of the proteasome would be to measure the number of molecules of 
substrate degraded by a single molecule of enzyme per second (kcat), by 
performing the measurement on purified proteasomes. On the other hand, Western 
Blot analysis performed by using antibodies against different subunits of the 
proteasome would determine the amount of enzyme present in the different 
samples. However, the unavailability of high numbers of primary HSPCs 
precluded the use of the latter two assays and thus we relied on the Vmax 
measurement, which is widely used and accepted for testing in vitro proteasome 
activity. 
In order to better understand the kinetic of the effect of cytokines on 
proteasome activity, we then performed a time-course analysis. We seeded 
CD34+ cells in serum-free medium with or without cytokines, harvested them at 
different time points and assayed the chymotryptic-like proteasome activity, 
which accounts for 90% of the total activity of this complex (Figure 4.6 b). 
Interestingly, we observed that the proteasome activity of fresh (non-cultured) 
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cells was similar to that of cells stimulated for 24 hours, whereas unstimulated 
cells progressively up-regulated proteasome activity in culture. Cytokines not only 
prevented proteasome activity up-regulation, but they also rapidly and strongly 
down-regulated it. Indeed, at the earliest time point analysed ( 6 hours) proteasome 
activity of stimulated cells accounts for less than 50% of the initial activity. 
Moreover, if we compare unstimulated with stimulated cells at this time point, the 
difference in specific activity is much more profound than that observed at 24 
hours. Indeed, at 24 hours stimulated cells activity was 60% of unstimulated cells, 
whereas at 6 hours it was 30%. 
In the in vitro experiments in which we used proteasome inhibitors on 
stimulated and unstimulated CD34+ ceIIs, we observed an additive effect of 
cytokines and proteasome inhibitor in enhancing transduction (see Figures 4.1-
4.4). In order to verify if this additive effect was present also at the proteasome 
activity level, we measured the proteasome activity 24 hours after treatment with 
cytokines, MG132 or their combination (Figure 4.6 c). MG132 down-regulated 
the proteasome activity more effectively than the cytokines, and the combination 
was slightly but not significantly more effective than the drug alone. 
Finally, we assessed the contribution of each individual cytokine to the 
observed proteasome activity down-regulation (Figure 4.6 d). Interestingly, we 
found that 3" out of 4 cytokines present in the complete cocktail affected 
proteasome activity. Indeed, we observed a moderate down-regulation of 
proteasome activitY when CD34+ cells were exposed to SCF, TPO or F1t3L, while 
no effect was seen with IL6. However, no cytokine tested alone reached the effect 
of the cocktail, indicating an additive effect of the three cytokines on proteasome 
activity down-regulation. 
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Overall, the rapid onset and the substantial extent of proteasome activity 
down-regulation induced by cytokines in HSPCs indicate a likely role of this 
response in mediating the enhancement of LV transduction. However, because the 
addition of cytokines to cells exposed to proteasome inhibitor further enhanced 
transduction without likely inducing a comparatively stronger proteasome activity 
down-regulation, it is conceivable that other pathways activated by cytokines 
beside their effect on the proteasome contribute to the increased permissiveness to 
L V transduction. 
4.3 Proteasome restriction in different cell types 
In order to verify if proteasome" restriction of LV s was common to 
different cell types, we evaluated the effect of MG 132 on the transduction of 
different cell lines, either ofhaematopoietic origin (K562 and U937) or not (293T 
and HeLa). Cells were transduced with a constant LV -GFP dose and with 
increasing MG132 doses, washed and analysed two weeks later by FACS. 
Surprisingly, FACS analysis showed that MG132 effect on the level of 
transduction was much lower for all the cell lines tested than that observed in 
HSPCs (Figure 4.7 a,b; compare with Figure 4.1). To exclude the possibility that 
proteasome inhibitor was not effective because the level of transduction for some 
cell lines had already reached saturation without the drug, we repeated the 
experiments using lower doses of vector and obtained similar results (data not 
shown). Then, we asked whether the responsiveness to proteasome inhibition 
could be linked to the proteasome activity of the cells. Thus, we assayed the 
proteasome chymotryptic-like activity in all cell types tested. Interestingly, we 
found a profound difference between haematopoietic progenitors and the cell lines 
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tested. Indeed, the activity in all cell line extracts was about one third to one 
fourth of that found in HSPCs, stimulated or not with cytokines, respectively 
(Figure 4.7 c). 
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Figure 4.7. Effect of proteasome inhibition on LV transduction of different cell lines. 
A) Frequency of GFP+ cells and B) MFI of293T, HeLa, U937 and K562 cells transduced with 
LV-GFP in presence of increasing concentrations (from 0.1 to 2 JlM) ofMG132 for 12 hours. 
Missing points at the highest doses in K562 and U937 curves are due to cell death because of 
MG 132 toxicity. Two to three experiments are shown for each cell line. C) CD34+ cells 
exposed (+cyt) or not (-cyt) to cytokines for 20-24 hours, HeLa, 293T, U937 and K562 cells 
were lysed and tested for proteasome chymotrypsin-like activity. Chymotrypsin-like activity 
was assayed by monitoring the production of 7-amino-4-methylcoumarin (amc) from 
fluorogenic peptide Suc-LL VY -arne. Values are mean±SD of 3 measurements from one of two 
experiments with similar results. 
We also tested the proteasome inhibitor on several primary differentiated human 
hematopoietic cells, such as T and B lymphocytes and monocytes, and in none of 
these cells we observed an increase in the level of LV transduction (data not 
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shown), suggesting that proteasome restriction is related to progenitor cells and 
that it is not active in differentiated cells. 
In order to determine if proteasome restriction was a specific feature of 
human cells, we then tested proteasome inhibition on murine haematopoietic 
progenitors. Murine HSPCs were enriched from bone marrow cells by lineage 
marker depletion and transduced for 24 hours in serum free medium with LV -GFP 
and with increasing doses ofMG132, in presence or absence ofIL3, SCF, FLT3L, 
and TPO. Cells were then washed, plated in suspension culture and analysed 2 
weeks later. Interestingly, FACS analysis revealed a MG 132 dose-dependent 
increase in the transduction efficiency, in both stimulated and not stimulated cells 
(Figure 4.8). Indeed, in murine HSPCs the response to proteasome inhibition was 
similar to that one observed in human HSPCs. 
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Figure 4.8. Effect of pro tea some inhibition on LV transduction of murine HSPCs. 
FVB mice bone marrow-derived lineage negative cells were transduced with 108 TU/ml of 
LV -GFP, with (+cyt) or without (-cyt) cytokines stimulation and in the presence of increasing 
doses of the proteasome inhibitor M G 132. Cells were analyzed two weeks after transduction. 
A) Percentage 'of GFP+ cells. B) Mean Fluorescence Intensity (MFI). Average of two 
experiments is shown. 
These results suggest that proteasome restriction of LV is a specific feature 
of HSPCs, both human and murine, and that it could be linked to the high 
proteasome activity observed in these ,cells. 
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4.4 Effect of proteasome inhibition on SRC lentiviral gene transfer 
We then verified the effect of proteasome inhibition on SRC transduction. We 
transduced CD34+ cells stimulated or not with cytokines with 2x107 TV/ml of 
LV-GFP and with or without O.7JlM MG132, performed in vitro assays, and 
transplanted them into NOD/SCID mice. We chose lower vector and MG132 
doses than those used in previous experiments to better detect drug-dependent 
enhancement of transduction and reduce a possible toxicity. As shown in Table 
4.1, suspension culture analysis confirmed our previous results, showing a strong 
enhancement in gene transfer when proteasome inhibitor was present during 
transduction in both cytokine-stimulated and unstimulated cells, whether assayed 
in suspension cultures or by CFC assay. 
Table 4.1. Proteasome inhibition. Analysis of HSPCs assayed in vitro 
%GFpA 
Suspension 
cultureB 
-cyt 42±21 
-cytMG 63±13 
+cyt 66±17 
+cytMG 90±9 
Average±Standard deviation are shown (n=4 per group) 
Apercentage of GFP expressing cells or colonies, assessed by : 
SF ACS analysis 
cFluorescence microscopy analysis 
MG: O,7~M MG132 
CFC assayC 
40±8 
59±4 
63±6 
86±14 
Six weeks after transplant we harvested NOD/SCID bone marrow and analysed it 
by F ACS and Q-PCR. F ACS analysis showed again a higher transduction 
frequency in stimulated cells compared to unstimulated. Moreover, we observed 
higher transduction levels in cells tra.nsduced without stimulation in presence of 
proteasome inhibitor compared to cells transduced without stimulation in absence 
of pro tea some inhibitor (-cyt MG versus -cyt). However, since we reached such a 
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high frequency of transduction in the stimulated cells, any possible further 
enhancement by MG 132 addition could not be detected (Figure 4.9 a). 
A 
• 
•• 
• 
•• 
ct •• • 
lL. 
~ 
'if. 
• • 
• 
-cyt -cyt MG +cyt +cyt MG 
B 
• 
• 
• 
-... 
•• 
• • ..!.LL • 
..!L- •• 
•• •• • 
--.- •• 
• 
-cyt -cyt MG .. +cyt +cyt MG 
C 
• •• 
• • • 
• 
• • e • 
----
~ 1 
----
-.--
::;) 
-----
• •• • 
.c. 
• '#. • •• 
• • 
-Cyt -cyt MG +cyt +cyt MG 
o Gated on CD4S+ Gated 01'1 C034+ Gated on C019+ Gated on CD13+ 
!I=:J~u~1 ~2%j\D 
II: .111 111 .. It os4 if ft Ii ..t ,i oil .., t4 .., " tJ .. 1/ 14 
.. 
GFP 
Figure 4.9. Effect of proteasome inhibition on SRC transduction. 
CD34+ cells were transduced with LV -GFP without any stimulation (-cyt), in the~ presence of 
O.7JlM MG132 (-cyt MG), in the presence of cytokines (+cyt) or in the presence of both 
cytokines and O.7JlM MG132 (+cyt MG), and transplanted in NOD/SCID mice. Mice bone 
marrow was analyzed 6 weeks after transplant by F ACS (A) or by quantitative real time PCR 
(B and C). A) Percentage of GFP-positive cells in the human graft. B) Number of LV 
integrated copies per human cell. C) Percentage of human engrafiment, calculated as ratio 
between human and total (human+murine) DNA. Each dot represents a mouse, for each group 
the average (-) is shown. D) F ACS analysis of a mouse transplanted with cells transduced in 
presence of cytokines and MG 132 and carrying 34 L V copies per cell; multilineage 
repopulation is shown by a similar percentage of GFP+ cells in all the indicated liIieages. 
Percentages were calculated within the gated populations. Human engrafiment level was 15%. 
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Thus, we performed Q-PCR on genomic DNA extracted from bone marrow-
derived cells. We developed specific primers and probe systems to evaluate the 
number of integrated vector copies per human cell and determine the level of 
human engraftment per mouse. Indeed, we used a system of primers and probe 
complementary to the L V Rev Responsive Element (RRE) sequence, a system 
complementary to the human Telomerase Reverse Transcriptase (TERT) gene and 
a system complementary to the mouse l3-actin gene (Figure 4.9 b,c). Proteasome 
inhibitor increased the average vector copy number by 2-fold in unstimulated cells 
and 1.5-fold in stimulated cells. When proteasome inhibitor was used on cells 
transduced in presence of cytokines we could reach the remarkable number of 34 
copies per human cell in the graft (highest score) and an average of 23 copies per 
cell (Figure 4.9 b; +cyt MG). Moreover, it should be highlighted that, consistently 
with the results shown before, cytokine treatment alone increased 3-fold the 
vector copy number per cell. The differences between the four groups were 
statistically significant (p-value=0.002; n=27). 
We also tested the percentage of human cells in the graft of all the mice to 
verify if such a high ,:,ector load and/or the potential MG132 toxicity could have 
affected SRC engraftment ability. Importantly, we obtained similar engraftment 
levels in all groups tested (p-value= 0.46; n=27). In addition, when we analysed 
BM-derived cells for the presence of the different lineages by FACS, we observed 
multilineage engraftment by transduced cells in all groups. A representative 
analysis of multilineage engraftment is shown in Figure 4.9 d. The mouse 
analysed in this panel carries the highest vector copy number scored. These 
findings suggest that, at least in this model, proteasome inhibition does not have a 
detrimental effect on SRC repopulating ability. 
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In conclusion, these results prove that proteasome effectively restricts 
lentiviral transduction in HSCs and highlight a new strategy to overcome the low 
permissiveness of human HSCs to LV gene transfer. 
5 . LV integration site selection in HSPCs 
As aforementioned, the aim of gene therapy is to reach efficient and safe 
gene transfer. Thus, having evaluated LV transduction efficiency in HSPCs we 
" aimed to evaluate some safety features of LVs. We investigated integration site 
selection of LV in HSPCs and compared it with integration site selection of ML V-
derived Retroviral Vectors (RV). Indeed, vector integration can have detrimental 
effects on HSPCs, mainly by altering gene expression and inducing aberrant 
developmental pathways and analysis of integration site selection can help to 
predict the consequence of the insertional mutagenesis induced by these vectors. 
In order to evaluate LV versus RV integrations in HSPCs, we developed 
genetic traps based on both vectors. We introduced a promoter trapping construct 
(Medico, Gambarotta et al. 2001) into LV and RV (ML V-based) and compared 
their trapping efficiency using a puromycin resistance-GFP (PuroR-GFP) reporter. 
We cloned the PuroR-GFP gene between a strong cellular splice acceptor (SA) and 
a polyadenylatio.n (polyA) site (Medico, Gambarotta et al. 2001), and inserted the 
resulting expression cassette in reverse orientation into SIN RV (Roberts, Cooke 
et al. 1998) and SIN LV (Follenzi, Ailles et al. "2000), immediately upstream to 
the modified 3' L TR. The reverse orientation prevents reporter expression from 
the 5' L TR of the transduced vector when the L TR is not fully inactivated, as in 
the case of the SIN RV (De Palma, Montini et al. 2005)(see Figure 2 enclosed 
article). With this cassette design reporter expression is dependent on vector 
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integration downstream to a transcriptionally active cellular promoter (Figure 
5.1). Indeed, only if the vector integrates with the appropriate orientation within a 
promoter-proximal intron or exon of a transcribed gene, a fusion messenger 
transcript will be produced and likely processed to express the reporter. The 
placement of the expression cassette close to the 3' end of the vector leaves most 
viral sequences outside of the fusion transcript, reducing their potential influence 
on reporter expression. The frequency and average level of reporter expression 
may thus readout the frequency of vector integration into active genes, their 
average expression level, and may uncover preferential integration in the 
proximity of cellular promoters. If target site selection differs between RVs and 
LV s according to these parameters, it will also result in quantifiable differences in 
their promoter trapping efficiency . 
••••••••• ~_E) ..... ~ 
'¥ 
Figure 5.1. A schematic of the vector trap integrated within the first intron of a cellular 
gene. 
The expression cassette is placed in reverse transcriptional orientation with respect to the vector 
framework. 'P, viral encapsidation signal, including the 5' portion of the gag gene (GA); RRE, 
rev responsive element, and cPPT, central polypurine tract (LT only); polyA, polyadenylation 
signal; SD and SA, splice donor and acceptor sites. 
We transduced human 293T cells with VSV-pseudotyped stocks of each 
vector trap. By analysing cell populations containing similar amounts of 
integrated vector, we found that promoter trapping efficiency, calculated as the 
ratio between expression and integration, was significantly higher (5 to 6 fold) for 
the RV than the LV trap (see Figure Ib enclosed article). We reproduced these 
findings in murine cell lines, such as liver progenitor MLP29 cells (see Figure lc 
enclosed article) and endothelial H5V cells. Trapping efficiency was calculated 
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from cultures expressing the reporter gene in le~s than 20% of the cells to avoid 
the possibility that multiple trapping events per cell led to non-linear dose-
response between integration and expression. These data, together with the 
mapping of LV - (L T) and R V -based (RT) promoter traps integration sites (see 
Table 1 and Figure 3 ~nclosed article), indicated that RV has a higher propensity 
than LV to integrate into promoter-proximal region. These results are consistent 
with data recently obtained by high-throughput mapping of RV and LV 
integrations (Hematti, Hong et al. 2004; Mitchell, Beitzel et al. 2004). 
Interestingly, also in primary cells, such as activated human peripheral b,lood 
mononucleated cells, RT trapping efficiency was higher than that of L T (on 
average 4 times) (see Table 2 enclosed article) and, as seen with continuous cell 
lines, the GFP MFI after puromycin selection was higher for the ML V than the 
.' 
HIV trap (1.3-fold), suggesting a preference of RV for targeting on average more 
active genes. 
We then analysed the behaviour of the promoter trapping vectors in 
HSPCs. 
Murine hematopoietic progenitors 
Mock 
Figure 5.2. Transduction of murine HSPCs by LT and RT. 
RT: 7.7% 
MR:.36 
F ACS analysis of GFP expression in murine hematopoietic progenitors transduced with 
matched amounts of the indicated vector traps and analyzed 5 days post-transduction. The 
frequency and MFI of GFP-positive cells are indicated. One experiment of two performed with 
similar results is shown. 
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Murine HSPCs were enriched from bone marrow cells by lineage marker 
depletion, stimulated with IL3, SCF, FLT3L, and TPO for 24 hrs to reach efficient 
transduction by both vector types, and transduced with doses of LT and RT 
matched to yield comparable vector integration amounts. F ACS analysis 
performed after 5 days of culture indicated a sharp difference in reporter gene 
expression, with the cultures transduced by R T containing a higher frequency of 
GFP-expressing cells and reaching a higher GFP MFI (Figure 5.2). 
CB-derived human CD34+ cells were stimulated for 36 hrs in medium 
containing cytokines and then transduced with RT and LT. This protocol was 
chosen in order to allow comparable transduction levels by RT and LT. We then 
treated or not the transduced cells with puromycin, and analysed them by FACS 
for GFP expression, and by clonogenic assays to determine the frequency of 
puromycin-resistant haematopoietic colonies. In a first experiment, cells were 
transduced with matched amounts of either vector to yield an average 20% 
transduction frequency, in order to allow calculating trapping efficiency from the 
assumption that vector-positive CFCs obtained in these conditions contain a single 
vector copy. 
A 
2r---- ---, 
L T: 0.3% 
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EtIfIY 
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RT: 1.4% 
B 
Figure 5.3. Transduction of human HSPCs by LT and RT. 
GFP 
A) FACS analysis of GFP expression in CD34+ cells stimulated for 36 hrs with a cytokine 
cocktail, transduced with matched vector amounts yielding low-copy «1) integration per cell, 
and analyzed after 1 week in suspension culture. The percentage of GFP-positive cells is 
indicated. Representative results of two experiments performed are shown. B) F ACS analysis 
of GFP expression (histogram) of puromycin-selected cells from the populations shown in A). 
DC, unselected cells. 
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Consistently with the results obtained in other c,ell types, the frequency of GFP-
positive cells in suspension culture' (Figure 5.3 a), and the frequency of 
puromycin-resistant CFCs (Table 5.1, expl) were significantly higher for cells 
transduced by RT than LT. PCR analysis for vector-specific sequences in 
haematopoietic colonies confirmed similar frequency of integration by both 
vectors at the predicted level (Table 5.1, expl), showing that also in human 
HSPCs RT trapped cellular promoters more efficiently than LT. Furthermore, the 
RT was expressed to an higher extent both in the absence of puromycin selection 
(not shown), or following selection (Figure 5.3 b). 
Table 5.1. Promoter trapping. CFC analysis of CD34+ cells transduced with 
LT and RT 
% vector positive 
, CFCsA 
% puro-resistent 
CFCsB 
Trapping 
efficiency (%)c 
LTexpl 23 0.5 2 
RTexpl 18 3.3 18 
LTexp2 96 7.1 «7· 
RTexp2 23 4.9 21 
CFC assays of the same cells shown in Figure 5.3 (expl) and from a different experiment that used 
a higher input of L T vector (exp2), plated in semi-solid medium containing or not puromycin. 
AFrequency ~fvector-positive CFCs determined by PCR performed on unselected CFCs 
B Frequency of puromycin-resistant CFCs calculated from the ratio between CFCs grown in 
medium with and without puromycin 
CFrequency of promoter trapping calculated as the ratio between puromycin-resistant CFCs and 
vector-positive CFCs 
• In the presence of multi-copy vector integration, the frequency of trapping (trapping efficiency) is 
overestimated 
In a second experiment, we increased the L T vector input and found that 
cultures matching the frequency of reporter expression obtained with the RT had 
multi-copy HIV integration in the CFCs (Table 5.1, exp2). Interestingly, also in 
these latter transduction conditions, (low-copy RT versus multi-copy LT 
integration), puromycin-selected RT-transduced cells expressed the reporter gene 
to a higher extent than L T -transduced cells (not shown). 
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These results provide direct, functional eyidence that R V s preferentially 
integrate close to highly active promoters in HSPCs, and can efficiently exploit 
them for proviral expression, whereas LV s do not have the same integration bias. 
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Chapter 6. 
Discussion 
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6.1 Early-acting cytokines and HSC engraftment 
U sing a stringent assay of competitive xenograft repopulation, we show that 
human CB HSCs, transduced to high efficiency by a short exposure to LV in 
presence of SCF, TPO, IL6 and Flt3L, maintain comparable repopulation capacity 
as cells transduced in the absence of stimulation. Both types of cells contributed 
similarly to the multi-lineage human graft, and yielded similar frequencies of 
haematopoietic progenitors, when the mouse BM was analysed 10 weeks after 
transplant. We also show that the enhancement of LV gene transfer is dependent 
on the synergy of all four cytokines. 
Our marking studies provides rigorous, and until now lacking, proof that 
early-acting cytokines, which are currently investigated for ex vivo HSC 
expansion, do not impair stem cell properties in the conditions tested. This is in 
apparent contrast with the results obtained in the NOD/SCID xenotransplant 
model by Dick's group (Mazurier, Gan et al. 2004). They showed that cytokine-
stimulated (with SCF, TPO, IL6, Flt3L and G-CSF) HSCs had an impaired 
engraftment ability with respect to non-stimulated HSCs in a competitive setting. 
Although the cocktail of cytokines they used is very similar to ours, they 
stimulated HSCs for 4 days, whereas we stimulated the cells only for 24 hours. 
Since we did not observe the detrimental effect on HSCs they showed, this 
indicates that, beside the choice of the cytokines, the period of ex vivo culture is 
critical to maintain HSC properties. 
Also, previous studies reported a decreased homing capacity of CB CFCs 
after exposure to some of the cytokines used in this study (Ahmed, Ings et al. 
2004). Although our results do not suggest such impairment, we cannot ex~lude 
that cytokine-stimulated cells _may compensate for a decreased homing capacity 
with a higher in vivo self-renewal and/or clonogenicity. A detailed clonal analysis 
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of the human graft in the repopulated mice may help clarifying these issues, 
although the biological heterogeneity and the small number of SRCs engrafting 
each mouse (AHles, Schmidt et al. 2002; Mazurier, Gan et al. 2004) make very 
difficult to reliably correlate differences in graft clonal composition to the 
experimental conditions used for the transplant. 
Cytokines may exert anti-apoptotic activity and/or trigger cell growth and 
replication, according to the target cell type and condition. Although the cell 
viability tended to decrease more rapidly in unstimulated CD34+ cells, the total 
number of cells in culture did not change significantly between the two conditions 
in the short time used in this study, and the SRCs contained within unstimulated 
cells remained fully competent to engraft and repopulate the mice. On the other 
hand, because the SRC assay does not provide for extended long-term follow-up 
and does not support T-Iymphopoiesis, we must caution that our analysis cannot 
exclude detrimental effects of the cytokines on these more-difficult-to-assess stem 
cell features. Further studies in newly described xenograft models (Weijer, 
Uittenbogaart et al. 2002; Traggiai, Chicha et al. 2004; Shultz, Lyons et al. 2005) 
or, more likely, the follow-up of patients treated with LV-mediated HSC gene 
therapy in upcoming trials will address these issues. 
As previously observed (Mikkola, Woods et al. 2000; ABles, Schmidt et 
al. 2002), the average gene expression level was higher in vivo, in the SRC 
progeny, than in the in vitro outgrowth of the sa~e transduced cell culture, both 
for cells stimulated and not stimulated with cytokines. This difference indicates a 
higher transduction rate of SRCs than the, more committed progenitors assayed in 
vitro, and may be due to a higher permissiveness of SRCs to LV transduction, or, 
more likely, to the fact that a,ctively cycling cells, such as committed progenitors, 
may transit through mitosis during the initial steps of transduction, after viral 
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entry and before integration, and thus dilute the vector genomes between the 
daughter cells, as compared to quiescent cells. 
6.2 HSC cell cycle and LV transduction 
The enhancement of SRC transduction by cytokines was not abrogated by treating 
the cells with the S-phase poison Ara-C after transduction and before 
transplantation. Thus, we conclude that this enhancement was not due to induction 
of cell progression into S-phase. Ara-C treated cells yielded a lower, although not 
statistically significant, level of human cell engraftment in transplanted mice (see 
Table 3.4), suggesting that a fraction of SRCs, which are induced to proliferate 
shortly after transplantation, may become sensitive to the delayed effect of Ara-C 
in vivo. We also observed that Ara-C decreased the transduction level of both 
cytokine-stimulated and non-stimulated SRCs. This suggests that a fraction of 
SRCs may become sensitive to Ara-C in vivo and that cells in this fraction are 
more permissive to LV. These more permissive cells may be those exiting from 
quiescence; because of an earlier S-phase induction upon transplantation, they 
may become sensitive to the delayed effect of Ara-C in vivo. The cells less 
susceptible to LV may be the quiescent cells; because of a delayed S-phase 
,', induction upon transplantation, they may be resistant to Ara-C. Because the SRCs 
successfully engrafting after Ara-C treatment were transduced to substantial 
levels, these findings strongly suggest that LV s are able to transduce quiescent 
SRCs. Because previous studies could not rule out that SRCs transduced by LV in 
the absence of cytokine stimulation represented the fraction of cells already 
committed to the cell cycle, our data now provide evidence that primitive human 
HSCs can be transduced as quiescent cells. In this respect, HSCs may behave 
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differently than lymphocytes that restrict LV transduction, and HIV -1 infection, in 
the Go phase of the cell cycle. 
Indeed, even though HIV and HIV -derived vectors can infect/transduce 
non-proliferating, including terminally differentiated and post-mitotic, cells 
(Weinberg, Matthews et al. 1991; Lewis, Hensel et al. 1992; Lewis and Emerman 
1994; Naldini, Blomer et al. 1996), they are restricted in naive T cells that are in 
the Go phase of the cell cycle (Korin and Zack 1999; Unutmaz, KewalRamani et 
al. 1999; Wu and Marsh 2001; Cavalieri, Cazzaniga et al. 2003; Verhoeyen, 
Dardalhon et al. 2003). It is still not clear at what stage of the viral cycle this 
block is active; what is known is that exiting from quiescence and entering the Glb 
phase, without the need for full activation and proliferation, is sufficient for 
rendering the cells permissive. Several hypotheses have been proposed to explain 
this phenomenon, including lack of sufficient levels of dNTPs or lack of 
necessary transcription factors, such as NF AT, in Go cells, but all of them have 
been disproved in certain experimental settings (Kinoshita, Chen et al. 1998; 
Korin and Zack 1999; Ducrey-Rundquist, Guyader et al. 2002; Oswald-Richter, 
Grill et al. 2004). Very recently APOBEC3G has been proposed as mediator of 
the Go block in T cells (Chiu, Soros et al. 2005). Although previous studies 
demonstrated that this cytidine deaminase restricts HIV only when incorporated 
into viral particles and only if the viral accessory protein Vif is absent, Chiu et al. 
have proposed a new model for APOBEC3G restriction. According to this model, 
APOBEC3G is not affected by Vif and can block HIV infection by impairing 
reverse transcription in quiescent target T cells as part of a low molecular mass 
ribonucleoprotein complex (for a comprehensive review on APOBEC family and 
retroviral restriction see (Harris and Liddament 2004; Cullen 2006). However, 
despite the big effort made to identify defects in HIV infection of resting T cells, 
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it should be outlined that in vivo situation could differ from what has been 
observed in vitro. Indeed, it has been shown that HIV can productively infect 
naIve quiescent T cells in human lymphoid tissue ex vivo and in vivo (Zhang, 
Schuler et al. 1999; Eckstein, Penn et al. 2001; Kinter, Moorthy et al. 2003). Thus, 
it is possible that the Go block of HIV and LV infection in T lymphocytes is 
related to the in vitro setting rather than reflecting the in vivo scenario, which 
could resembles what observed with HSCs: an inefficient, but still effective, 
transduction of Go cells. 
6.3 Proteasome restriction of LV 
Whereas HSCs can be transduced by LV in very short ex vivo culture, they require 
high vector concentration and stimulation with cytokines to reach high gene 
transfer frequency. Indeed, to obtain similar level of gene transfer in cell lines 
considered to be permissive to LV, such as HeLa or 293T, a vector dose that is 
between 100 and 1000 fold lower than what is needed for HSPCs is sufficient. 
This indicates that HSCs display low permissivity and/or some level of restriction 
to LV. 
In the last years several groups have reported that mammalian cells 
o express factors able to counteract retrovirus and lentivirus infection. Beside the 
aforementioned deaminating enzymes, different families of cytosolic proteins that 
inhibit replication by targeting viral uncoating have been identified (for a review 
on retroviral restrictive factors see (Goff 2004). Although the mechanism of 
action of these factors is mostly unknoWn, it was proposed that they could act by 
targeting the entering virus for degradation by the ubiquitin-proteasome pathway. 
Starting from these considerations, we tested if inhibition of proteasome could 
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rescue the restrictive phenotype of HSPCs. Treating the cells with either of two 
reversible proteasome inhibitors at the time of transduction increased significantly 
the frequency of transduced cells, indicating that this proteolytic particle 
represents a major rate-limiting factor in the LV transduction pathway, as it was 
previously observed for lymphocytes infected by HIV -1 (Schwartz, Marechal et 
al. 1998). These findings are relevant for both gene therapy application and basic 
biology studies. 
6.3.1 Relevance for gene therapy applications 
For gene therapy applications, proteasome inhibitors can be useful tools to 
enhance LV gene transfer efficiency in HSPCs. Indeed, direct measurement of 
integrated vector copy numbers in HSPCs transduced in the presence and absence 
of proteasome inhibitors showed a dramatic increase in transduction of cells 
exposed to the drugs. When we determined the ratio of vector particles 
administered that were able to integrate into the target cell chromatin using the 
best protocol (cytokine stimulation), we discovered that, without proteasome 
inhibition, only 10% of the transducing units used gave rise to effective 
transduction (see Figure 4.3; 10 copies per cell, using 108 TV/ml and 106 cells/ml, 
which means 10q transducing units per cell); when the proteasome inhibitor was 
present during the transduction, more than 50% of the total administered 
transducing units integrated into the target cells (50-60 copies per cell at highest 
dose of both PS341 and MG132). This indicates that a large excess of vector 
particles is uptaken but does not become integrated, and confirm at a molecular 
level that proteasome effectively restricts LV transduction in HSPCs.· The 
possibility to enhance transduction efficiency may be particularly useful when 
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using low infectivity LV s, such as LV encoding multiple transgenes or complex 
expression cassettes, for which reaching high particle concentration may be a 
challenge. Moreover, our findings may be of particular interest in the context of 
HSCs derived from BM and MPB. Indeed, these cells are known to be less 
susceptible to transduction than CB-derived HSCs, and, thus, the proteasome 
inhibition approach may be even more useful in this setting to enhance 
transduction efficiency. Although in this work we have shown the effect of 
proteasome inhibition on HSCs derived only from CB, we have tested MG132 on 
MPB-derived HSPCs and observed a significant increase in gene transfer 
efficiency (data not shown). 
We have investigated if the proteasome inhibitor can be used to enhance 
gene transfer in different cell types. Interestingly, we have found a much lower, if 
any, enhancement of transduction in all the cell lines tested (both haematopoietic 
and not) as compared to the enhancement obtained in HSPCs. We correlated the 
response to proteasome inhibition to the proteasome activity, with an 
enhancement of transduction due to proteasome inhibition related to high basal 
proteasome activity of the target cells. We have also tested proteasome inhibition 
on several primary differentiated hematopoietic cells, such as T and B 
lymphocytes and monocytes, and we have not observed an enhancement in LV 
gene transfer (daia not shown). These data suggest that proteasome restriction 
may be a specific feature of HSPCs. 
Two recent works (Groschel and Bushman 2005; Wei, Denton et al. 2005) 
reported increased HIV infection of some cell lines by proteasome inhibition. 
However, the cells were scored 2 days after infection, thus without rulin~ out 
transient effects of the treatment on the reporter gene expression. In addition, 
Groschel et al. (Groschel and Bushman 2005) used high doses of inhibitor and 
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correlated the observed effect with the induction of target cells arrest in the G2/M 
phase of the cell cycle. It is likely that because of the specific experimental 
conditions these observations involved a mechanism different than that observed 
in our work. Indeed, an effect due to an induction of the arrest in the G2/M phase 
in HSPCs is not likely since, at least in absence of cytokine stimulation, HSPCs 
are mostly not proliferating (see Figure 3.4). Moreover, we performed cell cycle 
analyses on HSPCs and did not observe significant changes in the cell cycle 
distribution between c~lls treated and not with the proteasome inhibitor (data not 
shown). 
6.3.2 Biological significance 
As aforementioned, the discovery of proteasome restriction of LV is relevant not 
only for gene therapy applications, but also for basic biology studies. Our findings 
can help to better understand the innate cellular defence against HIV. Indeed, 
although in this work we have documented evidence only of a restriction against 
an HIV -derived vector, we have indications that proteasome restriction is active 
also against a VSV -G-pseudotyped HIV (data not shown). The most intriguing 
issue is the mechanism by which the proteasome controls lentiviral infection. 
There are many open questions that need to be addressed and one of them regards 
the specificity of the restriction. Enhancement of gene transfer by proteasome 
inhibition has been shown for Adeno-Associated Vectors (AA V) (Duan, Yue et 
al. 2000; Douar, Poulard et al. 2001; Yan, Zak et al. 2002; Denby, Nicklin et al. 
2005; Hacker, Wingenfeld et al. 2005). Although the mechanism is not elucidated, 
Yan et af. showed an increase in capsid ubiquitination when proteasome was 
inhibited and proposed that this enhanced ubiquitination promoted the completion 
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of the AA V latent life cycle. This mechanism is probably specific for the life 
cycle of AA V and it is in contrast to what has been suggested for HIV. Indeed, 
Swartz et al. (Schwartz, Marechal et al. 1998) suggested that the incoming HIV is 
targeted by ubiquitin to proteasomal degradation. Thus, it is possible that different 
mechanisms are involved in HIV and AA V proteasome restriction. We cannot 
exclude that the restriction we reported is active against other viruses. However, 
our preliminary results would indicate some specificity for LV. In fact, 
proteasome inhibition did not enhance RV transduction either in human or in 
murine HSPCs (data not shown). 
The specificity of proteasome restriction is strictly linked to the molecular 
mechanism of the restriction itself and to the step in the infection process that is 
affected. Since we used VSV -G-pseudotyped vectors, we cannot formally exclude 
that the antiviral response mediated by the proteasome can be induced by or is 
specific to the VSV pathway of entry, rather than to HIV. However, both 
published results (Schwartz, Marechal et al. 1998) and our results using alternate-
pseudotyped L V and VSV -G-pseudotyped RV (data not shown) show that 
proteasome restriction is not VSV -G specific and that it is active also against non-
pseudotyped HIV. Thus, it is reasonable to suggest that the infection/transduction 
early block maps to a step following entry. Despite the intensive study of HIV 
biology in the last 20 years, the processes and the cellular proteins involved in the 
viral journey from the cell surface to the cell geno~e are not fully understood (for 
a review on HIV post-entry steps see (Dvorin and Malim 2003; Lehmann-Che and 
Saib 2004; Yamashita and Emerman 2006). In particular, uncoating and nuclear 
import still need to be clearly elucidated and the studies about protea~ome 
restriction may help to identify novel players in these processes. 
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We have formulated different hypotheses to explain the mechanism of this 
restriction. The different mechanisms we propose are not mutually exclusive and 
could all be involved in controlling transduction. The most obvious hypothesis is 
that the proteasome acts directly by degrading the uncoating vector core in the 
cytosol, most likely after it has been targeted for degradation by a specific 
ubiquitin conjugation system. Ubiquitination and targeting to proteasome of 
entering virus by a restrictive factor was postulated in the first studies about 
TRIM5a (Stremlau, Owens et al. 2004), however a recent work has described the 
activity of this factor as independent from proteasome activity (Perez-Caballero, 
Hatziioannou et al. 2005). An alternative hypothesis considers an indirect action 
of the proteasome: it could either degrade or modulate the activation of cytosolic 
factors affecting the early steps of transduction. Several cellular response and 
signalling pathways, such as the heat-shock response, NF -kB activation, apoptosis 
and cell cycle progression, among many others, are rapidly regulated by the 
proteasome activity (for a review see (Glickman and Ciechanover 2002; Goldberg 
2005) and this modulation may in turn affect the outcome of lentiviral infection. 
Of particular interest is the activation of NF-kB, because this transcription factor 
is involved in the inflammatory signalling pathways and it could possibly link 
what we described as proteasome restriction to the innate immune response to 
o -
viruses. A third hypothesis implies a role of proteasome as chromatin interacting 
factor. Indeed, a growing body of evidence demoI1strates that components of the 
proteasome are involved in the regulation of gene transcription. Although for a 
long time it has been postulated that only the 19S, and thus only the non-
proteolytic subunit of the complex, was involved in gene regulation, recen~ly a 
role of the proteolytic 20S particle has been also demonstrated (Morris, Kaiser et 
al. 2003; Gillette, Gonzalez et al. 2004). 20S proteasome has been shown to 
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regulate different steps in transcription by regulating turnover, exchange and 
recruitment of activators/repressors, by recruiting RNA polymerase and by 
degrading RNA polymerase in response to DNA damage (for a review see 
(Collins and Tansey 2006). Thus, the nuclear proteasome could influence LV 
transduction by affecting integration rather than uncoating or nuclear import. 
Indeed, proteasome could regulate chromatin accessibility, act during DNA 
damage response, which is activated by viral integration, and/or change the 
availability of some transcription factors interacting with the vector (see 
paragraph 6.5.1 Integration site selection). 
6.4 Early-acting cytokines and proteasome activity 
In this project we have" confirmed our previous results (Ailles, Schmidt et al. 
2002), which showed that SCF, TPO, FLT3L and IL6 improved LV transduction 
of HSCs. Then, we have investigated how the cytokines can enhance permissivity 
of these cells to gene transfer. Having found that they do not act by inducing early 
progression to the S-phase of the cell cycle or affecting LV pathway of entry, we 
asked if they could act at a post-entry level. Post-entry restrictive factors targeting 
uncoating, such as TRIMS a, are typically identified by saturating their activity 
,) with increasing viral input (Towers, Collins et al. 2002). When we performed 
~ 
dose-response curves in unstimulated and stimulated cells, we did not observed 
different slopes in the two conditions (data not shown). Thus, we could not 
overcome the relative resistance of unstimulated, as compared to cytokine-
stimulated, cells by increasing the vector input. This suggests that a saturable 
restrictive factor is not present in unstimulated cells and that cytokines do not 
enhance transduction by eliminating a cytosolic restriction factor. Instead, we 
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found that the enhancement of LV transduction by cytokines in HSPCs may 
involve, at least in part, down-regulation of the proteasome activity in target cells. 
By directly testing the proteasome activities in stimulated and 
unstimulated HSPCs, we showed that they were significantly down-regulated by 
exposure to the cytokines. Importantly, this cytokines response was rapid, with a 
maximal effect at the earliest time point analysed (6 hours), in which the 
proteasome activity of stimulated cells was 30% of the proteasome activity of 
unstimulated cells. Interestingly, these early time points (6-12 hours) correspond 
to the period in which the first steps of LV transduction take place. Although it is 
difficult to estimate the actual level of inhibition reached in cells treated with 
MG 132, the activity recovered after 24 hour exposure was similar to that 
recovered from cells exposed for 6 hours to cytokines, suggesting that the extent 
of down-regulation induced by the latter was substantial. However, when we 
tested the proteasome activity of cells treated with cytokines and MG 132 together 
we did not observe a significant additive effect of the two on the down-regulation 
of proteasome activity as compared to cells treated with MG 132 alone, whereas 
we observed an additive effect of cytokines and MG132 in enhancing the 
transduction (see Figures 4.1-4.3). This suggests that other mechanisms, beside 
proteasome down-regulation, are probably involved in the enhancement of LV 
permissiveness induced by cytokines. 
The down-regulation of proteasome activity.in HSPCs as an early response 
to cytokine stimulation is a novel and intriguing finding, as it likely affects several 
other cellular functions than permissiveness to gene transfer, and may represent a 
crucial effector in the signal transduction pathways triggered by the cyto~ine 
receptors. Until now and to our knowledge, rapid modulation of proteasome 
activity by extracellular signals has only been reported for the immunoproteasome 
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In dendritic cell (Macagno, Gilliet et al. 1999; Strehl, Seifert et al. 2005). 
Interestingly, SCF, TPO, and Flt3L all had an additive effect on the proteasome 
activity. Thus, the proteasome may represent a regulatory hotspot at the crossroad 
of multiple intracellular signalling pathways. Further studies will identify the 
signalling pathways from the cytokine receptors to the proteasome. 
6.5 Safety of LV gene transfer in HSPCs 
Our studies indicate that, according to the absence or presence of cytokines, HSC 
gene transfer can be tuned to limit the average level of vector integration, and 
reduce the risk of insertional mutagenesis, or instead to maximize the frequency 
of transduction and extent of transgene expression. Because L V integration 
preferentially targets active genes, the choice between these two conditions may 
also affect the potential spectrum of integration sites, making less or more likely 
that cytokine-responsive, growth-related genes are targeted. In preliminary studies 
performed using a promoter-trapping approach, however, we did not observe 
differences in the average expression level of vector integration sites between 
HSPCs transduced in the two conditions. 
The use of proteasome inhibitors during transduction further increased 
.} HSC transduction· by LV. Since we obtained a very high vector copy number in 
SRCs transduced in presence of cytokines and proteasome inhibitor, further 
studies are needed to assess the impact on the target cell genome and evaluate the 
possible consequences of the increased insertional mutagenesis. However, as 
shown in Figures 4.1-4.3, using proteasome inhibitors in absence of cytokine 
stimulation allows high-frequency transduction without necessarily increasing the 
average vector copy number to extremely high levels, thus providing a possible 
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new strategy to optimise gene transfer. It is conceivable that both minimal and 
maximal thresholds of vector copy numbers providing the best risk-benefit ratio 
will have to be set according to each proposed gene therapy application. 
Moreover, integration sites analysis comparing cells transduced in presence or 
absence of proteasome inhibitors would be interesting in light of new findings that 
suggest a role for proteasome in gene transcription (see above and for a review 
(Collins and Tansey 2006). If these results, mainly obtained in yeast, were 
confirmed, inhibition of proteasome could also affect the integration site selection 
ofLVs. 
6.5.1 Integration site selection 
We used a promoter trap built into L V and RV (ML V) vectors to evaluate 
integration site selection in the target cell genome. We found a highly significant 
difference in trapping efficiency between the two vectors and showed that this 
effect was dependent on a different integration pattern of the two viruses within 
transcribed genes. 
Our study provides direct, functional evidence that RV s preferentially 
integrate close to highly active promoters. Such results are consistent with recent 
studies that analy~ed integration sites and reported preferential occurrence within 
±5kb from transcription start sites of cellular genes (Wu, Li et al. 2003;-Hematti, 
Hong et al. 2004; Mitchell, Beitzel et at. 2004). Notably, with the promoter 
trapping approach used here, we were able to screen several hundred thousand 
integrations in primary HSPCs, for both RV and LV. By using a functional 
readout, our analysis did not rely on the sometimes uncertain "in silico" 
identification of genes and transcription regulatory elements and on our current 
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knowledge of the overall extent of genome transcription, and avoided possible 
biases due to the vector-genome junction retrieval procedures. 
Remarkably, one out of five RV integrations in human HSPCs resulted in 
reporter gene expression. Because only integrations occurring downstream of a 
promoter and with the proper orientation will express the reporter, the RV bias for 
integration proximal to active promoters may even be higher than previously 
estimated. This surprisingly high trapping efficiency may be dependent on 
specific experimental conditions, such as the inclusion of the wPRE element in 
the trap that enhances reporter gene expression by stabilizing the transcript 
(Zufferey, Donello et al. 1999). In addition, by comparing RV and LV integration 
in similarly infected cells, we consistently found that the RV trap was expressed 
to a slightly but significantly higher level than the LV trap, suggesting preferential 
RV integration into a subset of more actively transcribed genes. However, we 
cannot exclude that the different integration pattern of RV and L V within 
transcription units may playa role in this finding, given the complex interplay of 
factors affecting reporter protein expression, including mRNA and protein 
stability. If verified, the finding of RV integration into a subset of more actively 
transcribed genes will highlight the specificity of the rules governing integration 
site selection by different integrating viruses, making a strong case for virus-
specific interactions with cellular proteins tethering the integration complex to 
selected gene sets. Data validating this hypothesis ~re currently emerging by high-
throughput analysis of RV and LV integrations. Targeting of a highly transcribed 
gene subset by RV may reflect tethering of its integration complex by cellular 
components recruited at highly active or induced (growth-responsive) promoters. 
Promoter targeting may have evolved in the parental retroviruses to provide a 
fraction of their progeny with a supplementary cellular promoter, less susceptible 
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to silencing by genome surveillance mechanisms than the L TR promoter (Bestor 
2000). The proximity and functional relationship frequently established between 
RV proviruses and flanking cellular promoters in our study indicate that 
integration of enhancer-rich wild-type ML V L TR is likely to up-regulate 
transcription from cellular promoters and, depending on proviral position and 
orientation, overexpress the cognate genes, including proto-oncogenes. These 
results correlate with the well-known oncogenicity of wild-type ,,(-retroviruses 
(Mikkers and Berns 2003), and underline the risk of insertional mutagenesis by 
RVs. 
HIV and HIV -derived vectors have been reported to integrate more 
frequently within transcribed genes than outside of them (Schroder, Shinn et al. 
2002; Mitchell, Beitzel et al. 2004). However, since they insert throughout the 
transcriptional unit without showing a bias for promoter-proximal integration 
(Wu, Li et al. 2003) and our data), the promoter trapping efficiency of LV traps 
was much lower than that observed for· RV traps. Preferential intragenic 
integration of LV s was recently reported in primary haematopoietic cells (Imren, 
Fabry et al. 2004; Mitchell, Beitzel et al. 2004) and integration intensity was 
shown to positively correlate with transcriptional intensity in one study (Mitchell, 
Beitzel et al. 2004). Preferential insertion throughout transcriptionally permissive 
chromatin may iJ"enefit the lentivirus lifestyle, which spread horizontally in the 
cognate host species, target interphase chromati~ crossing the nucleopore, and 
e?,press their own transcription regulators. 
These results, together with the advanced LV engineering that fully 
inactivates the HIV L TR, suggest that LV s provide a safer integrating tool for 
gene therapy. Although further studies are required in order to fully confirm it, the 
first evidence of a low genotoxicity of LV integrations has been recently reported 
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(Montini, Cesana et al. 2006). Still, it remains to be determined the role of the 
L TR in the genotoxic risk of RV sand LV s. Indeed, Montini et ale tested a full 
LTR RV and a SIN-LTR LV. Thus, it is likely that, beside the different 
integration site selection patterns of the two vectors, the presence of 
transcriptionally active L TRs was a major determinant of the genotoxicity of RV s 
observed in this model. Indeed, very recently Baum's. group has tested an 
improved SIN-LTR RV design and observed a reduced transforming capacity of 
the SIN constructs with respect to the corresponding L TR vectors in an in vitro 
culture system (Modlich, Bohne et al. 2006; Schambach, Bohne et al. 2006). In 
conclusion, a full assessment of the actual genotoxic risk of retroviral vectors 
integration is still missing and further studies are needed to validate vector safety 
and to advance the prospective applications of HSC-based gene therapy. 
6.6 Concluding remarks 
In this project we have evaluated several aspects of LV transduction of HSPCs 
and assessed efficient protocols for safe HSC gene transfer. Moreover, we have 
brought to light novel cellular players in the cell host-virus interaction. Further 
studies will determine, on one hand, the safety of the proteasome inhibitor 
,"> approach for HSC gene therapy and, on the other, the molecular mechanisms of 
proteasome restriction of LV s. 
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